Antibodies to M(H)DM2 / 4 and their use in diagnosis and treatment of cancer

By specifically binding to extracellular accessible antibodies or fragments thereof to M(H)DM2/4, the problems of treating cancer and preventing metastasis in the prior art are solved, and effective inhibition and control of tumors are achieved.

CN111491661BActive Publication Date: 2024-11-01NOMOCAN PHARMACEUTICALS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880062611.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-07-27
Filing Date
2018-07-26
Publication Date
2024-11-01
Estimated Expiration
2038-07-26

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat cancer, especially metastatic cancer, and prevent metastasis in patients.

Method used

An extracellular accessible antibody or fragment thereof specifically bound to M(H)DM2/4 was developed to inhibit tumor growth and metastasis, and the antibody or fragment did not bind to cell penetrating peptides or cytotoxic components. And specifically binds to specific peptide sequences such as MCNTNMSVPTDGAVT, TTSQIPASEQE or CPVCRQPIQMIVLTYFP to form antibody-drug conjugates to enhance therapeutic effects.

Benefits of technology

Through specific binding and the design of antibody-drug conjugates, tumor growth and metastasis are significantly inhibited, the targeted and effective treatment is improved, and the killing ability of cancer cells is enhanced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111491661B_ABST
    Figure CN111491661B_ABST
Patent Text Reader

Abstract

The present invention relates to specific anti-M(H)DM2 / 4 antibodies or antigen-binding fragments thereof, pharmaceutical compositions comprising anti-M(H)DM2 / 4 antibodies or antigen-binding fragments thereof, antibody-drug conjugates comprising anti-M(H)DM2 / 4 antibodies or antigen-binding fragments thereof bound to cytotoxic drugs, and the use of such antibodies, fragments, compositions and conjugates for treating cancer and / or for preventing metastasis. In particular, the present invention describes specific antibodies or antigen-binding fragments thereof that specifically bind to extracellular accessible epitopes of M(H)DM2 / 4 and inhibit tumor growth in vivo, pharmaceutical compositions comprising such antibodies or fragments, antibody-drug conjugates comprising such antibodies or fragments, and the use of such antibodies, fragments, compositions and conjugates for treating cancer or for preventing metastasis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 1. Cross-reference to related applications

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 537,914, filed on July 27, 2017, which is incorporated herein by reference in its entirety.

[0003] 2. Reference to electronically submitted sequence listing

[0004] This application incorporates by reference the sequence listing filed with this application, which is an ASCII text file named "14160-006-228_ST25", created on July 25, 2018, and has a size of 88,287 bytes. Technical Field

[0005] The present invention relates to specific anti-M(H)DM2 / 4 antibodies or antigen-binding fragments thereof, pharmaceutical compositions comprising the anti-M(H)DM2 / 4 antibodies or antigen-binding fragments thereof, antibody-drug conjugates comprising the anti-M(H)DM2 / 4 antibodies or antigen-binding fragments thereof conjugated to a cytotoxic drug, and the use of such antibodies, fragments, compositions and conjugates for treating cancer and / or for preventing metastasis. Background Art

[0006] MDM2 (MDM2 is the mouse homolog of HDM2) protein consists of 489 amino acids and contains a p53 binding domain, two nuclear localization signals (amino acids 176-182 and 464-471) and a zinc finger motif (amino acids 297-326 and 436-477) (see UniProt website, UniProt accession number P23804). Its human homolog HDM2 consists of 491 amino acids and contains a p53 binding domain, two nuclear localization signals (amino acids 179-185 and 466-473) and a zinc finger motif (amino acids 299-328 and 438-479) (see UniProt website, UniProt accession number Q00987). Mouse protein MDM4 (also known as MDMX) is a homolog of the MDM2 protein (see UniProt website, UniProt accession number 035618), and both MDM2 and MDM4 are major negative regulators of p53 (Wade et al., 2013, Nat Rev. Cancer 13: 83-96; Marine et al., 2004, Cell Cycle 3: 900-904; Momand et al., 2011, Gene 486: 23-30). HDM4 (also known as HDMX) is the human homolog of MDM4 (see UniProt website, UniProt accession number 015151). The most conserved domain within all M(H)DM2 and M(H)DM4 proteins is the RING domain, which is involved in the ubiquitination of its target proteins (including the p53 protein) and the heterodimerization between M(H)DM2 and M(H)DM4. M(H)DM4 is required for M(H)DM2-mediated polyubiquitination of p53. The distinguishing feature of M(H)DM2 and M(H)DM4 is their very complex expression pattern. Multiple sizes of transcripts and protein products of M(H)DM2 have been determined in cancer cells by many groups (Olson et al., 1993, Oncogene 8:2353-2360; Bartel et al., 2002, Cancer Cell 2:9-15 ("Bartel 2002"); Sigalas et al., 1996, Nat. Med. 2:912-917 ("Sigalas 1996"); Iwakuma & Lozano, 2003, Mol. Cancer Res. 1:993-1000 ("Iwakuma & Lozano 2003")). Many types of human cancer overexpress MDM2 protein, and a common feature between these cancers is the associated increase in mdm2 splice variants.These M(H)DM2 variants have been shown to be expressed in a variety of tumors, such as human ovarian cancer, bladder cancer, breast cancer, and astrocytoma, glioblastoma, leukemia, and childhood rhabdomyosarcoma (reviewed by Iwakuma & Lozano 2003; Rosso et al., 2014, Subcell Biochem. 85:247-61 ("Rosso 2014")). Most interestingly, they have been found to be more common in advanced tumors (Bartel 2002). M(H)DM2 transcripts of various sizes, which are splice variants of M(H)DM2 mRNA, have been reported to be more frequently expressed in tumor cells than in normal cells (Bartel et al., 2004, Mol. Cancer Res. 2:29 ("Bartel 2004")). It has been proposed that an mRNA surveillance system exists in non-transformed cells that degrades spliced ​​transcripts and protects cells from errors in transcription, mRNA processing, or mRNA trafficking, whereas this system may not function properly in transformed cells (Bartel 2004). Furthermore, some of these variants in cancer cells encode protein products that have been shown to transform NIH3T3 cells in vitro, while others promote tumor formation in mouse models (Sigalas 1996; Volk et al., 2009, Mol Cancer Res. 7(6):863–869).

[0007] To date, more than 70 different M(H)DM2 splice variants have been identified (Bartel 2002; Bartel 2004; Rosso 2014). Some variants, such as MDM2-A and MDM2-B, are common to several tumor types (Sigalas 1996). Others are found only in specific tumors, such as MDM2-FB25 and MDM2-FB26 in childhood rhabdomyosarcoma. Several short forms of these alternatively spliced ​​MDM2 transcripts are associated with high-grade malignancy in human ovarian tumors, bladder cancer, and astrocytic tumors (Sigalas 1996; Matsumoto et al., 1998, Cancer Res. 58:609-613; Tamborini et al., 2001, Int. J. Cancer 92:790-796; Steinman et al., 2004, JBC 279:4877-4886). Aberrant mdm2 (281-, 254-, and 219-bp) and alternative mdm2 (653-bp) splicing products have also been shown to be closely associated with shortened overall survival in breast cancer patients (Lukas et al., 2001, Cancer Res. 61:3212).

[0008] Several studies have evaluated the cellular localization of various human and mouse M(H)DM2 protein variants to predict potential activity. In 25% of non-small cell lung cancers, M(H)DM2 variants are abnormally localized in the cytoplasm (Evans et al., 2001, Oncogene 20:4041-4049). This result led to the discovery that the cytoplasmic compartmentalization of full-length M(H)DM2 is due to the binding and sequestration of an alternative spliced ​​M(H)DM2 product (HDM2ALT1). In another study, MDM2-D150-230 was localized to the cytoplasm of U20S cells (Schuster et al., 2007, Mol. Cancer Res. 5:403-412 ("Schuster 2007")). Both M(H)DM2 protein variants lack a portion of the NH2-terminal region containing the nuclear localization signal (NLS), suggesting that loss of this signal prevents both proteins from entering the nucleus (Schuster 2007). Taken together, these data indicate that the cellular localization of M(H)DM2 protein variants is highly complex.

[0009] Several M(H)DM4 protein variants have also been characterized, including the splice variant MDMX-S (Lenos and Jochemsen, 2011, J. Biomed Biotechnol., doi: 10.1155 / 2011 / 876173).

[0010] HDM2 is found to be expressed in the plasma membrane of cancer cells (Sarafraz-Yazdi et al., 2010, PNAS 107:1918-1923 ("Sarafraz-Yazdi 2010"). In addition, anticancer peptides PNC-27 and PNC-28 have been developed that bind to HDM2 expressed in cancer cell membranes and kill cancer cells by inducing necrosis (Sarafraz-Yazdi 2010; Davitt et al., 2014, Annals Clin. Lab. Sci. 44:241-248) (the amino acid sequences of PNC-27 and PNC-28 are provided in Table 1 of U.S. Patent Application Publication No. 2012 / 0177566). PNC-27 has been reported to bind within amino acids 25-109 of HDM2 (Do et al., 2003, Oncogene 22(10):1431-1444 ("Do 2003"); Chène, 2003, Nat. Rev. Cancer 3(2):102-109). In addition, U.S. Patent Application Publication No. 2012 / 0177566 discloses a method for selectively causing cell necrosis by administering to cells a compound comprising a HDM-2 targeting component and a cytotoxic component linked to the HDM-2 targeting component (such as PNC-27 and PNC-28), wherein the compound comprises a membrane active form. The membrane-active function of the PNC-27 and PNC-28 peptides (comprising a membrane-resident peptide ("MRP") and a p53 sequence) is achieved only when the cargo (i.e., p53 sequence component) is linked to the MRP component to form a cytotoxic structure (Kanovsky et al., 2001, PNAS 98:12438-12443 ("Kanovsky 2001"); Bowne et al., 2008, Ann Surg Oncol. 15:3588-3600 ("Bowne 2008"). When either the MRP component or the HDM-2 targeting component (i.e., the p53 component) was used, respectively, they were found to be non-cytotoxic to cancer cells (Kanovsky 2001; Do 2003), indicating a lack of activity when the MRP component alone and the HDM-2 targeting component alone were expressed. When recombinantly expressed in cells, the HDM-2 targeting component was observed to induce apoptosis (Bowne 2008). U.S. Patent No. 9,765,117 discloses HDM2 targeting peptides and fusion peptides comprising the HDM2 targeting peptide and a transmembrane penetrating sequence, such as MRP; discloses that MRP is required for inducing cell necrosis (see column 4, lines 27-28). U.S. Patent No. 9,765,117 shows that in the absence of MRP in cancer cells, expression of a p53 HDM2 targeting sequence induces p53-dependent cell apoptosis rather than tumor necrosis (see column 4, lines 29-32).

[0011] Cell penetrating peptides ("CPPs") (such as MRPs, membrane transduction domains of antennapedia, transactivating transcriptional activators ("TATs"), and penetratin peptides) enable cell membrane delivery of peptides and molecules attached to the peptides to the plasma membrane lipid bilayer, including the lipid bilayer of normal healthy cells. These peptides have been shown to effectively transport various bioactive molecules within living cells (Bechara et al., 2013, FEBS Lett. 587: 1693-1702, Dupont et al., 2015, Methods Mol. Biol. 1324: 29-37). The use of these CPPs (e.g., MRPs, membrane transduction domain of Antennapedia, TAT, and penetratin peptides) linked to various cargoes (e.g., other peptides, DNA, RNA, small molecules, antibodies, or fragments thereof) has been shown to improve the pharmacokinetics, biodistribution, retention, uptake, and delivery of these cargoes to various tumors in vivo and in vitro (Torchilin et al., 2003, PNAS 100:1972-1977; Shin et al., 2014, J. Biomed. Mater Res. A. 102:575-587; Kleemann et al., 2005, J. Control Release 109:299-316; Olson et al., 2009, Integr. Biol (Camb) 1:382-393; Jain et al., 2005, Cancer Res. 65:7840-7846; William et al., 2002, PNAS 99:10423-10428; Bolhassani, 2011, Biochim Biophys. Acta 1816:232-246). Although most of these CPPs are used as cargo delivery entities, penetratin and MRP peptides have been reported to form unique cytotoxic membrane-active structures when linked to their cargo (Rosal et al., 2005, Adv Drug Deliv Rev 57:653-60 ("Rosal 2005"); Bowne 2008; Kanovsky 2001). PNC-27 and PNC-28 peptides are examples of penetratin- / MRP-cargo conjugates that exhibit cytotoxic function that is dependent on the attachment and association of their cargo with the MRP, which is required for the formation of their membrane-active structure and, therefore, their cytotoxic function (Kanovsky 2001; Rosal 2005; Bowne 2008).

[0012] There has long been an unmet need in the art to effectively treat cancer, such as metastatic cancer, and prevent metastasis in patients. 5. Summary of the Invention

[0014] In one aspect, described herein is an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4. Specifically, described herein is an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment inhibits tumor growth in vivo (or inhibits tumor cell proliferation in vivo). In certain embodiments, the antibodies or fragments described herein do not bind to a cell-penetrating peptide (e.g., a membrane-resident peptide). In certain embodiments, the antibodies or fragments described herein do not bind to a cytotoxic component (i.e., do not bind to a cytotoxic agent).

[0015] In one aspect, described herein are antibodies or fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide wherein the sequence of the peptide consists of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3). In particular, described herein are antibodies or fragments that specifically bind to M(H)DM2 / 4 (e.g., HDM2), wherein the antibody or fragment specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide wherein the sequence of the peptide consists of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3). In one embodiment, the antibody or fragment binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide, wherein the sequence of the peptide is MCNTNMSVPTDGAVT (SEQ ID NO: 1). In one embodiment, the antibody or fragment binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide, wherein the sequence of the peptide is TTSQIPASEQE (SEQ ID NO: 2). In one embodiment, the antibody or fragment binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide, wherein the sequence of the peptide is CPVCRQPIQMIVLTYFP (SEQ ID NO: 3). In certain embodiments, described herein is an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 contained within a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In one embodiment, described herein is an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, which is contained within the peptide of SEQ ID NO: 1. In one embodiment, described herein is an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, which is contained within the peptide of SEQ ID NO: 2. In one embodiment, described herein is an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, which is contained within the peptide of SEQ ID NO: 3.

[0016] In one aspect, described herein is a humanized antibody or fragment thereof that specifically binds to HDM2, comprising: (i) a heavy chain variable region (VH) comprising a VH complementarity determining region ("CDR") 1, a VH CDR2, and a VH CDR3; wherein the VH CDR1, VH CDR2, and VH CDR3 are the CDRs of a VH having an amino acid sequence selected from the group consisting of SEQ ID NO: 36, SEQ ID NO: 38, and SEQ ID NO: 40; or (ii) a light chain variable region (VL) comprising a VL CDR1, VL CDR2, and VL CDR3; wherein the VL CDR1, VL CDR2, and VL CDR3 are the CDRs of a VL having an amino acid sequence selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 39, and SEQ ID NO: 41. In one embodiment, a humanized antibody or fragment that specifically binds to HDM2 comprises a VH, wherein VH CDR 1, VH CDR 2, and VH CDR 3 belong to a VH having the amino acid sequence of SEQ ID NO: 36. In one embodiment, a humanized antibody or fragment that specifically binds to HDM2 comprises a VH, wherein VH CDR 1, VH CDR 2, and VH CDR3 belong to a VH having the amino acid sequence of SEQ ID NO: 38. In one embodiment, a humanized antibody or fragment that specifically binds to HDM2 comprises a VH, wherein VH CDR 1, VH CDR 2, and VH CDR3 belong to a VH having the amino acid sequence of SEQ ID NO: 40. In one embodiment, a humanized antibody or fragment that specifically binds to HDM2 comprises a VL wherein VL CDR1, VL CDR2, and VL CDR3 belong to a VL having the amino acid sequence of SEQ ID NO: 37 (and optionally, a VH wherein VH CDR1, VH CDR2, and VH CDR3 belong to a VH having the amino acid sequence of SEQ ID NO: 36). In one embodiment, a humanized antibody or fragment that specifically binds to HDM2 comprises a VL wherein VL CDR1, VL CDR2, and VL CDR3 belong to a VL having the amino acid sequence of SEQ ID NO: 39 (and optionally, a VH wherein VH CDR1, VH CDR2, and VH CDR3 belong to a VH having the amino acid sequence of SEQ ID NO: 38). In one embodiment, a humanized antibody or fragment that specifically binds to HDM2 comprises a VL wherein VL CDR 1, VL CDR 2, and VL CDR 3 belong to a VL having the amino acid sequence of SEQ ID NO: 41 (and optionally, a VH wherein VH CDR 1, VH CDR 2, and VH CDR 3 belong to a VH having the amino acid sequence of SEQ ID NO: 40).

[0017] In one aspect, described herein is an antibody or fragment thereof that specifically binds to M(H)DM2 / 4, the antibody or fragment comprising a heavy chain variable region (VH) comprising a VH complementarity determining region ("CDR") 1, a VH CDR 2, and a VH CDR 3, wherein:

[0018] (i) the VH CDR 1 has the amino acid sequence GFTFTHY (SEQ ID NO: 18), the VH CDR 2 has the amino acid sequence RNKAKGYT (SEQ ID NO: 19), and the VH CDR 3 has the amino acid sequence DIGDN (SEQ ID NO: 20);

[0019] (ii) the VH CDR 1 has the amino acid sequence GFTFTHYYMS (SEQ ID NO: 42), the VH CDR 2 has the amino acid sequence FIRNKAKGYTAE (SEQ ID NO: 45), and the VH CDR 3 has the amino acid sequence DIGDN (SEQ ID NO: 20);

[0020] (iii) the VH CDR 1 has the amino acid sequence HYYMS (SEQ ID NO: 43), the VH CDR 2 has the amino acid sequence FIRNKAKGYTAEYSASVKG (SEQ ID NO: 46), and the VH CDR 3 has the amino acid sequence DIGDN (SEQ ID NO: 20);

[0021] (iv) the VH CDR 1 has the amino acid sequence THYYMS (SEQ ID NO: 44), the VH CDR 2 has the amino acid sequence WLGFIRNKAKGYTAE (SEQ ID NO: 47), and the VH CDR 3 has the amino acid sequence ARDIGD (SEQ ID NO: 48); or

[0022] (v) the VH CDR 1 has the amino acid sequence FTFTHYY (SEQ ID NO: 144), the VH CDR 2 has the amino acid sequence IRNKAKGYTA (SEQ ID NO: 145), and the VH CDR 3 has the amino acid sequence ARDIGDN (SEQ ID NO: 146).

[0023] In one aspect, described herein is an antibody or fragment thereof that specifically binds to M(H)DM2 / 4 (e.g., HDM2), comprising a heavy chain variable region (VH) comprising a VH complementarity determining region ("CDR") 1, a VH CDR 2, and a VH CDR 3, wherein:

[0024] (i) the VH CDR 1 has the amino acid sequence GDTLSGS (SEQ ID NO: 24), the VH CDR 2 has the amino acid sequence HLNRGT (SEQ ID NO: 25), and the VH CDR 3 has the amino acid sequence SPGFAY (SEQ ID NO: 26);

[0025] (ii) the VH CDR 1 has the amino acid sequence GDTLSGSWMH (SEQ ID NO: 52), the VH CDR 2 has the amino acid sequence EIHLNRGTTN (SEQ ID NO: 55), and the VH CDR 3 has the amino acid sequence SPGFAY (SEQ ID NO: 26);

[0026] (iii) the VH CDR 1 has the amino acid sequence GSWMH (SEQ ID NO: 53), the VH CDR 2 has the amino acid sequence EIHLNRGTTNYNEKFKG (SEQ ID NO: 56), and the VH CDR 3 has the amino acid sequence SPGFAY (SEQ ID NO: 26);

[0027] (iv) the VH CDR 1 has the amino acid sequence SGSWMH (SEQ ID NO: 54), the VH CDR 2 has the amino acid sequence WIGEIHLNRGTTN (SEQ ID NO: 57), and the VH CDR 3 has the amino acid sequence ARSPGFA (SEQ ID NO: 58); or

[0028] (v) the VH CDR 1 has the amino acid sequence GDTLSGSW (SEQ ID NO: 148), the VH CDR 2 has the amino acid sequence IHLNRGTT (SEQ ID NO: 143), and the VH CDR 3 has the amino acid sequence ARSPGFA (SEQ ID NO: 58).

[0029] In one aspect, provided herein is an antibody or fragment thereof that specifically binds to M(H)DM2 / 4 (e.g., HDM2), the antibody or fragment comprising a heavy chain variable region (VH), the heavy chain variable region (VH) comprising a VH complementarity determining region ("CDR") 1, a VH CDR 2, and a VH CDR 3, wherein:

[0030] (i) the VH CDR 1 has the amino acid sequence GYTFTSY (SEQ ID NO: 30), the VH CDR 2 has the amino acid sequence NPRNGG (SEQ ID NO: 31), and the VH CDR 3 has the amino acid sequence SGYYAMDY (SEQ ID NO: 32);

[0031] (ii) the VH CDR 1 has the amino acid sequence GYTFTSYYMY (SEQ ID NO: 62), the VH CDR 2 has the amino acid sequence GINPRNGGTN (SEQ ID NO: 65), and the VH CDR 3 has the amino acid sequence SGYYAMDY (SEQ ID NO: 32);

[0032] (iii) the VH CDR 1 has the amino acid sequence SYYMY (SEQ ID NO: 63), the VH CDR 2 has the amino acid sequence GINPRNGGTNFNEKFKN (SEQ ID NO: 66), and the VH CDR 3 has the amino acid sequence SGYYAMDY (SEQ ID NO: 32); or

[0033] (iv) the VH CDR 1 has the amino acid sequence TSYYMY (SEQ ID NO: 64), the VH CDR 2 has the amino acid sequence WIGGINPRNGGTN (SEQ ID NO: 67), and the VH CDR 3 has the amino acid sequence TRSGYYAMD (SEQ ID NO: 68).

[0034] In one aspect, described herein is a humanized antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising a heavy chain variable region (VH) comprising a VH complementarity determining region ("CDR") 1, a VH CDR 2, and a VH CDR 3, wherein:

[0035] (i) the VH CDR 1 has the amino acid sequence GFTFTHY (SEQ ID NO: 18), the VH CDR 2 has the amino acid sequence RNKAKGYT (SEQ ID NO: 19), and the VH CDR 3 has the amino acid sequence DIGDN (SEQ ID NO: 20);

[0036] (ii) the VH CDR 1 has the amino acid sequence GFTFTHYYMS (SEQ ID NO: 42), the VH CDR 2 has the amino acid sequence FIRNKAKGYTAE (SEQ ID NO: 45), and the VH CDR 3 has the amino acid sequence DIGDN (SEQ ID NO: 20);

[0037] (iii) the VH CDR 1 has the amino acid sequence HYYMS (SEQ ID NO: 43), the VH CDR 2 has the amino acid sequence FIRNKAKGYTAEYSASVKG (SEQ ID NO: 46), and the VH CDR 3 has the amino acid sequence DIGDN (SEQ ID NO: 20);

[0038] (iv) the VH CDR 1 has the amino acid sequence THYYMS (SEQ ID NO: 44), the VH CDR 2 has the amino acid sequence WLGFIRNKAKGYTAE (SEQ ID NO: 47), and the VH CDR 3 has the amino acid sequence ARDIGD (SEQ ID NO: 48); or

[0039] (v) the VH CDR 1 has the amino acid sequence FTFTHYY (SEQ ID NO: 144), the VH CDR 2 has the amino acid sequence IRNKAKGYTA (SEQ ID NO: 145), and the VH CDR 3 has the amino acid sequence ARDIGDN (SEQ ID NO: 146).

[0040] In one aspect, described herein is a humanized antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising a VH, wherein the VH comprises a VH CDR1, a VH CDR2, and a VH CDR 3, wherein:

[0041] (i) the VH CDR 3 has the amino acid sequence DIGDN (SEQ ID NO: 20);

[0042] (ii) the VH CDR 3 has the amino acid sequence ARDIGD (SEQ ID NO: 48); or

[0043] (iii) the VH CDR 3 has the amino acid sequence ARDIGDN (SEQ ID NO: 146).

[0044] In one aspect, described herein is a humanized antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising a light chain variable region (VL) comprising a VL complementarity determining region ("CDR") 1, a VL CDR 2, and a VL CDR 3, wherein:

[0045] (i) the VL CDR 1 has the amino acid sequence RSSKNLLHSNGITYLY (SEQ ID NO: 21), the VLCDR 2 has the amino acid sequence RVSNLAS (SEQ ID NO: 22), and the VL CDR 3 has the amino acid sequence AQLLELPYT (SEQ ID NO: 23);

[0046] (ii) the VL CDR 1 has the amino acid sequence LHSNGITYLYWY (SEQ ID NO: 49), the VL CDR 2 has the amino acid sequence LLISRVSNLA (SEQ ID NO: 50), and the VL CDR 3 has the amino acid sequence AQLLELPY (SEQ ID NO: 51); or

[0047] (iii) the VL CDR 1 has the amino acid sequence KNLLHSNGITY (SEQ ID NO: 147), the VL CDR2 has the amino acid sequence RVS and the VL CDR 3 has the amino acid sequence AQLLELPYT (SEQ ID NO: 23).

[0048] In one aspect, described herein is a humanized antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising:

[0049] (a) a heavy chain variable region (VH), comprising VH complementarity determining region ("CDR") 1, VH CDR 2, and VH CDR 3, wherein:

[0050] (i) the VH CDR 1 has the amino acid sequence GFTFTHY (SEQ ID NO: 18), the VH CDR 2 has the amino acid sequence RNKAKGYT (SEQ ID NO: 19), and the VH CDR 3 has the amino acid sequence DIGDN (SEQ ID NO: 20);

[0051] (ii) the VH CDR 1 has the amino acid sequence GFTFTHYYMS (SEQ ID NO: 42), the VH CDR 2 has the amino acid sequence FIRNKAKGYTAE (SEQ ID NO: 45), and the VH CDR 3 has the amino acid sequence DIGDN (SEQ ID NO: 20);

[0052] (iii) the VH CDR 1 has the amino acid sequence HYYMS (SEQ ID NO: 43), the VH CDR 2 has the amino acid sequence FIRNKAKGYTAEYSASVKG (SEQ ID NO: 46), and the VH CDR 3 has the amino acid sequence DIGDN (SEQ ID NO: 20);

[0053] (iv) the VH CDR 1 has the amino acid sequence THYYMS (SEQ ID NO: 44), the VH CDR 2 has the amino acid sequence WLGFIRNKAKGYTAE (SEQ ID NO: 47), and the VH CDR 3 has the amino acid sequence ARDIGD (SEQ ID NO: 48); or

[0054] (v) the VH CDR 1 has the amino acid sequence FTFTHYY (SEQ ID NO: 144), the VH CDR 2 has the amino acid sequence IRNKAKGYTA (SEQ ID NO: 145), and the VH CDR 3 has the amino acid sequence ARDIGDN (SEQ ID NO: 146); and

[0055] (b) a light chain variable region (VL), comprising VL complementarity determining region ("CDR") 1, VL CDR 2, and VL CDR 3, wherein:

[0056] (i) the VL CDR 1 has the amino acid sequence RSSKNLLHSNGITYLY (SEQ ID NO: 21), the VLCDR 2 has the amino acid sequence RVSNLAS (SEQ ID NO: 22), and the VL CDR 3 has the amino acid sequence AQLLELPYT (SEQ ID NO: 23);

[0057] (ii) the VL CDR 1 has the amino acid sequence LHSNGITYLYWY (SEQ ID NO: 49), the VL CDR 2 has the amino acid sequence LLISRVSNLA (SEQ ID NO: 50), and the VL CDR 3 has the amino acid sequence AQLLELPY (SEQ ID NO: 51); or

[0058] (iii) the VL CDR 1 has the amino acid sequence KNLLHSNGITY (SEQ ID NO: 147), the VL CDR2 has the amino acid sequence RVS and the VL CDR 3 has the amino acid sequence AQLLELPYT (SEQ ID NO: 23).

[0059] In one aspect, described herein is an antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising a heavy chain variable region (VH) comprising a VH complementarity determining region ("CDR") 1, a VH CDR 2, and a VH CDR3, wherein:

[0060] (i) the VH CDR 1 has the amino acid sequence GDTLSGS (SEQ ID NO: 24), the VH CDR 2 has the amino acid sequence HLNRGT (SEQ ID NO: 25), and the VH CDR 3 has the amino acid sequence SPGFAY (SEQ ID NO: 26);

[0061] (ii) the VH CDR 1 has the amino acid sequence GDTLSGSWMH (SEQ ID NO: 52), the VH CDR 2 has the amino acid sequence EIHLNRGTTN (SEQ ID NO: 55), and the VH CDR 3 has the amino acid sequence SPGFAY (SEQ ID NO: 26);

[0062] (iii) the VH CDR 1 has the amino acid sequence GSWMH (SEQ ID NO: 53), the VH CDR 2 has the amino acid sequence EIHLNRGTTNYNEKFKG (SEQ ID NO: 56), and the VH CDR 3 has the amino acid sequence SPGFAY (SEQ ID NO: 26);

[0063] (iv) the VH CDR 1 has the amino acid sequence SGSWMH (SEQ ID NO: 54), the VH CDR 2 has the amino acid sequence WIGEIHLNRGTTN (SEQ ID NO: 57), and the VH CDR 3 has the amino acid sequence ARSPGFA (SEQ ID NO: 58); or

[0064] (v) the VH CDR 1 has the amino acid sequence GDTLSGSW (SEQ ID NO: 148), the VH CDR 2 has the amino acid sequence IHLNRGTT (SEQ ID NO: 143), and the VH CDR 3 has the amino acid sequence ARSPGFA (SEQ ID NO: 58).

[0065] In one aspect, described herein is an antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising a VH, wherein the VH comprises a VH CDR1, a VH CDR2, and a VH CDR 3, wherein:

[0066] (i) the VH CDR 3 has the amino acid sequence SPGFAY (SEQ ID NO: 26); or

[0067] (ii) the VH CDR 3 has the amino acid sequence ARSPGFA (SEQ ID NO: 58).

[0068] In one aspect, described herein is an antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising a light chain variable region (VL) comprising a VL complementarity determining region ("CDR") 1, a VL CDR 2, and a VL CDR3, wherein:

[0069] (i) the VL CDR 1 has the amino acid sequence RSSKSLLHSNGNSYLY (SEQ ID NO: 27), the VL CDR 2 has the amino acid sequence RMSNLAS (SEQ ID NO: 28), and the VL CDR 3 has the amino acid sequence MQHLEYPFT (SEQ ID NO: 29);

[0070] (ii) the VL CDR 1 has the amino acid sequence LHSNGNSYLYWF (SEQ ID NO: 59), the VL CDR 2 has the amino acid sequence LLIYRMSNLA (SEQ ID NO: 60), and the VL CDR 3 has the amino acid sequence MQHLEYPF (SEQ ID NO: 61); or

[0071] (iii) the VL CDR 1 has the amino acid sequence KSLLHSNGNSY (SEQ ID NO: 141), the VL CDR2 has the amino acid sequence RMS and the VL CDR 3 has the amino acid sequence MQHLEYPFT (SEQ ID NO: 29).

[0072] In one aspect, described herein is an antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising:

[0073] (a) a heavy chain variable region (VH), comprising VH complementarity determining region ("CDR") 1, VH CDR 2, and VH CDR 3, wherein:

[0074] (i) the VH CDR 1 has the amino acid sequence GDTLSGS (SEQ ID NO: 24), the VH CDR 2 has the amino acid sequence HLNRGT (SEQ ID NO: 25), and the VH CDR 3 has the amino acid sequence SPGFAY (SEQ ID NO: 26);

[0075] (ii) the VH CDR 1 has the amino acid sequence GDTLSGSWMH (SEQ ID NO: 52), the VH CDR 2 has the amino acid sequence EIHLNRGTTN (SEQ ID NO: 55), and the VH CDR 3 has the amino acid sequence SPGFAY (SEQ ID NO: 26);

[0076] (iii) the VH CDR 1 has the amino acid sequence GSWMH (SEQ ID NO: 53), the VH CDR 2 has the amino acid sequence EIHLNRGTTNYNEKFKG (SEQ ID NO: 56), and the VH CDR 3 has the amino acid sequence SPGFAY (SEQ ID NO: 26);

[0077] (iv) the VH CDR 1 has the amino acid sequence SGSWMH (SEQ ID NO: 54), the VH CDR 2 has the amino acid sequence WIGEIHLNRGTTN (SEQ ID NO: 57), and the VH CDR 3 has the amino acid sequence ARSPGFA (SEQ ID NO: 58); or

[0078] (v) the VH CDR 1 has the amino acid sequence GDTLSGSW (SEQ ID NO: 148), the VH CDR 2 has the amino acid sequence IHLNRGTT (SEQ ID NO: 143), and the VH CDR 3 has the amino acid sequence ARSPGFA (SEQ ID NO: 58); and

[0079] (b) a light chain variable region (VL), comprising VL complementarity determining region ("CDR") 1, VL CDR 2, and VL CDR 3, wherein:

[0080] (i) the VL CDR 1 has the amino acid sequence RSSKSLLHSNGNSYLY (SEQ ID NO: 27), the VL CDR 2 has the amino acid sequence RMSNLAS (SEQ ID NO: 28), and the VL CDR 3 has the amino acid sequence MQHLEYPFT (SEQ ID NO: 29);

[0081] (ii) the VL CDR 1 has the amino acid sequence LHSNGNSYLYWF (SEQ ID NO: 59), the VL CDR 2 has the amino acid sequence LLIYRMSNLA (SEQ ID NO: 60), and the VL CDR 3 has the amino acid sequence MQHLEYPF (SEQ ID NO: 61); or

[0082] (iii) the VL CDR 1 has the amino acid sequence KSLLHSNGNSY (SEQ ID NO: 141), the VL CDR2 has the amino acid sequence RMS and the VL CDR 3 has the amino acid sequence MQHLEYPFT (SEQ ID NO: 29).

[0083] In one aspect, described herein is an antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising a heavy chain variable region (VH) comprising a VH complementarity determining region ("CDR") 1, a VH CDR 2, and a VH CDR3, wherein:

[0084] (i) the VH CDR 1 has the amino acid sequence GYTFTSY (SEQ ID NO: 30), the VH CDR 2 has the amino acid sequence NPRNGG (SEQ ID NO: 31), and the VH CDR 3 has the amino acid sequence SGYYAMDY (SEQ ID NO: 32);

[0085] (ii) the VH CDR 1 has the amino acid sequence GYTFTSYYMY (SEQ ID NO: 62), the VH CDR 2 has the amino acid sequence GINPRNGGTN (SEQ ID NO: 65), and the VH CDR 3 has the amino acid sequence SGYYAMDY (SEQ ID NO: 32);

[0086] (iii) the VH CDR 1 has the amino acid sequence SYYMY (SEQ ID NO: 63), the VH CDR 2 has the amino acid sequence GINPRNGGTNFNEKFKN (SEQ ID NO: 66), and the VH CDR 3 has the amino acid sequence SGYYAMDY (SEQ ID NO: 32); or

[0087] (iv) the VH CDR 1 has the amino acid sequence TSYYMY (SEQ ID NO: 64), the VH CDR 2 has the amino acid sequence WIGGINPRNGGTN (SEQ ID NO: 67), and the VH CDR 3 has the amino acid sequence TRSGYYAMD (SEQ ID NO: 68).

[0088] In one aspect, described herein is an antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising a VH, wherein the VH comprises a VH CDR1, a VH CDR2, and a VH CDR 3, wherein:

[0089] (i) the VH CDR 3 has the amino acid sequence SGYYAMDY (SEQ ID NO: 32); or

[0090] (ii) the VH CDR 3 has the amino acid sequence TRSGYYAMD (SEQ ID NO: 68).

[0091] In one aspect, described herein are antibodies or fragments further comprising a light chain variable region (VL) comprising a VL complementarity determining region ("CDR") 1, a VL CDR 2, and a VL CDR 3, wherein:

[0092] (i) the VL CDR 1 has the amino acid sequence RASQDISNFLN (SEQ ID NO: 33), the VL CDR 2 has the amino acid sequence YTSRLHS (SEQ ID NO: 34), and the VL CDR 3 has the amino acid sequence QQGNTLPRT (SEQ ID NO: 35); or

[0093] (ii) the VL CDR 1 has the amino acid sequence SNFLNWY (SEQ ID NO: 69), the VL CDR 2 has the amino acid sequence LLIYYTSRLH (SEQ ID NO: 70), and the VL CDR 3 has the amino acid sequence QQGNTLPR (SEQ ID NO: 71).

[0094] In one aspect, described herein is an antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising:

[0095] (a) a heavy chain variable region (VH), comprising VH complementarity determining region ("CDR") 1, VH CDR 2, and VH CDR 3, wherein:

[0096] (i) the VH CDR 1 has the amino acid sequence GYTFTSY (SEQ ID NO: 30), the VH CDR 2 has the amino acid sequence NPRNGG (SEQ ID NO: 31), and the VH CDR 3 has the amino acid sequence SGYYAMDY (SEQ ID NO: 32);

[0097] (ii) the VH CDR 1 has the amino acid sequence GYTFTSYYMY (SEQ ID NO: 62), the VH CDR 2 has the amino acid sequence GINPRNGGTN (SEQ ID NO: 65), and the VH CDR 3 has the amino acid sequence SGYYAMDY (SEQ ID NO: 32);

[0098] (iii) the VH CDR 1 has the amino acid sequence SYYMY (SEQ ID NO: 63), the VH CDR 2 has the amino acid sequence GINPRNGGTNFNEKFKN (SEQ ID NO: 66), and the VH CDR 3 has the amino acid sequence SGYYAMDY (SEQ ID NO: 32); or

[0099] (iv) the VH CDR 1 has the amino acid sequence TSYYMY (SEQ ID NO: 64), the VH CDR 2 has the amino acid sequence WIGGINPRNGGTN (SEQ ID NO: 67), and the VH CDR 3 has the amino acid sequence TRSGYYAMD (SEQ ID NO: 68); and

[0100] (b) a light chain variable region (VL), comprising VL complementarity determining region ("CDR") 1, VL CDR 2, and VL CDR 3, wherein:

[0101] (i) the VL CDR 1 has the amino acid sequence RASQDISNFLN (SEQ ID NO: 33), the VL CDR 2 has the amino acid sequence YTSRLHS (SEQ ID NO: 34), and the VL CDR 3 has the amino acid sequence QQGNTLPRT (SEQ ID NO: 35); or

[0102] (ii) the VL CDR 1 has the amino acid sequence SNFLNWY (SEQ ID NO: 69), the VL CDR 2 has the amino acid sequence LLIYYTSRLH (SEQ ID NO: 70), and the VL CDR 3 has the amino acid sequence QQGNTLPR (SEQ ID NO: 71).

[0103] In one aspect, described herein is an antibody or fragment thereof that specifically binds to HDM2, comprising a VH having the amino acid sequence of SEQ ID NO: 36, or a VH having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 36.

[0104] In one aspect, described herein are antibodies or fragments thereof that specifically bind to HDM2, comprising a VL having the amino acid sequence of SEQ ID NO: 37, or a VL having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 37 (and optionally, a VH having the amino acid sequence of SEQ ID NO: 36, or a VH having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 36).

[0105] In one aspect, described herein is an antibody or fragment thereof that specifically binds to HDM2, comprising a VH having the amino acid sequence of SEQ ID NO: 38, or a VH having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 38.

[0106] In one aspect, described herein are antibodies or fragments thereof that specifically bind to HDM2, comprising a VL having the amino acid sequence of SEQ ID NO: 39, or a VL having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 39 (and optionally, a VH having the amino acid sequence of SEQ ID NO: 38, or a VH having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 38).

[0107] In one aspect, described herein are antibodies or fragments thereof that specifically bind to HDM2, comprising a VH having the amino acid sequence of SEQ ID NO: 40, or a VH having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 40.

[0108] In one aspect, described herein are antibodies or fragments thereof that specifically bind to HDM2, comprising a VL having the amino acid sequence of SEQ ID NO: 41, or a VL having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 41 (and optionally, a VH having the amino acid sequence of SEQ ID NO: 40, or a VH having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 40).

[0109] In preferred embodiments, the anti-M(H)DM2 / 4 antibodies described herein are monoclonal antibodies. In certain embodiments, the anti-M(H)DM2 / 4 antibodies described herein are human antibodies, humanized antibodies, or chimeric antibodies (e.g., human monoclonal antibodies, humanized monoclonal antibodies, or chimeric monoclonal antibodies). In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein are human antibodies. In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein are humanized antibodies. In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein are chimeric antibodies.

[0110] In certain embodiments, the anti-M(H)DM2 / 4 antibodies described herein are purified antibodies.

[0111] In certain embodiments, the anti-M(H)DM2 / 4 antibodies described herein are immunoglobulins (e.g., IgG or IgM). In one embodiment, the immunoglobulin is IgG. In one embodiment, the immunoglobulin is IgM. In certain embodiments, the immunoglobulin is of the IgG1 isotype. In other embodiments, the immunoglobulin is of the IgG3 isotype. In other embodiments, the immunoglobulin is of the IgG2 isotype. In certain embodiments, the anti-M(H)DM2 / 4 antibodies described herein comprise an Fc region, wherein the Fc region is a human IgG Fc region or a human IgM Fc region. In specific embodiments, the anti-M(H)DM2 / 4 antibodies described herein comprise an Fc region that is a human IgG1 Fc region, a human IgG2 Fc region, or a human IgG3 Fc region. In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein comprise a human IgG1 Fc region. In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein comprise a human IgG3 Fc region. In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein comprise a human IgG2 Fc region. In one embodiment, an anti-M(H)DM2 / 4 antibody described herein comprises a human IgM Fc region. In one embodiment, an anti-M(H)DM2 / 4 antibody described herein comprises a human IgE Fc region.

[0112] In certain embodiments, the anti-M(H)DM2 / 4 antibodies or fragments described herein are antigen-binding fragments of anti-M(H)DM2 / 4 antibodies. In certain embodiments, the antibodies or fragments described herein are Fv fragments, Fab fragments, Fab′ fragments, F(ab′)2 fragments, single-chain antibody molecules, or single-chain Fv (scFv). In one embodiment, the antibodies or fragments described herein are Fv fragments. In one embodiment, the antibodies or fragments described herein are Fab fragments. In one embodiment, the antibodies or fragments described herein are Fab′ fragments. In one embodiment, the antibodies or fragments described herein are F(ab′)2 fragments. In one embodiment, the antibodies or fragments described herein are single-chain antibody molecules. In one embodiment, the antibodies or fragments described herein are single-chain Fv (scFv).

[0113] In certain embodiments, the anti-M(H)DM2 / 4 antibodies or antigen-binding fragments described herein mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC). In one embodiment, the anti-M(H)DM2 / 4 antibodies or antigen-binding fragments mediate complement-dependent cytotoxicity (CDC).

[0114] In certain embodiments, the anti-M(H)DM2 / 4 antibodies described herein are bispecific antibodies that also specifically bind to cell surface antigens of effector cells (e.g., T cells, B lymphocytes, neutrophils, macrophages, natural killer cells, or dendritic cells).

[0115] In one embodiment, the antibodies or fragments described herein specifically bind to an extracellularly accessible epitope of M(H)DM2 (e.g., HDM2) and do not bind to M(H)DM4 (e.g., HDM4). In another embodiment, the antibodies or fragments described herein specifically bind to an extracellularly accessible epitope of both M(H)DM2 (e.g., HDM2) and M(H)DM4 (e.g., HDM4). In one embodiment, the antibodies or fragments described herein specifically bind to an extracellularly accessible epitope of HDM2 and, optionally, may also bind to an extracellularly accessible epitope of MDM2.

[0116] In a specific embodiment, the anti-HDM2 antibodies or fragments described herein specifically bind to HDM2 within the amino acids of SEQ ID NO: 1, which are amino acids 1 to 15 of HDM2 (SEQ ID NO: 4). In another specific embodiment, the anti-HDM2 antibodies described herein specifically bind to HDM2 within the amino acids of SEQ ID NO: 2, which are amino acids 15 to 25 of HDM2 (SEQ ID NO: 4). In another specific embodiment, the anti-HDM2 antibodies described herein specifically bind to HDM2 within the amino acids of SEQ ID NO: 3, which are amino acids 475-491 of HDM2 (SEQ ID NO: 4). In another specific embodiment, the anti-HDM2 antibodies described herein specifically bind to HDM2 within amino acids 19 to 50 of SEQ ID NO: 4. In another specific embodiment, the anti-HDM2 antibodies described herein specifically bind to amino acids 154 to 167 of SEQ ID NO: 4. In yet another specific embodiment, the anti-HDM2 antibodies described herein specifically bind to amino acids 1 to 60 of SEQ ID NO: 4. In yet another specific embodiment, the anti-HDM2 antibodies described herein specifically bind within amino acids 1 to 100 of SEQ ID NO:4. In another specific embodiment, the anti-HDM2 antibodies described herein specifically bind within amino acids 100 to 110 of SEQ ID NO:4. In another specific embodiment, the anti-HDM2 antibodies described herein specifically bind within amino acids 50 to 6 of SEQ ID NO:4. In yet another specific embodiment, the anti-HDM2 antibodies described herein specifically bind within amino acids 1 to 109 of SEQ ID NO:4. In another specific embodiment, the anti-HDM2 antibodies described herein specifically bind within amino acids 26 to 60 of SEQ ID NO:4. In one specific embodiment, the anti-HDM2 antibodies described herein specifically bind within the terminal 60 amino acids of the C-terminus of HDM2 on the plasma membrane of cancer cells. In another specific embodiment, the anti-HDM2 antibodies described herein specifically bind within the terminal 100 amino acids of the C-terminus of HDM2 on the plasma membrane of cancer cells.

[0117] In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein do not bind within amino acids 101 to 200 of SEQ ID NO: 4. In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein do not bind to HDM2 or an epitope of MDM2 bound by "MDM2 Monoclonal Antibody (M01) Clone 1A7" (Abnova, Catalog No. H00004193-M01). In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein do not compete with "MDM2 Monoclonal Antibody (M01) Clone 1A7" (Abnova, Catalog No. H00004193-M01) for binding to HDM2.

[0118] In another embodiment, the anti-M(H)DM2 / 4 antibodies described herein bind within amino acids 101 to 200 of SEQ ID NO: 4. In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein bind to HDM2 or an epitope of MDM2 bound by "MDM2 Monoclonal Antibody (M01) Clone 1A7" (Abnova, Catalog No. H00004193-M01). In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein compete with "MDM2 Monoclonal Antibody (M01) Clone 1A7" (Abnova, Catalog No. H00004193-M01) for binding to HDM2.

[0119] In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein do not bind within amino acids 153 to 222 of SEQ ID NO: 4. In one embodiment, the anti-M(H)DM2 / 4 antibodies described herein do not bind within amino acids 26 to 169 of SEQ ID NO: 4. In specific embodiments, the anti-M(H)DM2 / 4 antibodies described herein do not bind within amino acids 26 to 222 of SEQ ID NO: 4.

[0120] In certain embodiments, the M(H)DM2 / 4 exposed on the surface of cancer cells and targeted by the antibodies or fragments described herein is a variant of M(H)DM2 / 4 lacking one or more nuclear localization signal domains. In specific embodiments, the HDM2 exposed on the surface of cancer cells and targeted by the antibodies or fragments described herein is a variant of HDM2 lacking the sequence of amino acids 179 to 185 of SEQ ID NO: 4 and / or the sequence of amino acids 464 to 471 of SEQ ID NO: 4. In one embodiment, the HDM2 exposed on the surface of cancer cells and targeted by the antibodies or fragments described herein is a variant of HDM2 lacking the sequence of amino acids 181 to 185 of SEQ ID NO: 4.

[0121] In one aspect, provided herein are antibodies or fragments thereof that compete for binding to M(H)DM2 / 4 with an anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibody or fragment thereof described herein. Preferably, such an antibody or fragment that competes for binding is a monoclonal antibody or fragment thereof.

[0122] In one aspect, provided herein are antibodies or fragments thereof that compete for binding to M(H)DM2 / 4 with a mouse anti-HDM2 immunoglobulin (preferably IgG) antibody selected from the group consisting of: (i) an antibody comprising a heavy chain variable region (VH) having the amino acid sequence of SEQ ID NO: 36 and a light chain variable region (VL) having the amino acid sequence of SEQ ID NO: 37; (ii) an antibody comprising a VH having the amino acid sequence of SEQ ID NO: 38 and a VL having the amino acid sequence of SEQ ID NO: 39; and (iii) an antibody comprising a VH having the amino acid sequence of SEQ ID NO: 40 and a VL having the amino acid sequence of SEQ ID NO: 41.

[0123] In one aspect, provided herein are antibodies or fragments thereof that: (i) compete for binding to a peptide of sequence SEQ ID NO: 1 with a mouse anti-HDM2 IgG1 antibody comprising a heavy chain variable region (VH) having the amino acid sequence of SEQ ID NO: 36 and a light chain variable region (VL) having the amino acid sequence of SEQ ID NO: 37; or (ii) compete for binding to a peptide of sequence SEQ ID NO: 2 with a mouse anti-HDM2 IgG3 antibody comprising a VH having the amino acid sequence of SEQ ID NO: 38 and a VL having the amino acid sequence of SEQ ID NO: 39; or (iii) compete for binding to a peptide of sequence SEQ ID NO: 3 with a mouse IgM antibody comprising a VH having the amino acid sequence of SEQ ID NO: 40 and a VL having the amino acid sequence of SEQ ID NO: 41.

[0124] In one aspect, provided herein are antibody-drug conjugates comprising any of the antibodies or fragments described herein (e.g., an antibody-drug conjugate wherein an anti-M(H)DM2 / 4 antibody or fragment described herein is covalently bound to a cytotoxic drug).

[0125] In one aspect, provided herein are pharmaceutical compositions comprising a therapeutically effective amount of any of the antibodies or fragments described herein.

[0126] In one aspect, provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject: (i) any anti-M(H)DM2 / 4 antibody described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide); or an antibody-drug conjugate comprising the antibody or fragment bound to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one aspect, provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject: an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2), wherein the antibody or fragment is not bound to a cytotoxic component. In one aspect, provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject: (i) any anti-HDM2 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment thereof that binds to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one embodiment, the method comprises administering to the subject an antibody-drug conjugate comprising an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2 / 4 that is bound to a cytotoxic drug, wherein the antibody or fragment is not bound to a cell-penetrating peptide. In one embodiment, provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide, wherein the sequence of the peptide consists of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3). In one embodiment, provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, which is contained within a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0127] In one aspect, provided herein are methods for inhibiting tumor growth in a subject in need thereof, comprising administering to the subject: (i) any anti-M(H)DM2 / 4 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment that is bound to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one aspect, provided herein are methods for inhibiting tumor growth in a subject in need thereof, comprising administering to the subject: an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2), wherein the antibody or fragment is not bound to a cytotoxic component. In one aspect, provided herein are methods for inhibiting tumor growth in a subject in need thereof, the method comprising administering to the subject: (i) any anti-HDM2 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment thereof that binds to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one embodiment, the method comprises administering to the subject an antibody-drug conjugate comprising an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2 / 4 that is bound to a cytotoxic drug, wherein the antibody or fragment is not bound to a cell-penetrating peptide. In one embodiment, provided herein are methods of inhibiting tumor growth in a subject in need thereof, comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide, wherein the sequence of the peptide consists of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3). In one embodiment, provided herein are methods of inhibiting tumor growth in a subject in need thereof, comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, which is contained within a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0128] In one aspect, provided herein are methods for inhibiting tumor progression in a subject in need thereof, comprising administering to the subject: (i) any anti-M(H)DM2 / 4 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment that binds to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one aspect, provided herein are methods for inhibiting tumor progression in a subject in need thereof, comprising administering to the subject: an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2), wherein the antibody or fragment is not bound to a cytotoxic component. In one aspect, provided herein are methods for inhibiting tumor progression in a subject in need thereof, the methods comprising administering to the subject: (i) any anti-HDM2 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment thereof that binds to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one embodiment, the method comprises administering to the subject an antibody-drug conjugate comprising an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2 / 4 that is bound to a cytotoxic drug, wherein the antibody or fragment is not bound to a cell-penetrating peptide. In one embodiment, provided herein are methods for inhibiting tumor progression in a subject in need thereof, comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide, wherein the sequence of the peptide consists of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3). In one embodiment, provided herein are methods for inhibiting tumor progression in a subject in need thereof, comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, which is contained within a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0129] In one aspect, provided herein are methods for preventing the recurrence or relapse of cancer in a subject in need thereof (e.g., a subject in remission from cancer), the methods comprising administering to the subject: (i) any anti-M(H)DM2 / 4 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment that binds to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one aspect, provided herein are methods for preventing the recurrence or relapse of cancer in a subject in need thereof (e.g., a subject in remission from cancer), the methods comprising administering to the subject: an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2), wherein the antibody or fragment is not bound to a cytotoxic component. In one aspect, provided herein are methods for preventing recurrence or relapse of cancer in a subject in need thereof (e.g., a subject in remission from cancer), the method comprising administering to the subject: (i) any anti-HDM2 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment thereof that binds to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one embodiment, the method comprises administering to the subject an antibody-drug conjugate comprising an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2 / 4 that is bound to a cytotoxic drug, wherein the antibody or fragment is not bound to a cell-penetrating peptide. In one embodiment, provided herein are methods for preventing recurrence or relapse of cancer in a subject in need thereof (e.g., a subject in remission from cancer), comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide, wherein the sequence of the peptide consists of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3).In one embodiment, provided herein are methods for preventing recurrence or relapse of cancer in a subject in need thereof (e.g., a subject in remission from cancer), comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 that is contained within a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0130] In one aspect, provided herein are methods for improving survival in a subject having cancer (e.g., relative to a subject not treated with an anti-M(H)DM2 / 4 antibody or fragment), comprising administering to the subject: (i) any anti-M(H)DM2 / 4 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment is not bound to a cell penetrating peptide (e.g., a membrane resident peptide), or an antibody-drug conjugate comprising an antibody or fragment bound to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one aspect, provided herein are methods for improving survival in a subject having cancer (e.g., relative to a subject not treated with an anti-M(H)DM2 / 4 antibody or fragment), comprising administering to the subject: an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2), wherein the antibody or fragment is not bound to a cytotoxic component. In one aspect, provided herein are methods for improving survival in a subject having cancer (e.g., relative to a subject not treated with an anti-M(H)DM2 / 4 antibody or fragment), comprising administering to the subject: (i) any anti-HDM2 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising the antibody or fragment bound to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one embodiment, the method comprises administering to the subject an antibody-drug conjugate comprising an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 conjugated to a cytotoxic drug, wherein the antibody or fragment is not bound to a cell penetrating peptide. In one embodiment, provided herein are methods for improving survival in a subject having cancer (e.g., relative to a subject not treated with an anti-M(H)DM2 / 4 antibody or fragment), the method comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide, wherein the sequence of the peptide consists of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3).In one embodiment, provided herein are methods for improving survival in a subject having cancer (e.g., relative to a subject not treated with an anti-M(H)DM2 / 4 antibody or fragment), the method comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 that is contained within a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0131] In one aspect, provided herein are methods for preventing metastasis in a subject having cancer, comprising administering to the subject: (i) any anti-M(H)DM2 / 4 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment that is bound to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one aspect, provided herein are methods for preventing metastasis in a subject in need thereof, comprising administering to the subject: an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2), wherein the antibody or fragment is not bound to a cytotoxic component. In one aspect, provided herein are methods for preventing metastasis in a subject having cancer, the method comprising administering to the subject: (i) any anti-HDM2 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment thereof that binds to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one embodiment, the method comprises administering to the subject an antibody-drug conjugate comprising an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2 / 4 that is bound to a cytotoxic drug, wherein the antibody or fragment is not bound to a cell-penetrating peptide. In one embodiment, provided herein are methods for preventing metastasis in a subject having cancer, comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide, wherein the sequence of the peptide consists of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3). In one embodiment, provided herein are methods for preventing metastasis in a subject having cancer, comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, which is contained within a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0132] In one aspect, provided herein are methods for inhibiting metastasis (e.g., reducing the number, size, or invasiveness of metastases) in a subject having metastatic cancer, comprising administering to the subject: (i) any anti-M(H)DM2 / 4 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an exposed extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment that is bound to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one aspect, provided herein are methods for inhibiting metastasis in a subject in need thereof, comprising administering to the subject: an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2), wherein the antibody or fragment is not bound to a cytotoxic component. In one aspect, provided herein are methods for inhibiting metastasis (e.g., reducing the number, size, or invasiveness of metastases) in a subject with metastatic cancer, the method comprising administering to the subject: (i) any anti-HDM2 antibody or fragment described herein; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2, wherein the antibody or fragment is not bound to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment thereof that binds to a cytotoxic drug (i.e., the antibody or fragment is not bound to a cell-penetrating peptide), (iii) any pharmaceutical composition described herein, or (iv) any antibody-drug conjugate described herein. In one embodiment, the method comprises administering to the subject an antibody-drug conjugate comprising an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2 / 4 that is bound to a cytotoxic drug, wherein the antibody or fragment is not bound to a cell-penetrating peptide. In one embodiment, provided herein are methods for inhibiting metastasis (e.g., reducing the number, size, or invasiveness of metastases) in a subject having metastatic cancer, the method comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide, wherein the sequence of the peptide consists of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3).In one embodiment, provided herein are methods for inhibiting metastasis (e.g., reducing the number, size, or invasiveness of metastases) in a subject having metastatic cancer, the method comprising administering to the subject an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 that is contained within a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

[0133] In one aspect, provided herein are methods for selecting and treating a subject (e.g., a human) having cancer, the methods comprising: (a) identifying a subject having cancer in which an antibody or fragment thereof (e.g., a labeled antibody or fragment) that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) is bound to the surface of intact cells of the cancer; and (b) administering to the subject: (i) any M(H)DM2 / 4 (e.g., anti-HDM2) antibody or fragment described herein, or an anti-M(H)DM2 / 4 antibody or fragment thereof comprising the antibody or fragment (e.g., an anti-M(H)DM2 / 4 antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4), wherein the antibody or fragment specifically binds to a peptide, wherein the sequence of the peptide is represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. NO:3) antibody-drug conjugate; (ii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2), wherein the antibody or fragment does not bind to a cell-penetrating peptide (e.g., a membrane-resident peptide), or an antibody-drug conjugate comprising an antibody or fragment that binds to a cytotoxic drug (i.e., the antibody or fragment does not bind to a cell-penetrating peptide), (iii) an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2), wherein the antibody or fragment does not bind to a cytotoxic component, (iv) any pharmaceutical composition described herein, or (v) any antibody-drug conjugate described herein. The antibody or fragment thereof of step (b) can be the same or different from the antibody or fragment thereof of step (a). In certain embodiments, the methods provided herein further comprise a step of determining whether the antibody or fragment thereof is bound to the surface of intact cells of the cancer (e.g., using FACS or cell-based ELISA analysis) prior to step (b) (using any anti-M(H)DM2 / 4 antibody described herein). In one embodiment, the methods provided herein further comprise the step of obtaining intact cells of the cancer prior to the determining step (e.g., by biopsy of a cancerous tumor in the subject, or by obtaining a blood sample having circulating cancer cells from the subject). In one embodiment, the method comprises administering to the subject an antibody-drug conjugate comprising an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 conjugated to a cytotoxic drug, wherein the antibody or fragment is not conjugated to a cell penetrating peptide.

[0134] In one aspect, provided herein are methods for selecting a subject (e.g., a human) for treatment and treating cancer in a subject, the methods comprising: (a) selecting a subject having cancer for treatment by: (i) obtaining intact cancer cells from the subject (e.g., by biopsy of a cancerous tumor from the subject, or by obtaining a blood sample having circulating cancer cells from the subject), and (ii) determining whether an antibody or fragment thereof (e.g., a labeled antibody or fragment) that specifically binds to M(H)DM2 / 4 (e.g., an antibody or fragment that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4, such as any anti-M(H)DM2 / 4 antibody or fragment described herein) is bound to the surface of the intact cancer cells obtained from the subject (e.g., using FACS or cell-based ELISA analysis), and (b) if binding is detected in step (a), administering the antibody or fragment to the subject, wherein the antibody or fragment is not bound to a cell penetrating peptide. In one aspect, provided herein are methods of selecting a subject for treatment and treating cancer in a subject, the methods comprising: (a) selecting a subject having cancer for treatment by: (i) obtaining intact cancer cells from the subject (e.g., by performing a biopsy of a cancerous tumor from the subject, or by obtaining a blood sample having circulating cancer cells from the subject), and (ii) determining whether an antibody or fragment thereof that specifically binds to HDM2 (e.g., an antibody or fragment that specifically binds to an extracellularly accessible epitope of HDM2, such as any anti-HDM2 / 4 antibody or fragment described herein) is bound to the surface of the intact cancer cells obtained from the subject (e.g., using FACS or cell-based ELISA analysis), and (b) if binding is detected in step (a), administering the antibody or fragment to the subject, wherein the antibody or fragment is not bound to a cell penetrating peptide.

[0135] In certain embodiments, the cancer treated according to the methods described herein is a type of cancer known to metastasize. In some embodiments, the cancer treated according to the methods described herein is an advanced cancer. In other embodiments, the cancer treated according to the methods described herein is an early stage cancer. In specific embodiments, the cancer treated according to the methods described herein is a metastatic cancer. The cancer treated can be a solid cancer or a non-solid cancer (e.g., leukemia).

[0136] In certain embodiments, the cancer treated according to the methods described herein is cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, melanoma (e.g., uveal melanoma), breast cancer, colorectal cancer (e.g., colon cancer), bladder cancer, astrocytoma, glioblastoma, childhood rhabdomyosarcoma, or lung cancer (e.g., non-small cell lung cancer). In specific embodiments, the cancer treated according to the methods described herein is melanoma, pancreatic cancer, breast cancer, or ovarian cancer. In one embodiment, the cancer treated according to the methods described herein is lung cancer. In one embodiment, the cancer treated according to the methods described herein is colorectal cancer. In one embodiment, the cancer treated according to the methods described herein is colon cancer. In one embodiment, the cancer treated according to the methods described herein is melanoma. In one embodiment, the cancer treated according to the methods described herein is pancreatic cancer. In one embodiment, the cancer treated according to the methods described herein is breast cancer. In one embodiment, the cancer treated according to the methods described herein is ovarian cancer.

[0137] The subject treated according to the methods described herein can be a human or a non-human animal (such as a mammal). In a preferred embodiment, the subject is a human.

[0138] In certain embodiments, the anti-M(H)DM2 / 4 antibodies or fragments described herein are administered intravenously, intraperitoneally, intramuscularly, subcutaneously, or intratumorally. In other embodiments, the anti-M(H)DM2 / 4 antibodies or fragments described herein are administered orally.

[0139] In certain embodiments, the subject treated according to the methods described herein is also administered an additional anti-cancer treatment (e.g., vaccine, targeted therapy, chemotherapy, radiotherapy, surgery or immunotherapy) different from the antibody or fragment or antibody-drug conjugate. In one embodiment, additional treatment is a vaccine. In one embodiment, additional treatment is targeted therapy. In one embodiment, additional treatment is chemotherapy (e.g., a combination of gemcitabine, paclitaxel, albumin-bound paclitaxel or gemcitabine and albumin-bound paclitaxel). In one embodiment, additional treatment is immunotherapy. In one embodiment, additional treatment is radiotherapy. In one embodiment, additional treatment is surgery (e.g., removing part or all of the cancerous tumor being treated). In a specific embodiment, additional treatment is an inhibitor of one or more checkpoint inhibitory molecule functions (e.g., inhibitors, such as inhibitory antibodies for one or more of the following: CTLA-4, PD-1, PD-L1, PD-L2, TIM-3, OX40 and LAG-3). In certain embodiments, additional treatment is not a cell cycle inhibitor. In specific embodiments, a cell cycle inhibitor is not administered to a subject treated using the methods described herein during treatment with the antibody or fragment. In certain embodiments, an anti-M(H)DM2 / 4 antibody or fragment described herein is administered alone without any additional anti-cancer therapy (e.g., no additional anti-cancer therapy is administered to a subject treated using the methods described herein during treatment with the antibody or fragment).

[0140] In certain embodiments, a subject treated according to the methods described herein is further administered chemotherapy, wherein the chemotherapy is cisplatin. In certain embodiments, a subject treated according to the methods described herein is further administered chemotherapy, wherein the chemotherapy is 5-FU. In certain embodiments, a subject treated according to the methods described herein is further administered chemotherapy, wherein the chemotherapy is paclitaxel. In certain embodiments, a subject treated according to the methods described herein is further administered chemotherapy, wherein the chemotherapy is paclitaxel formulated as albumin-bound particles (e.g., ). In certain embodiments, chemotherapy is further administered to the subject treated according to the methods described herein, wherein the chemotherapy is gemcitabine (e.g., wherein the cancer being treated is pancreatic cancer). In certain embodiments, chemotherapy is further administered to the subject treated according to the methods described herein, wherein the chemotherapy is albumin-bound paclitaxel (e.g., wherein the cancer being treated is pancreatic cancer). In certain embodiments, the cancer is pancreatic cancer, and chemotherapy is further administered to the subject treated according to the methods described herein, wherein the chemotherapy is a combination of gemcitabine and albumin-bound paclitaxel. In certain embodiments, the dosage of gemcitabine and / or albumin-bound paclitaxel administered is lower than the dosage when gemcitabine and / or albumin-bound paclitaxel is not administered in combination with an anti-cancer antibody (e.g., an anti-M(H)DM2 / 4 antibody or fragment as described herein). In certain embodiments, wherein the subject is a human, gemcitabine is administered at a dose of less than 1,500 mg / m 2 and / or nab-paclitaxel at a dose of less than 300 mg / m 2 In one embodiment, wherein the subject is a human, gemcitabine is administered at a dose equal to or less than 1,000 mg / m 2 and / or nab-paclitaxel at a dose equal to or less than 125 mg / m 2 In one embodiment, wherein the subject is a human, gemcitabine is administered at a dose equal to or less than 500 mg / m 2 and / or nab-paclitaxel at a dose equal to or less than 62.5 mg / m 2 In certain embodiments, the combination of gemcitabine and nab-paclitaxel is administered every 2 weeks or less frequently.

[0141] In certain embodiments, the subject treated according to the methods described herein is resistant to other cancer treatments (e.g., vaccines, targeted therapy, chemotherapy, radiotherapy, surgery, or immunotherapy). In specific embodiments, the subject treated according to the methods described herein is resistant to chemotherapy. In one embodiment, the subject treated according to the methods described herein has chemotherapy-resistant ovarian cancer. In other embodiments, the subject treated according to the methods described herein is resistant to inhibitors of one or more inhibitory immune checkpoint molecules. In other embodiments, the subject treated according to the methods described herein is resistant to radiation therapy.

[0142] In a specific embodiment, the anti-M(H)DM2 / 4 antibodies or fragments used in the methods described herein specifically bind within amino acids 19 to 50 of SEQ ID NO: 4. In another specific embodiment, the anti-M(H)DM2 / 4 antibodies used in the methods described herein specifically bind within amino acids 154 to 167 of SEQ ID NO: 4. In yet another specific embodiment, the anti-M(H)DM2 / 4 antibodies used in the methods described herein specifically bind within amino acids 1 to 60 of SEQ ID NO: 4. In yet another specific embodiment, the anti-M(H)DM2 / 4 antibodies used in the methods described herein specifically bind within amino acids 1 to 100 of SEQ ID NO: 4. In yet another specific embodiment, the anti-M(H)DM2 / 4 antibodies used in the methods described herein specifically bind within amino acids 1 to 109 of SEQ ID NO: 4. In another specific embodiment, the anti-M(H)DM2 / 4 antibodies used in the methods described herein specifically bind within amino acids 26 to 60 of SEQ ID NO: 4. In a specific embodiment, the anti-M(H)DM2 / 4 antibodies used in the methods described herein specifically bind within the terminal 60 amino acids of the C-terminus of HDM2 on the plasma membrane of cancer cells. In another specific embodiment, the anti-M(H)DM2 / 4 antibodies used in the methods described herein specifically bind within the terminal 100 amino acids of the C-terminus of HDM2 on the plasma membrane of cancer cells. In a specific embodiment, the anti-M(H)DM2 / 4 antibodies used in the methods described herein specifically bind within amino acids 101 to 200 of SEQ ID NO:4.

[0143] In specific embodiments, the anti-M(H)DM2 / 4 antibodies or fragments used in the methods described herein compete for binding to M(H)DM2 / 4 with the mouse anti-HDM2 antibody OP145 (described herein, see, e.g., Table 10). In other specific embodiments, the anti-M(H)DM2 / 4 antibodies or fragments used in the methods described herein compete for binding to M(H)DM2 / 4 with the mouse anti-HDM2 antibody 965 (SMP14) (described herein, see, e.g., Tables 3 and 10). In yet other specific embodiments, the anti-M(H)DM2 / 4 antibodies or fragments used in the methods described herein compete for binding to M(H)DM2 / 4 with the rabbit anti-HDM2 antibody sc-813 (N-20) (described herein, see, e.g., Table 10). In another embodiment, the anti-M(H)DM2 / 4 antibodies or fragments used in the methods described herein compete for binding to M(H)DM2 / 4 with the rabbit anti-HDM2 antibody sc-812 (C-18) (described herein, see, e.g., Table 10). In another embodiment, the anti-M(H)DM2 / 4 antibody or fragment used in the methods described herein competes for binding to M(H)DM2 / 4 with the mouse anti-HDM2 antibody M01 clone 1A7 (described herein, see, e.g., Table 3).

[0144] In certain aspects, provided herein are methods for treating cancer or preventing metastasis in a subject in need thereof, comprising administering to the subject any of the anti-M(H)DM2 / 4 antibodies described herein (e.g., an antibody that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 on the surface of the cancer cell), wherein the antibody comprises a human IgG Fc region that mediates complement dependent cytotoxicity (CDC) and / or antibody-dependent cell-mediated cytotoxicity (ADCC). In some of these embodiments, the extracellular region of HDM2 targeted by the anti-HDM2 antibodies or fragments used herein is within one of the following amino acid regions of HDM2: amino acids of SEQ ID NO: 1 (which are amino acids 1 to 15 of SEQ ID NO: 4), amino acids of SEQ ID NO: 2 (which are amino acids 15 to 25 of SEQ ID NO: 4), amino acids of SEQ ID NO: 3 (which are amino acids 475 to 491 of SEQ ID NO: 4), amino acids 19 to 50 of SEQ ID NO: 4, amino acids 50 to 60 of SEQ ID NO: 4, amino acids 100 to 110 of SEQ ID NO: 4, amino acids 154 to 167 of SEQ ID NO: 4, amino acids 1 to 60 of SEQ ID NO: 4, or the terminal 60 amino acids of the C-terminus of HDM2 on the plasma membrane of a cancer cell. In certain embodiments of the methods described in this paragraph, the cancer is leukemia, lung cancer, colon cancer, melanoma, pancreatic cancer, breast cancer, or ovarian cancer.

[0145] In one aspect, provided herein are methods for diagnosing cancer in a subject (e.g., a human), the method comprising: (a) detecting whether an antibody or fragment thereof (e.g., a labeled antibody or fragment) that specifically binds to M(H)DM2 / 4 (e.g., HDM2) is bound to the surface of intact cells of the subject, wherein the antibody or fragment is any anti-M(H)DM2 / 4 antibody or fragment described herein (in preferred examples, wherein the antibody or fragment is any anti-M(H)DM2 / 4 antibody or fragment that specifically binds to a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3); and (b) if binding is detected in step (a), diagnosing the subject with cancer. In one embodiment, the diagnostic method is an ex vivo method. In one embodiment, the diagnostic method further comprises obtaining intact cells from the subject prior to step (a). In one embodiment, the diagnostic method comprises administering the antibody or fragment to the subject prior to the detecting in step (a), and wherein the detecting is performed by in vivo imaging of the subject.

[0146] 5.1 Terminology

[0147] As used herein, the term "HDM2" refers to the protein product of human E3 ubiquitin-protein ligase (SEQ ID NO: 4) of UniProt Accession No. Q00987 (i.e., full-length HDM2 protein) or any splice variant of the full-length HDM2 protein known in the art or described herein. The amino acid sequences of exemplary splice variants of the full-length HDM2 protein are shown in SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

[0148] As used herein, the term "MDM2" refers to the protein product of the mouse E3 ubiquitin-protein ligase of UniProt Accession No. P23804 (SEQ ID NO: 5) (i.e., full-length MDM2 protein) or any splice variant of the full-length MDM2 protein known in the art or described herein.

[0149] As used herein, the term "M(H)DM2" refers to HDM2, MDM2, or an E3 ubiquitin-protein ligase from species other than human and mouse that is a homolog of HDM2 or MDM2.

[0150] As used herein, the term "HDM4" refers to the human protein of UniProt Accession No. 015151 (SEQ ID NO: 6) (ie, full-length HDM4 protein) or the protein product of any splice variant of the full-length HDM4 protein known in the art or described herein.

[0151] As used herein, the term "MDM4" refers to the mouse protein of UniProt accession number 035618 (i.e., full-length MDM4 protein) or the protein product of any splice variant of the full-length MDM4 protein known in the art or described herein. The amino acid sequence of an exemplary splice variant of the full-length MDM4 protein is shown as SEQ ID NO: 6. Other splice variants of the full-length MDM4 protein known in the art include, but are not limited to, MDM4-S, MDM4-A, MDM4-G, MDM4-XALT1 / XALT2, and MDM4-211.

[0152] As used herein, the term "M(H)DM4" refers to HDM4 (also known as HDMX), MDM4 (also known as MDMX), or a protein from a species other than human and mouse that is a homolog of HDM4 or MDM4.

[0153] As used herein, the term "M(H)DM2 / 4" refers to HDM2, MDM2, HDM4, MDM4, or a protein from a species other than human and mouse that is a homolog of HDM2, MDM2, HDM4, or MDM4.

[0154] As used herein, the term "about" when used to modify a numerical value means that a deviation of up to 10% above or below the numerical value remains within the intended meaning of the stated value.

[0155] As used herein, the term "intact" with respect to cells refers to cells that are viable or fixed but not permeabilized.

[0156] As used herein, the term "extracellularly accessible" with respect to an epitope of M(H)DM2 / 4 refers to an epitope of M(H)DM2 / 4 that is available for binding to an antibody outside of the cell when M(H)DM2 / 4 is expressed by intact cells (without the need for intracellular trafficking of the antibody). An antibody or fragment thereof can be determined to bind to an extracellularly accessible epitope of M(H)DM2 / 4 when the antibody binds to M(H)DM2 / 4 expressed by intact cells while the antibody is extracellular.

[0157] As used herein, the term "VL" refers to the light chain variable region of an antibody.

[0158] As used herein, the term "VH" refers to the heavy chain variable region of an antibody.

[0159] As used herein, the term "percent (%) amino acid sequence identity" or "percent sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in various ways known in the art, for example, using publicly available computer software such as BLASTp, BLAST-2, ALIGN (e.g., ALIGN-2) or Megalign (DNASTAR) software. 6. Brief Description of the Figures

[0161] Figures 1A-D show monoclonal antibodies NMC-103, NMC-204, and NMC-303 that specifically bind to NMC-P1 (SEQ ID NO: 1), NMC-P2 (SEQ ID NO: 2), and NMC-P3 (SEQ ID NO: 3) peptide antigens, respectively, in peptide-ELISA experiments. (A) NMC-103 binds to the NMC-P1 peptide, while NMC-204 shows no binding to NMC-P1. (B) NMC-204 binds to the NMC-P2 peptide, while NMC-103 does not bind to NMC-P2. (C) NMC-303 binds to the NMC-P3 peptide, while NMC-204 does not bind to NMC-P3. (D) While NMC-103 binds to NMC-P1, preincubation of the NMC-P1 peptide with NMC-103 on the plate eliminates NMC-103 binding to the NMC-P1 peptide. In contrast, preincubation of NMC-103 with NMC-P2 or NMC-P3 did not affect the binding of NMC-103 to NMC-P1.

[0162] Figure 2 The monoclonal antibodies NMC-103, NMC-204, and NMC-303 were shown to bind to the HDM2 recombinant protein.

[0163] Figures 3A-B show that monoclonal antibody NMC-103 binds to an extracellularly accessible epitope of HDM2 on intact human (A) and murine (B) cancer cells.

[0164] Figures 4A-B show that monoclonal antibody NMC-204 binds to an extracellularly accessible epitope of HDM2 on intact human (A) and murine (B) cancer cells.

[0165] Figures 5A-B show that monoclonal antibody NMC-303 binds to an extracellularly accessible epitope of HDM2 on intact human (A) and murine (B) cancer cells.

[0166] Figure 6The monoclonal antibody NMC-204 was shown to bind to an extracellularly accessible epitope of HDM2 on intact human cancer cells, but not on intact normal human peripheral blood mononuclear cells.

[0167] Figures 7A-B depict binding curves of monoclonal antibodies NMC-103 (A) and NMC-204 (B) binding to intact MIA PaCa-2 cells.

[0168] Figures 8A-C show that the binding of monoclonal antibody NMC-103 to the extracellular accessible epitope of HDM2 on the plasma membrane of intact human pancreatic cancer MIA PaCa-2 cells is competed by NMC-P1 peptide (A), the binding of monoclonal antibody NMC-204 to the extracellular accessible epitope of HDM2 on the plasma membrane of intact human pancreatic cancer MIA PaCa-2 cells is competed by NMC-P2 peptide (B), and the binding of monoclonal antibody NMC-303 to the extracellular accessible epitope of HDM2 on the plasma membrane of intact human pancreatic cancer MIA PaCa-2 cells is competed by NMC-P3 peptide (C).

[0169] Figure 9 We show that binding of monoclonal antibody NMC-103 to an extracellularly accessible epitope of HDM2 on the plasma membrane of intact human pancreatic cancer MIA PaCa-2 cells is competed for by full-length recombinant HDM2 protein.

[0170] Figure 10 Shown are the cell-ELISA binding results of monoclonal antibody NMC-103, monoclonal antibody NMC-204, an antibody against E-cadherin, and an antibody against cytochrome C to intact human pancreatic MiaPaCa-2 cells.

[0171] Figure 11 AC represent flow cytometry data of the percentage of cells stained with monoclonal antibodies NMC-103 (A), NMC-204 (B), and anti-Na+ / K+ ATPase α-1 (C), respectively.

[0172] Figures 12A-D show that monoclonal antibodies NMC-103 (A and D) and NMC-204 (B and D), but not anti-cytochrome C antibodies (C and D), inhibit cell proliferation of intact human pancreatic MIAPaCa-2 cells.

[0173] Figures 13A-C show that monoclonal antibody NMC-103 induces complement-mediated cytotoxicity against human pancreatic MIAPaCa-2 cells in the presence of normal human serum (B and C) compared to cells treated with normal human serum in the absence of any antibody (A).

[0174] Figures 14A-B show the lack of binding of many commercially available monoclonal antibodies to NMC-P1 (A) or NMC-P2 (B).

[0175] Figure 15A -B shows that the anti-HDM2 antibody called "MDM2 monoclonal antibody (M01) clone 1A7" (Abnova, catalog number H00004193-M01) reacts with intact cancer cells (A), but the anti-HDM2 antibody called "anti-MDM2 (Ab-4) mouse mAb (2A9C1.18)" (EMDMillipore, catalog number OP144) and the anti-HDM2 antibody called "anti-MDM2 (Ab-1) mouse mAb (IF2)" (EMDMillipore, catalog number OP46) do not react with intact cancer cells (B).

[0176] Figure 16 Depicted are the effects of monoclonal antibody NMC-204 on tumor volume in the LL / 2 syngeneic mouse model of lung cancer.

[0177] 17A-B depict the effects of monoclonal antibody NMC-103 on tumor volume (A) and tumor cell proliferation (B) in the MC-38 syngeneic mouse model of colon cancer.

[0178] 18A-B depict the effects of monoclonal antibody NMC-204 on tumor volume (A) and tumor cell proliferation (B) in the MC-38 syngeneic mouse model of colon cancer.

[0179] Figure 19 The effects of monoclonal antibody NMC-103 (2 mg / kg) alone, the combination of low-dose gemcitabine (25 mg / kg) and nab-paclitaxel (5 mg / kg), the combination of low-dose gemcitabine (25 mg / kg), nab-paclitaxel (5 mg / kg) and NMC-103 (2 mg / kg), and isotype control mouse IgG1 (2 mg / kg) on ​​tumor volume in the Panc-2 syngeneic mouse model of pancreatic cancer are depicted. 3 Processing starts when

[0180] Figure 20 Depicted are the DNA and protein sequences of the heavy and light chain variable regions of monoclonal antibody NMC-103, respectively.

[0181] Figure 21 Depicted are the DNA and protein sequences of the heavy and light chain variable regions of monoclonal antibody NMC-204, respectively.

[0182] Figure 22The DNA and protein sequences of the heavy and light chain variable regions of monoclonal antibody NMC-303 are depicted, respectively. The leader sequences preceding the DNA and protein sequences of the heavy and light chain variable regions are shown in bold (but not underlined).

[0183] Figure 23 Shown are tumor sizes of mice treated with an anti-HDM2 antibody designated "MDM2 Monoclonal Antibody (M01) Clone 1A7" (Abnova, Catalog No. H00004193-M01), tumor sizes of mice treated with NMC-103, tumor sizes of mice treated with NMC-204, and tumor sizes of mice treated with an isotype control.

[0184] Figure 24A-F. Anti-HDM2-specific antibodies stain the surface of cancer cells but not normal cells. Intact cells released with EDTA or trypsin were blocked with 5% human serum albumin. Cells were then incubated on ice for 90 minutes with either the polyclonal N-20 M(H)DM2-specific antibody (sc-813, N-20, rabbit IgG; from Santa Cruz; "N-20") or the monoclonal M(H)DM2-specific OP145 antibody (OP145, mouse IgG1; from Calbiochem; "OP145"). Another set of cells prepared under the same conditions was incubated with the same antibodies, which were pre-incubated with the corresponding blocking peptide before incubation with the cells. Following primary antibody incubation, cells were washed three times with ice-cold PBS and then incubated with a FITC secondary antibody for 60 minutes. Cells were then washed three times with PBS and processed on a FACS analyzer. Human melanoma cells (24A, 24B, and 24C), primary human ovarian cancer cells (24D and 24E), and normal mouse spleen cells (24F). Figure 24A: The area under the curve (AUC) 1 represents cells incubated with goat anti-rabbit secondary antibody alone; the area under the curve (AUC) 2 represents cells incubated with anti-HDM2 polyclonal antibody N-20, followed by goat anti-rabbit secondary antibody, pre-incubated with its blocking peptide; the area under the curve (AUC) 3 represents cells incubated with anti-HDM2 polyclonal antibody N-20, followed by goat anti-rabbit secondary antibody. Figure 24B: The area under the curve No. 1 represents cells incubated with goat anti-mouse secondary antibody only; the area under the curve No. 2 represents cells incubated with anti-HDM2 monoclonal antibody OP145, followed by goat anti-rabbit secondary antibody, wherein the anti-HDM2 monoclonal antibody OP145 was pre-incubated with its blocking peptide; the area under the curve No. 3 represents cells incubated with anti-HDM2 monoclonal antibody OP145, followed by goat anti-mouse secondary antibody. Figure 24C: Area under the curve No. 1 represents cells incubated with goat anti-rabbit secondary antibody only; area under the curve No. 2 represents cells incubated with anti-HDM2 polyclonal antibody N-20 followed by trypsin release with goat anti-rabbit secondary antibody; area under the curve No. 3 represents cells incubated with anti-HDM2 polyclonal antibody N-20 followed by EDTA release with goat anti-rabbit secondary antibody, wherein the anti-HDM2 polyclonal antibody N-20 was pre-incubated with its blocking peptide; area under the curve No. 4 represents cells incubated with anti-HDM2 polyclonal antibody N-20 followed by EDTA release with goat anti-rabbit secondary antibody. Figure 24D and E: The area under the curve No. 1 represents cells incubated with goat anti-rabbit secondary antibody only; the area under the curve No. 2 represents cells incubated with anti-HDM2 polyclonal antibody N-20, followed by goat anti-rabbit secondary antibody, wherein the anti-HDM2 polyclonal antibody N-20 was pre-incubated with its blocking peptide; the area under the curve No. 3 represents cells incubated with anti-HDM2 polyclonal antibody N-20, followed by goat anti-rabbit secondary antibody.Figure 24F: Area under the curve No. 1 represents cells incubated with goat anti-rabbit secondary antibody only; area under the curve No. 2 represents cells released by trypsin after incubation with anti-HDM2 polyclonal antibody N-20 followed by incubation with goat anti-rabbit secondary antibody; area under the curve No. 3 represents cells released by EDTA after incubation with anti-HDM2 polyclonal antibody N-20 followed by incubation with goat anti-rabbit secondary antibody, wherein the anti-HDM2 polyclonal antibody N-20 was pre-incubated with its blocking peptide; area under the curve No. 4 represents cells released by EDTA after incubation with anti-HDM2 polyclonal antibody N-20 followed by incubation with goat anti-rabbit secondary antibody.

[0185] Figure 25A-C. (A) Human pancreatic or ovarian cancer cells and normal human fibroblasts treated with normal human serum (NHS) alone, NHS + anti-HDM2 OP145 monoclonal antibody (mouse IgG1, from Calbiochem, "OP145"), or a control antibody (NHS + cytochrome c). When cancer cells were treated with OP145 antibody in the presence of NHS, extensive cell death as shown by propidium iodide (PI) staining was observed (see Figures b and e), while the same antibody had no effect on the survival of normal human fibroblasts (see Figure g). A control antibody to cytochrome c did not show cytotoxicity (see Figure c) beyond that observed in untreated cells (see Figure a). The absence or minimal PI staining in Figures a, c, d, f, and g indicates a lack of cell death. The cell death marker PI was visualized using an Olympus FluoView FV1000 confocal laser scanning biological microscope configured on an Olympus IX81 inverted microscope. (B) Rodent pancreatic cancer cells were treated with anti-HDM2 antibody and a control cytochrome c antibody. When cells were treated with the anti-HDM2 antibodies N-20 (polyclonal, sc-813N-20, rabbit IgG, from Santa Cruz, “N-20”) or C-18 (polyclonal, sc-812C-18, rabbit IgG; from Santa Cruz, “C-18”), extensive cell death as indicated by propidium iodide (PI) staining was observed (see panels b and e), whereas no cytotoxicity was observed when cells were treated with the anti-HDM2 monoclonal OP46 antibody (OP46 (Ab-1); mouse IgG1; from Calbiochem, “OP46”) (see panel e). (C) M(H)DM2-specific antibodies were cytotoxic to pancreatic cancer MiaPaCa-2 cells in the presence of NHS. Schematic representation of the quantification of M(H)DM2-specific antibody-dependent complement cytotoxicity against human pancreatic cancer cells. Cells treated with anti-M(H)DM2 (C-18) antibody in the presence of NHS showed cytotoxicity within 15-30 min after treatment, while anti-HDM2 OP46 showed cytotoxic effects that did not exceed those observed when cells were treated with control anti-cytochrome C antibody or when cells were treated with NHS in the absence of anti-M(H)DM2 antibody.

[0186] Figure 26 Tumor sizes of mice treated with the anti-HDM2 antibody OP145 and mice treated with PBS control (in the Panc02 syngeneic mouse model of pancreatic cancer) are shown. The x-axis shows the number of days after tumor cell injection into the mice. The y-axis shows the number of days after tumor cell injection into the mice. 3 The arrows indicate the date of treatment initiation.

[0187] Figure 27 Depicted are the effects of monoclonal antibody NMC-103 (10 mg / kg) alone, the combination of low-dose gemcitabine (25 mg / kg) and nab-paclitaxel (5 mg / kg), the combination of low-dose gemcitabine (25 mg / kg), nab-paclitaxel (5 mg / kg) and NMC-103 (10 mg / kg), and isotype control mouse IgG1 (10 mg / kg) on ​​tumor volume in the Panc-2 syngeneic mouse model of pancreatic cancer (n=8 mice per group). When mice had tumors reaching approximately 80-100 mm 3 Treatment in this study was initiated at .

[0188] Figure 28 The Kaplan Meier survival analysis is depicted, which shows that when Figure 27 Survival benefit of mice receiving NMC-103 alone or in combination with chemotherapy compared with chemotherapy alone or control antibody under the experimental conditions described in .

[0189] Figure 29 Shows the previous Figure 27 The mice treated with NMC-103 became immune to tumor restimulation after drug withdrawal. To evaluate the long-term antitumor effect of NMC-103, mice that had previously received the combination of G+nP, mice in group C (mice previously treated with NMC-103) and mice in group D (mice previously treated with the combination of NMC-103+G+nP) were inoculated with a second round of Panc-2 on the left dorsal flank (2×10 6 Tumor growth was monitored for 10 days, at which time 90 mm was measured in mice from Group B. 3 No tumors were observed in the two groups of mice (Groups C and D) that had previously received the NMC-103 antibody.

[0190] Figure 30 The effect of a single dose of monoclonal antibody NMC-103 (10 mg / kg) or isotype control mouse IgG1 (10 mg / kg) on ​​tumor volume in the Panc-2 syngeneic mouse model of pancreatic cancer is depicted in the treatment of large tumors (i.e., advanced cancer) when added to a low-dose gemcitabine (25 mg / kg) and nab-paclitaxel (5 mg / kg) combination therapy. Mice were treated with standard pancreatic cancer treatment (gemcitabine (25 mg / kg) + nab-paclitaxel (5 mg / kg)) for 19 days, at which time they reached approximately 450 mm 3The mice were then randomly divided into two groups and received a single dose of either isotype control mouse IgG1 (10 mg / kg) or NMC-103 (10 mg / kg). As shown in the figure, a single ip injection of NMC-103 reduced the tumor size by almost half (from 438 mm to 638 mm) 6 days after treatment. 3 to 233mm 3 ).

[0191] Figure 31 The effect of the monoclonal antibody NMC-103 on tumor volume in the MC-38 syngeneic mouse model of colon cancer is depicted. As shown in the figure, mice treated with 10 mg / kg of NMC-103 twice a week for 2 weeks had an average tumor size of 210 mm 3 , while the mice in the group treated with 10 mg / kg of isotype control antibody grew rapidly, reaching 1168 mm on day 12. 3 Compared to mice treated with 0.4 mg / kg of NMC-103 ( FIG. 17 ), these data support a dose-dependent antitumor effect of the NMC-103 antibody.

[0192] Figure 32A and 32B The effect of a chimeric form of the monoclonal antibody NMC-303 is depicted. Isotype class switching was performed on mouse NMC-303 to convert it from mouse IgM to chimeric IgG1. The mouse heavy and light chain variable regions were cloned into human Igγ-1 chain and human Igκ chain as constant regions. A total of eight (8) BALB / c mice were injected subcutaneously with CT-26. The mice were then divided into two groups (n=4) and received: A) control antibody (10 mg / kg), B) a chimeric form of the NMC-303 antibody (10 mg / kg) twice a week for 3 weeks. Figure 32A The results showed that on day 24 after tumor inoculation, the average tumor size of mice treated with the chimeric form of NMC-303 (10 mg / kg) reached 726 mm3, while the average tumor size of mice treated with the control antibody (10 mg / kg) was 1746 mm3. Figure 32B Shown are individual mouse tumor sizes at day 24 after tumor inoculation. 7. Specific Implementation Methods

[0194] Provided herein are antibodies or antigen-binding fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2). In specific embodiments, the extracellularly accessible epitope is contained within SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. The antibodies provided herein are described in Section 5.1 below. Also provided herein are antibody-drug conjugates comprising an antibody or fragment described herein that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) conjugated (e.g., covalently) to a cytotoxic drug. Also provided herein are antibodies or antigen-binding fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2), wherein the antibody or fragment does not bind to a cytotoxic component.

[0195] Also provided herein are pharmaceutical compositions comprising an antibody or fragment described herein that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2). In certain embodiments, such pharmaceutical compositions comprise a therapeutically effective amount of such an antibody or fragment (i.e., an amount that can be used to treat cancer in a subject, for example, by achieving one or more anti-tumor effects described herein).

[0196] Also provided herein are nucleic acids encoding the antibodies and antigen-binding fragments described herein. In certain embodiments, provided herein are vectors and cells comprising nucleic acids encoding such antibodies or antigen-binding fragments thereof. Also provided are cells that recombinantly produce the antibodies or antigen-binding fragments described herein.

[0197] Chimeric antigen receptor (CAR) is an engineered receptor that provides both antigen binding and immune cell activation functions (Sadelain et al., 2013, Cancer Discovery 3: 388-398). CAR is also provided herein, comprising a single-chain variable fragment (scFv) specifically bound to an extracellular accessible epitope of M (H) DM2 / 4, such as the scFv of the VH and VL of the anti-M (H) DM2 / 4 antibodies described herein, which is fused to (e.g., CD3 ζ) transmembrane domains via a linker, fused to intracellular T cell activation domains such as CD3 ζ intracellular domains, optionally also fused to costimulatory domains (e.g., CD28 intracellular domains). T cells expressing such CARs are also provided.

[0198] Also provided herein are peptides having an amino acid sequence of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3). The peptides can be, for example, synthetic or recombinant. In some embodiments, the peptides are purified. In some embodiments, the peptides are labeled with a detectable marker (e.g., a fluorescent marker or an isotope). In some embodiments, the peptides are labeled (e.g., with a GST, His, Strep, myc, FLAG, or HA tag). In some embodiments, a cysteine ​​is added to one of the ends of the peptide (which can allow for connection to a carrier protein). In some embodiments, the peptides are connected to a carrier protein (e.g., to keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), ovalbumin, thyroglobulin, tetanus toxoid, or diphtheria toxoid). Also provided herein are nucleic acids encoding the peptides described herein. Also provided herein are vectors and cells comprising nucleic acids encoding the peptides described herein. Also provided are cells that recombinantly produce the peptides described herein. Also provided herein are uses of the peptides described herein as immunogens. The peptides of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 described herein comprise extracellularly accessible epitopes of MDM2 and HDM2. In particular, provided herein are methods for producing anti-M(H)DM2 / 4 antibodies (e.g., antibodies that specifically bind to M(H)DM2 / 4) by immunizing an animal (e.g., a mouse or rabbit) with the peptides described herein. Also provided herein are methods for screening for antibodies that bind to one or more of the peptides described herein (e.g., using an ELISA with plate-bound peptides). Also provided herein are methods for identifying anti-M(H)DM2 / 4 antibodies suitable for therapeutic use in treating cancer or preventing metastasis, or suitable for use in cancer diagnosis, the methods comprising contacting an anti-M(H)DM2 / 4 antibody with a peptide described herein under conditions suitable for binding between the antibody and the peptide, and detecting or measuring binding that occurs between the antibody and the peptide, wherein detection of binding between the antibody and the peptide is suitable for therapeutic or diagnostic use. For example, provided herein are methods for identifying an anti-M(H)DM2 / 4 antibody suitable for therapeutic use by contacting an anti-M(H)DM2 / 4 antibody with a peptide described herein under conditions suitable for binding between the antibody and the peptide, and detecting or measuring binding that occurs between the antibody and the peptide, and if binding between the antibody and the peptide is detected, using the antibody in a method for treating cancer described herein.In another example, provided herein are methods for identifying anti-M(H)DM2 / 4 antibodies suitable for diagnostic use, the method being performed by contacting an anti-M(H)DM2 / 4 antibody with a peptide described herein under conditions suitable for binding between the antibody and the peptide, and detecting or measuring binding that occurs between the antibody and the peptide, and if binding between the antibody and the peptide is detected, using the antibody in a method for diagnosing cancer described herein.

[0199] Also provided herein are methods for treating cancer, inhibiting tumor growth or proliferation, inhibiting tumor progression, and / or preventing metastasis in a subject by administering to the subject an anti-HDM2 / 4 antibody or fragment described herein, particularly an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2 / 4 (particularly, a region exposed on the plasma membrane surface of cancer cells). Preferably, the antibody or fragment thereof specifically binds to an extracellularly accessible epitope of HDM2 (particularly, a region exposed on the plasma membrane surface of cancer cells). In certain embodiments, the antibody or fragment (e.g., for use in the methods described herein) does not bind, or only minimally binds, to the plasma membrane surface of normal cells of the tissue type from which the cancer in the subject originates.

[0200] When the subject being treated is a human, in certain embodiments, the antibodies or fragments thereof used herein specifically bind to extracellularly accessible epitopes of HDM2 and / or HDM4 (regions exposed on the plasma membrane surface of cancer cells). In one embodiment for treating humans, the antibodies or fragments thereof used herein specifically bind to extracellularly accessible epitopes of HDM2 (regions exposed on the plasma membrane surface of cancer cells) (optionally, such antibodies or fragments do not bind to HDM4). In one embodiment for treating humans, the antibodies or fragments thereof used herein specifically bind to extracellularly accessible epitopes of HDM4 (regions exposed on the plasma membrane surface of cancer cells) (optionally, such antibodies or fragments do not bind to HDM2).

[0201] When the subject is a non-human animal (e.g., a mammal such as a dog or cat), the antibody or fragment thereof used herein binds to an extracellularly accessible epitope of M(H)DM2 / 4 (a region exposed on the plasma membrane surface of cancer cells), wherein M(H)DM2 / 4 is a homolog of HDM2 and / or HDM4 expressed in such an animal. In one embodiment, the antibody or fragment thereof used herein binds to an extracellularly accessible epitope of M(H)DM2 (a region exposed on the plasma membrane surface of cancer cells), wherein M(H)DM2 is a homolog of HDM2 expressed in such an animal (optionally, such an antibody or fragment does not bind to M(H)DM4). In one embodiment, the antibody or fragment thereof used herein binds to an extracellularly accessible epitope of M(H)DM4 (a region exposed on the plasma membrane surface of cancer cells), wherein M(H)DM4 is a homolog of HDM4 expressed in such an animal (optionally, such an antibody or fragment does not bind to M(H)DM2).

[0202] The following description of the present invention is primarily directed to HDM2 and antibodies and antibody fragments thereof, which should be understood as being for use in treating humans; it will be clear to those skilled in the art that this description should also be considered applicable to: (i) HDM4 and antibodies and antibody fragments thereof, and their use in treating humans (unless otherwise explicitly stated or indicated by the context), and (ii) M(H)DM2 / 4 and antibodies and antibody fragments thereof, and their use in treating non-human animals, such as mammals (unless otherwise explicitly stated or indicated by the context). In preferred embodiments, the patient or subject treated using the methods described herein is a human.

[0203] In preferred embodiments, the anti-HDM2 antibodies or fragments thereof used according to the methods described herein mediate complement dependent cytotoxicity (CDC), mediate antibody-dependent cell-mediated cytotoxicity (ADCC), and / or are conjugated to one or more cytotoxic drugs (e.g., antibody-drug conjugates). In preferred embodiments, the present invention provides for the use of antibodies that mediate complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).

[0204] In certain embodiments, the anti-HDM2 antibodies or fragments thereof used according to the methods described herein are not bound to cell penetrating peptides. Cell penetrating peptides can be inserted into the cytoplasmic membrane and transported to the molecules connected thereto into the cell. Such cell penetrating peptides include but are not limited to membrane resident peptides (MRPs), membrane transduction domains of antennapedia, transactivating transcription activators (TATs), and penetratin peptides. In certain embodiments, the anti-HDM2 antibodies or fragments thereof used according to the methods described herein are not connected to membrane resident peptides (MRPs), membrane transduction domains of antennapedia, TATs, and / or penetratin peptides. In certain embodiments, the anti-HDM2 antibodies or fragments thereof used according to the methods described herein are not connected to any peptide sequence that can be inserted into the lipid bilayer of the cytoplasmic membrane. In one embodiment, the anti-HDM2 antibodies or fragments thereof used according to the methods described herein are not connected to MRPs. In one embodiment, the anti-HDM2 antibodies or fragments thereof used according to the methods described herein are not connected to penetratin peptides.

[0205] The examples described herein demonstrate that individual antibodies targeting HDM-2 exhibit selective cytotoxicity against cancer cells. Furthermore, as described in the examples herein, it has been shown that extracellularly accessible epitopes of HDM2 are suitable therapeutic targets for anti-HDM2 antibodies, and that cancer cells expressing HDM2 on their surfaces can be successfully targeted and destroyed by antibodies directed against such extracellular regions of HDM2. In particular, the data provided in the examples demonstrate that selected HDM2-specific antibodies can bind to extracellularly accessible sequences of HDM2 on the surface membrane of intact cancer cells, while exhibiting minimal binding to the surface membrane of normal human blood mononuclear cells. Furthermore, the data provided in the examples demonstrate that such HDM2-specific antibodies can inhibit the growth of cancer cells both in vitro and in vivo, strongly suggesting that they may be used as therapeutic agents in vivo. Furthermore, the data provided in the examples demonstrate that such HDM2-specific antibodies can have synergistic anti-tumor effects when combined with chemotherapeutic drugs.

[0206] 7.1 Antibody

[0207] Provided herein are antibodies or antigen-binding fragments thereof that (immuno)specifically bind to an extracellularly accessible epitope (a region exposed on the plasma membrane surface of a cell) of M(H)DM2 / 4 (e.g., HDM2). As used herein, the terms "specifically bind" and "binding" do not exclude cross-reactivity of the antibody or antigen-binding fragment; thus, for example, an antibody or antigen-binding fragment thereof that (immuno)specifically binds to an extracellularly accessible epitope of HDM2 exposed on the plasma membrane surface of a cell may also specifically bind to (cross-react with) MDM2. In particular, provided herein are anti-M(H)DM2 / 4 antibodies and fragments thereof that (immuno)specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 and have an anti-tumor effect (e.g., inhibit tumor growth in vivo). In specific embodiments, the antibody or antigen-binding fragment thereof specifically binds to an epitope of M(H)DM2 / 4 that is extracellularly accessible on cancer cells but not on non-cancerous cells (e.g., non-cancerous cells of the same organ type or tissue type as the cancer cells). In other specific embodiments, the antibody or antigen-binding fragment thereof specifically binds to an epitope of M(H)DM2 / 4 that has increased exposure or accessibility on the plasma membrane surface of cancer cells relative to its exposure or accessibility on the plasma membrane surface of non-cancerous cells (e.g., non-cancerous cells of an organ or tissue of a host). Also provided herein are antibodies or antigen-binding fragments thereof that (immuno)specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) that do not bind to a cell-penetrating peptide (e.g., a membrane-resident peptide).

[0208] Also provided herein are antibodies or antigen-binding fragments thereof that (immuno)specifically bind to M(H)DM2 / 4 (e.g., HDM2), particularly an extracellularly accessible epitope of M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide whose sequence consists of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3). In certain embodiments, provided herein are antibodies or antigen-binding fragments thereof that (immuno)specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2), in particular M(H)DM2 / 4, wherein the antibody or fragment specifically binds to a peptide whose sequence consists of MCNTNMSVPTDGAVT (SEQ ID NO: 1), TTSQIPASEQE (SEQ ID NO: 2), or CPVCRQPIQMIVLTYFP (SEQ ID NO: 3); and wherein such an antibody or fragment has an anti-tumor effect in vivo, and / or wherein such an antibody or fragment does not bind to a cell-penetrating peptide.

[0209] Also provided herein are anti-M(H)DM2 / 4 antibodies and fragments having heavy chain variable regions and / or light chain variable regions as described herein (see, e.g., sequences of heavy chain variable regions and / or light chain variable regions of antibodies NMC-103, NMC-204, and NMC-303 provided herein, see, e.g., Sections 8 and Figure 20-22 Also provided herein are anti-M(H)DM2 / 4 antibodies and fragments having one or more of the complementarity determining regions (CDRs) described herein (see, e.g., Tables 4-9 and Figure 20-22 CDRs provided in ).

[0210] CDRs are defined in various ways in the art, including Kabat, Chothia, AbM, Contact, and IMGT. In some aspects, the CDRs of an antibody can be defined according to the Kabat system based on sequence variability (see, e.g., Kabat EA & Wu TT (1971) Ann NY Acad Sci 190:382-391; Kabat EA et al., (1991) Sequences of Proteins of Immunological Interest, 5th ed., US Department of Health and Human Services, NIH Publication No. 91-3242). In a specific embodiment, with respect to the Kabat system, (i) the VH CDR1 is present at amino acids 31 to 35 of the heavy chain; (ii) the VH CDR2 is present at amino acids 50 to 68 or 50 to 66 of the heavy chain; and (iii) the VH CDR3 is present at amino acids 101 to 105, 99 to 104, or 99 to 106 of the heavy chain. In a specific embodiment, with respect to the Kabat system, (i) the VL CDR1 is present at amino acids 24 to 39 or 24 to 34 of the light chain; (ii) the VH CDR2 is present at amino acids 55 to 61 or 50 to 56 of the light chain; and (iii) the VH CDR3 is present at amino acids 94 to 102 or 89 to 97 of the light chain. As is well known to those skilled in the art, with respect to the Kabat system, the actual linear amino acid sequence of an antibody variable domain may contain fewer or additional amino acids due to shortening or lengthening of the framework regions (FRs) and / or CDRs, and therefore, the Kabat number of an amino acid is not necessarily the same as its linear amino acid number. The Kabat CDR positions may vary depending on the antibody and may be determined according to methods known in the art. In a specific embodiment, the CDRs of the antibodies described herein are determined using the Kabat system. In a specific embodiment, the CDRs of the antibodies described herein are determined using the Kabat system.

[0211] In certain aspects, the CDRs of an antibody can be defined according to the Chothia system based on the position of loop regions of immunoglobulin structures (see, e.g., Chothia C & Lesk AM, (1987), J Mol Biol 196:901-917; Al-Lazikani B et al., (1997) J Mol Biol 273:927-948; Chothia C et al., (1992) J Mol Biol 227:799-817; Tramontano A et al., (1990) J Mol Biol 215(1):175-82; and U.S. Patent No. 7,709,226). The term "Chothia CDR" and similar terms are recognized in the art and refer to antibody CDR sequences determined according to the method of Chothia and Lesk, 1987, J. Mol. Biol., 196:901-917, which are referred to herein as "Chothia CDRs" (see also, e.g., U.S. Patent No. 7,709,226 and Martin, A., "Protein Sequence and Structure Analysis of Antibody Variable Domains", in Antibody Engineering, Kontermann and Dübel, eds., Chapter 31, pp. 422-439, Springer-Verlag, Berlin (2001)). In a specific embodiment, the amino acid residues in the VH region are numbered using the Kabat numbering system, with respect to the Chothia system, (i) the VH CDR1 is present at amino acids 26 to 32 of the heavy chain; (ii) the VH CDR2 is present at amino acids 52 to 59 or 52 to 57 of the heavy chain; and (iii) the VH CDR3 is present at amino acids 101 to 105, 99 to 104, or 99 to 106 of the heavy chain. In a specific embodiment, the amino acid residues in the VL region are numbered using the Kabat numbering system, with respect to the Chothia system, (i) the VL CDR1 is present at amino acids 24 to 39 or 24 to 34 of the light chain; (ii) the VL CDR2 is present at amino acids 55 to 61 or 50 to 56 of the light chain; and (iii) the VL CDR3 is present at amino acids 94 to 102 or 89 to 97 of the light chain. Chothia CDR positions can vary depending on the antibody and can be determined according to methods known in the art. In a specific embodiment, the CDRs of the antibodies described herein are determined using the Chothia system.

[0212] In certain aspects, the CDRs of an antibody can be defined according to the AbM system based on AbM hypervariable regions, which represents a compromise between Kabat CDRs and Chothia structural loops, and wherein CDRs are determined using Oxford Molecular's AbM antibody modeling software (Oxford Molecular Group, Inc.). In specific embodiments, with respect to the AbM system, the amino acid residues in the VH region are numbered using the Kabat numbering system, (i) the VH CDR1 is present at amino acids 26 to 35 of the heavy chain; (ii) the VH CDR2 is present at amino acids 50 to 61 or 50 to 59 of the heavy chain; and (iii) the VH CDR3 is present at amino acids 101 to 105, 99 to 104, or 99 to 106 of the heavy chain. In a specific embodiment, with respect to the AbM system, the amino acid residues in the VL region are numbered using the Kabat numbering system, (i) the VL CDR1 is present at amino acids 24 to 39 or 24 to 34 of the light chain; (ii) the VH CDR2 is present at amino acids 55 to 61 or 50 to 56 of the light chain; and (iii) the VH CDR3 is present at amino acids 94 to 102 or 89 to 97 of the light chain. The AbM CDR positions can vary depending on the antibody and can be determined according to methods known in the art. In a specific embodiment, the CDRs of the antibodies described herein are determined using the AbM numbering system.

[0213] In certain aspects, the CDRs of an antibody can be defined according to the IMGT system (see theinternational ImMunoGeneTics information website imgt.org, founder and director: Marie-Paule Lefranc, Montpellier, France; see, e.g., Lefranc, M.-P., 1999, The Immunologist, 7:132-136 and Lefranc, M.-P. et al., 1999, Nucleic Acids Res., 27:209-212, both of which are herein incorporated by reference in their entireties). In specific embodiments, with respect to the IMGT system, (i) the VH CDR1 is present at amino acids 27 to 33 or 26 to 33 of the heavy chain; (ii) the VH CDR2 is present at amino acids 51 to 60 or 51 to 58 of the heavy chain; and (iii) the VH CDR3 is present at amino acids 99 to 105 or 97 to 103 of the heavy chain. In a specific embodiment, with respect to the IMGT system, (i) the VL CDR1 is present at amino acids 27 to 37 of the light chain; (ii) the VH CDR2 is present at amino acids 55 to 57 of the light chain; and (iii) the VH CDR3 is present at amino acids 94 to 102 of the light chain. IMGT CDR positions can vary depending on the antibody and can be determined according to methods known in the art. In a specific embodiment, the CDRs of the antibodies described herein are determined using the IMGT system.

[0214] In some aspects, the CDRs of an antibody can be defined according to the Contact system. Contact definitions are based on analysis of available complex crystal structures (bioinf.org.uk / abs) (see MacCallum RM et al., (1996) J Mol Biol 5:732-745; see also, e.g., Martin A. "Protein Sequence and Structure Analysis of Antibody Variable Domains", Antibody Engineering, Kontermann and Dübel, eds., Chapter 31, pp. 422-439, Springer-Verlag, Berlin (2001)). In a specific embodiment, the amino acid residues in the VH region are numbered using the Kabat numbering system with respect to the Contact system, (i) the VH CDR1 is present at amino acid positions 30 to 35 of the heavy chain; (ii) the VH CDR2 is present at amino acid positions 47 to 61 or 47 to 59 of the heavy chain; and (iii) the VH CDR3 is present at amino acid positions 99 to 104, 97 to 103, or 97 to 105 of the heavy chain. In a specific embodiment, the amino acid residues in the VL region are numbered using the Kabat numbering system with respect to the Contact system, (i) the VLCDR1 is present at amino acid positions 30 to 41 or 30 to 36 of the light chain; (ii) the VH CDR2 is present at amino acid positions 51 to 60 or 46 to 55 of the light chain; and (iii) the VH CDR3 is present at amino acid positions 94 to 101 or 89 to 96 of the light chain. Contact CDR positions may vary depending on the antibody and can be determined according to methods known in the art. In a specific embodiment, the CDRs of the antibodies described herein are determined using the Contact system.

[0215] In specific embodiments, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise the CDRs of any of the antibodies described herein (any of antibodies NMC-103, NMC-204, and NMC-303), the CDRs being defined according to any of the above systems.

[0216] In certain embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) and comprise a heavy chain variable region (VH) having one, two, or all three VH CDRs (preferably all three VH CDRs) of any anti-HDM2 antibody described herein (e.g., NMC-103, NMC-204, or NMC-303). As known in the art, a VH comprises VH CDRs surrounded by a framework region (CDR and FR sequences appear in the following order in a VH: FR1-VH CDR 1-FR2-VH CDR 2-FR3-VH CDR 3-FR4), optionally wherein the framework region is a human framework region. In certain embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) and comprise a heavy chain variable region (VH) having one, two, or all three VH CDRs of the VH having the amino acid sequence of SEQ ID NO: 36 (which is the VH of NMC-103). In certain embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) and comprise a heavy chain variable region (VH) having one, two, or all three VH CDRs of the VH having the amino acid sequence of SEQ ID NO: 38 (which is the VH of NMC-204). In certain embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) and comprise a heavy chain variable region (VH) having one, two, or all three VH CDRs of the VH of SEQ ID NO: 40 (which is the VH of NMC-303). In certain embodiments, such antibodies or fragments are humanized antibodies or fragments.

[0217] In certain embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) and comprise a light chain variable region (VL) having one, two, or all three VL CDRs (preferably all three VL CDRs) of any anti-HDM2 antibody described herein (e.g., NMC-103, NMC-204, or NMC-303). As known in the art, a VL comprises VL CDRs surrounded by a framework region (CDR and FR sequences appear in the following order in VL: FR1-VL CDR 1-FR2-VL CDR 2-FR3-VL CDR 3-FR4); optionally, the framework region is a human framework region. In certain embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) and comprise a light chain variable region (VL) having one, two, or all three VL CDRs of the VL of SEQ ID NO: 37 (which is the VL of NMC-103). In certain embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) and comprise a light chain variable region (VL) having one, two, or all three VL CDRs of the VL of SEQ ID NO: 39 (which is the VL of NMC-204). In certain embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) and comprise a light chain variable region (VL) having one, two, or all three VL CDRs of the VL of SEQ ID NO: 40 (which is the VL of NMC-303). In certain embodiments, such antibodies or fragments are humanized antibodies or fragments.

[0218] In certain embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 (e.g., HDM2) and comprise a heavy chain variable region (VH) having one, two, or all three VH CDRs (preferably all three VH CDRs) of any anti-HDM2 antibody described herein (such as NMC-103, NMC-204, or NMC-303) and a light chain variable region (VL) having one, two, or all three VL CDRs (preferably all three VL CDRs) of such an anti-HDM2 antibody.

[0219] In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a heavy chain variable region (VH) having one, two, or all three VH CDRs identified in Table 4 (providing the VH CDRs for NMC-103). In one embodiment, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a VH CDR3 ("CDR-H3") identified in Table 3. In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a light chain variable region (VL) having one, two, or all three VL CDRs identified in Table 5 (providing the VL CDRs for NMC-103). In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a heavy chain variable region (VH) having one, two, or all three VH CDRs identified in Table 4; and a light chain variable region (VL) having one, two, or all three VL CDRs identified in Table 5.

[0220] In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a heavy chain variable region (VH) having one, two, or all three VH CDRs identified in Table 6 (providing the VH CDRs for NMC-204). In one embodiment, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a VH CDR3 ("CDR-H3") identified in Table 6. In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a light chain variable region (VL) having one, two, or all three VL CDRs identified in Table 7 (providing the VL CDRs for NMC-204). In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a heavy chain variable region (VH) having one, two, or all three VH CDRs identified in Table 6; and a light chain variable region (VL) having one, two, or all three VL CDRs identified in Table 7.

[0221] In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a heavy chain variable region (VH) having one, two, or all three VH CDRs identified in Table 8 (providing the VH CDRs for NMC-303). In one embodiment, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a VH CDR3 ("CDR-H3") identified in Table 8. In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a light chain variable region (VL) having one, two, or all three VL CDRs identified in Table 9 (providing the VL CDRs for NMC-303). In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2 and comprise a heavy chain variable region (VH) having one, two, or all three VH CDRs identified in Table 8; and a light chain variable region (VL) having one, two, or all three VL CDRs identified in Table 9.

[0222] In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2, comprising the VH of any of the antibodies described herein, such as those described in Section 8 or Figure 20-22 The VH of any antibody provided herein (e.g., VH of NMC-103, VH of NMC-204, or VH of NMC-303), or a VH having at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity thereto. In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2, comprising the VL of any antibody described herein, such as in Section 8 or Figure 20-22 The VL of any of the antibodies provided (e.g., the VL of NMC-103, the VL of NMC-204, or the VL of NMC-303), or a VL having at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity thereto. In certain embodiments, substitutions, insertions, or deletions in these sequences occur in regions outside of the CDRs (i.e., in the FRs).

[0223] In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2, comprising the VH and VL of any of the antibodies described herein, such as those described in Section 8 or Figure 20-22 The VH and VL of any of the provided antibodies (e.g., the VH and VL of NMC-103, the VH and VL of NMC-204, or the VH and VL of NMC-303), or a VH and VL having at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity thereto.

[0224] In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2, comprising: (i) a VH having the amino acid sequence of SEQ ID NO: 36, or a VH having at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity thereto; and / or (ii) a VL having the amino acid sequence of SEQ ID NO: 37, or a VL having at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity thereto.

[0225] In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2, comprising: (i) a VH having the amino acid sequence of SEQ ID NO: 38, or a VH having at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity thereto; and / or (ii) a VL having the amino acid sequence of SEQ ID NO: 39, or a VL having at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity thereto.

[0226] In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to HDM2, comprising: (i) a VH having the amino acid sequence of SEQ ID NO: 40, or a VH having at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity thereto; and / or (ii) a VL having the amino acid sequence of SEQ ID NO: 41, or a VL having at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity thereto.

[0227] In certain aspects, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise one or more Kabat VL CDRs of the VL of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303), and / or one or more Kabat VH CDRs of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303). In one embodiment, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise Kabat VH CDR 3 of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303). In one embodiment, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise the three Kabat VL CDRs of the VL of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303) and / or the three Kabat VH CDRs of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303).

[0228] In certain aspects, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise one or more Chothia VL CDRs of the VL of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303), and / or one or more Chothia VH CDRs of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303). In one embodiment, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise a Chothia VH CDR 3 of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303). In one embodiment, provided herein is an antibody or fragment thereof that specifically binds to M(H)DM2 / 4 (e.g., HDM2) and comprises the three Chothia VL CDRs of the VL of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303) and / or the three Chothia VHCDRs of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303).

[0229] In certain aspects, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise one or more AbM VL CDRs of the VL of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303), and / or one or more AbM VH CDRs of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303). In one embodiment, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise an AbM VH CDR 3 of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303). In one embodiment, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise the three AbM VL CDRs of the VL of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303) and / or the three AbM VH CDRs of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303).

[0230] In certain aspects, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise one or more Contact VL CDRs of the VL of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303), and / or one or more Contact VH CDRs of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303). In one embodiment, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise Contact VH CDR 3 of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303). In one embodiment, provided herein is an antibody or fragment thereof that specifically binds to M(H)DM2 / 4 (e.g., HDM2) and comprises the three Contact VL CDRs of the VL of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303) and / or the three Contact VHCDRs of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303).

[0231] In certain aspects, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise one or more IMGT VL CDRs of the VL of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303), and / or one or more IMGT VH CDRs of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303). In one embodiment, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise an IMGT VH CDR 3 of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303). In one embodiment, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise the three IMGT VL CDRs of the VL of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303) and / or the three IMGT VH CDRs of the VH of any of the antibodies described herein (any of NMC-103, NMC-204, and NMC-303).

[0232] In certain embodiments, provided herein are antibodies or fragments thereof that specifically bind to M(H)DM2 / 4 (e.g., HDM2) and comprise a combination of Kabat CDRs, Chothia CDRs, AbM CDRs, IMGT CDRs, and Contact CDRs (or a combination of CDRs defined by any two, three, four, or five of these CDR definition systems).

[0233] In specific embodiments, the position of one or more CDRs along the VH (e.g., CDR1, CDR2, or CDR3) and / or VL (e.g., CDR1, CDR2, or CDR3) regions of the antibodies described herein can be varied by one, two, three, four, five, or six amino acid positions, so long as immunospecific binding to M(H)DM2 / 4 (e.g., HDM2) is maintained (e.g., substantially maintained, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%). For example, in one embodiment, the positions of the CDRs defining any of the antibodies described herein (any of antibodies NMC-103, NMC-204, and NMC-303) can be altered by shifting the N-terminal and / or C-terminal boundaries of the CDRs by one, two, three, four, five, or six amino acids, so long as immunospecific binding to M(H)DM2 / 4 (e.g., HDM2) is maintained (e.g., substantially maintained, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%). In another embodiment, the length of one or more CDRs along the VH (e.g., CDR1, CDR2, or CDR3) and / or VL (e.g., CDR1, CDR2, or CDR3) regions of an antibody described herein can be varied (e.g., shortened or lengthened) by one, two, three, four, five, or more amino acids, so long as immunospecific binding to M(H)DM2 / 4 (e.g., HDM2) is maintained (e.g., substantially maintained, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%).

[0234] In a specific embodiment, the anti-M(H)DM2 / 4 (e.g., HDM2) antibodies described herein are humanized immunoglobulins (e.g., IgG) comprising three VH CDRs and three VL CDRs (i.e., VH CDR1, VH CDR2, VH CDR3, VL CDR1, VLCDR2, and VL CDR3) of any of the antibodies described herein (any of the murine antibodies NMC-103, NMC-204, and NMC-303), respectively, a human or humanized framework region, and a human or humanized constant region; the present invention also provides antigen-binding fragments of such humanized antibodies. Non-limiting examples of human framework regions are described in the art, for example, see Kabat et al. (1991). Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Journal No. 91-3242. In certain embodiments, a humanized anti-M(H)DM2 / 4 (e.g., HDM2) antibody or antigen-binding fragment thereof comprises a VH having a VH CDR1, VH CDR2, and VH CDR3 as described herein (e.g., those of MNC-103, NMC-204, or NMC-303), surrounded by a VH framework region that is human or derived from a human framework region. In certain embodiments, an anti-M(H)DM2 / 4 (e.g., HDM2) antibody or antigen-binding fragment thereof comprises a VL having a VL CDR1, VL CDR2, and VL CDR3 as described herein (e.g., those of MNC-103, NMC-204, or NMC-303), surrounded by a VL framework region that is human or derived from a human framework region. In certain embodiments, an anti-M(H)DM2 / 4 (e.g., HDM2) antibody or antigen-binding fragment thereof comprises (i) a VH having a VH CDR1, VH CDR2, and VH CDR3 as described herein (e.g., those of MNC-103, NMC-204, or NMC-303), surrounded by a VH framework region that is human or derived from a human framework region; and (ii) a VL having a VL CDR1, VL CDR2, and VL CDR3 as described herein (e.g., those of MNC-103, NMC-204, or NMC-303), surrounded by a VL framework region that is human or derived from a human framework region.

[0235] Human framework regions that can be used include, but are not limited to: (i) framework regions selected using the "best fit" method (see, e.g., Sims et al. J. Immunol. 151: 2296 (1993)); (ii) framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, 89: 4285 (1992); and Presta et al. J. Immunol., 151: 2623 (1993)). ); (iii) human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008)); and (iv) framework regions derived from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272: 10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271: 22611-22618 (1996)). For a list of human framework regions, see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998).

[0236] In a specific embodiment, one or more of the CDRs of the anti-M(H)DM2 / 4 (e.g., HDM2) or antigen-binding fragments thereof described herein can be inserted into known framework regions using conventional recombinant DNA techniques. The framework regions can be naturally occurring or shared framework regions, and are preferably human framework regions.

[0237] In certain embodiments, polynucleotides comprising a combination of framework regions and CDRs are described herein that encode an anti-M(H)DM2 / 4 (e.g., HDM2) antibody or antigen-binding fragment thereof that specifically binds to M(H)DM2 / 4 (e.g., HDM2). One or more (e.g., one, two, or three) amino acid substitutions may be made within the framework regions, preferably one or more (e.g., one, two, or three) amino acid substitutions that improve binding of the antibody to M(H)DM2 / 4 (e.g., HDM2).

[0238] In alternative embodiments where the antibody or fragment thereof has not been humanized, the framework regions in the variable domain may be those of a native (eg, murine) antibody.

[0239] The antibodies provided herein include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules (i.e., molecules having an antigen binding site) that specifically bind to an extracellular region (epitope) of M(H)DM2 / 4 that is accessible on the plasma membrane surface of cancer cells (e.g., an epitope that is expressed or exposed at a higher level on the plasma membrane of cancer cells than on non-cancerous cells (e.g., when such cancer cells and non-cancerous cells originate from the same tissue)).

[0240] In preferred embodiments, the anti-M(H)DM2 / 4 antibodies described herein are monoclonal antibodies or fragments thereof. The antibodies and fragments described herein are preferably human, humanized or chimeric. Human antibodies can be human immunoglobulins, which can be isolated from human immunoglobulin libraries or isolated from mice or other animals expressing antibodies from human genes. In one embodiment, the antibodies provided herein are human antibodies (or fragments of human antibodies). In one embodiment, the antibodies provided herein are humanized antibodies (or fragments of human antibodies). In one embodiment, the antibodies provided herein are chimeric antibodies (or fragments of chimeric antibodies) (wherein chimeric antibodies are antibodies having a variable region of one species (e.g., mouse) and a constant region of another species (e.g., human)). Preferably, the antibodies provided herein are human, humanized or chimeric monoclonal antibodies (which are particularly suitable for treating human subjects). In one embodiment, the antibodies provided herein are synthetic antibodies. In one embodiment, the antibodies provided herein are multispecific antibodies (e.g., bispecific antibodies). In one embodiment, the antibodies provided herein are single-chain antibodies, e.g., single-chain Fv (scFv). In one embodiment, provided herein are antigen-binding fragments of anti-M(H)DM2 / 4 antibodies, wherein the fragment can be, but is not limited to, an Fv fragment, a Fab fragment, a F(ab') fragment, a F(ab')2 fragment, or a disulfide-linked Fv (sdFv). In one embodiment, the antigen-binding fragment provided herein is an Fv fragment. In one embodiment, the antigen-binding fragment provided herein is a Fab fragment. In one embodiment, the antigen-binding fragment provided herein is a F(ab')2 fragment. In one embodiment, the antigen-binding fragment provided herein is a F(ab') fragment.

[0241] In a specific embodiment, the antibodies provided herein are multispecific antibodies (e.g., bispecific antibodies) that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 exposed on the plasma membrane surface of cancer cells and specifically bind to a second antigen, wherein such binding allows effector cells to retarget tumor cells (for examples of such engineered bispecific antibodies for different targets, see Chames et al., 2009, MAbs 1:539-547, which describes an antibody called catumaxomab, which is a T cell targeting agent). In one embodiment, the antibodies provided herein are multispecific antibodies (e.g., bispecific antibodies) that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 exposed on the plasma membrane surface of cancer cells and also bind to an antigen exposed on the plasma membrane surface of effector cells. Effector cells include, but are not limited to, T cells, natural killer cells, neutrophils, macrophages, dendritic cells, and B lymphocytes. In one embodiment, the antibodies provided herein are multispecific antibodies (e.g., bispecific antibodies) that specifically bind to an extracellular accessible epitope of M(H)DM2 / 4 exposed on the plasma membrane surface of cancer cells and further specifically bind to an antigen exposed on the surface of T cells (e.g., cytotoxic T cells). In one embodiment, the antibodies provided herein are multispecific antibodies (e.g., bispecific antibodies) that specifically bind to an extracellular accessible epitope of M(H)DM2 / 4 exposed on the plasma membrane surface of cancer cells and further specifically bind to CD3. In a specific embodiment, the antibodies provided herein are multispecific antibodies (e.g., bispecific antibodies) that specifically bind to an extracellular accessible epitope of M(H)DM2 / 4 exposed on the plasma membrane surface of cancer cells and further specifically bind to an antigen exposed on the surface of natural killer cells, neutrophils, macrophages, dendritic cells, and / or B-lymphocytes. In specific embodiments, the antibodies provided herein are multispecific antibodies (e.g., bispecific antibodies) that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 exposed on the plasma membrane surface of cancer cells and further specifically bind to an antigen exposed on the surface of neutrophils, macrophages, dendritic cells, and / or B-lymphocytes. In specific embodiments, the antibodies provided herein are multispecific antibodies (e.g., bispecific antibodies) that specifically bind to an extracellularly accessible epitope of M(H)DM2 / 4 exposed on the plasma membrane surface of cancer cells and further specifically bind to an antigen exposed on the surface of natural killer cells, macrophages, and / or dendritic cells.

[0242] In preferred embodiments, where human subjects are treated, the antibody used is a human, humanized or chimeric monoclonal antibody or antigen-binding fragment thereof.

[0243] In certain embodiments, for example, in the case of treating non-human subjects, such as cats, dogs, cattle and other domesticated, farm and wild animals, the antibody can be an antibody or fragment suitable for the species being treated (i.e., of the species). The antibodies described herein can be from any animal species, such as a mammal (e.g., mouse, donkey, sheep, rabbit, goat, guinea pig, camel, horse, dog, cat) or bird (e.g., chicken).

[0244] In a specific embodiment, wherein the antibody is an immunoglobulin, the immunoglobulin molecule that can be used is any type (e.g., IgG, IgE, IgM, IgD, IgA, IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, IgA2) or subclass of immunoglobulin molecule. In a preferred embodiment, the antibody is an immunoglobulin, and particularly an IgG. In another embodiment, the antibody is an IgM.

[0245] In preferred embodiments, the anti-M(H)DM2 / 4 antibodies or fragments described herein are antibodies or fragments that mediate complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and / or cytotoxicity due to a cytotoxic drug to which the antibody or fragment is bound.

[0246] In specific embodiments, the anti-M(H)DM2 / 4 antibodies or fragments described herein are those that are capable of inducing cytotoxicity against cancer cells targeted by the antibody or fragment, wherein the cytotoxicity can be attributed to complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), or to the cytotoxicity of a drug conjugated to the antibody (where the antibody is in the form of an antibody-drug conjugate).

[0247] In a specific embodiment, the anti-M(H)DM2 / 4 antibody or fragment described herein is an antibody or fragment that mediates complement dependent cytotoxicity (CDC). Methods for preparing antibodies with CDC function are known in the art. In some embodiments where CDC activity is desired, the Fc region of the antibody described herein is human IgG (e.g., IgG1, IgG2, IgG3, IgG4) type or human IgM type. In some embodiments where CDC activity is desired, the Fc region of the antibody described herein is mouse IgG (e.g., IgG1, IgG2a, IgG2b, IgG3) or mouse IgM type. In one embodiment, the Fc region of the antibody described herein is human IgG1 isotype. In one embodiment, the Fc region of the antibody described herein is human IgG3 isotype. In one embodiment, the Fc region of the antibody described herein is human IgG2 isotype. In one embodiment, the Fc region of the antibody described herein is bioengineered (e.g., mutated) to increase its CDC activity. In one embodiment, the antibody or fragment is a bispecific antibody or fragment that specifically binds to two different extracellular epitopes on M(H)DM2 / 4 (which can, for example, result in amplified complement activation, increased deposition of fragments (C3b, iC3b, C3d, C3g, C4b) on the surface membrane of cancer cells, and / or enhanced killing of cancer cells by MAC). In another embodiment, the antibody or fragment is a bispecific antibody or fragment that specifically binds to an extracellular epitope of M(H)DM2 / 4 and an extracellular epitope of complement regulatory protein (CRP) (which can, for example, prevent newly deposited immunoreactive fragments (C3b, iC3b, C3d, C3g, C4b) from being degraded by CRP, amplify activation of the complement cascade, and / or amplify MAC-induced cancer cell lysis). Such a bispecific anti-M(H)DM2 / 4 antibody or fragment can increase CDC activity, increase ADCC activity, increase antibody-dependent cellular phagocytosis (ADCP) of neutrophils and macrophages, or increase CDC, ADCC, and ADCP.

[0248] In specific embodiments, the anti-M(H)DM2 / 4 antibody or fragment described herein is an antibody or fragment that mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and / or antibody-dependent cellular phagocytosis (ADCP).

[0249] The method for preparing the antibody with ADCC function is known in the art. The method for preparing the antibody with ADCP function is known in the art. Generally, the Fc region of the antibody mediates its combination with the Fc receptor FcR on neutrophils, macrophages, natural killer cells, eosinophils and mast cells, which causes ADCC and on neutrophils, macrophages and dendritic cells, thereby causing ADCP. In some embodiments where ADCC and / or ADCP activity is desired, the Fc region of the antibody as described herein is human IgG (e.g., IgG1, IgG2, IgG3) type or human IgE type. In one embodiment, the Fc region of the antibody as described herein is human IgG1 isotype.

[0250] In one embodiment, the Fc region of an antibody as described herein is bioengineered (e.g., by cross-linking, by disulfide bond formation, by oligosaccharide addition, or by mutation) to increase its ADCC and / or ADCP activity. In one embodiment, the Fc region of an antibody as described herein is mutated to increase the lifespan of the intact antibody (e.g., according to Vaccaro et al., 2005, Nat Biotechnol. 23: 1283-8128, the disclosure of which is incorporated herein by reference). In another embodiment, amino acid substitutions in the Fc CH2 and CH3 domains can be used to direct efficacy toward ADCC / ADCP and away from CDC, or to increase the efficiency of all three cytotoxic activities (i.e., ADCC, ADCP, and CDC). In another embodiment, the CH2 and / or CH3 domains of the Fc region of the antibodies described herein are modified at their glycosylation sites to remove / reduce fucose residues to facilitate improved ADCC and / or ADCP function (e.g., according to the methods described in, for example, Satoh et al., 2006, Expert Opin Biol Ther. 6: 1161-1173 and / or Liu et al., 2015, Ca Immunol Res. 3: 173-183, the disclosures of which are incorporated herein by reference).

[0251] In a specific embodiment, the anti-M(H)DM2 / 4 antibodies described herein having an IgG Fc region are bioengineered in their Fc region to change the N-glycan structure at their glycosylation sites to a G0 glycan type that is capped with GlcNAc (N-acetylglucosamine) and lacks fucose and sialic acid residues (which can lead to, for example, activation of both the classical and alternative pathways of the complement pathway and increased binding to lectins, including mannose-binding lectins secreted during inflammatory responses).

[0252] In one embodiment, the Fc region of an antibody as described herein is of human IgG1 isotype and has an alanine substitution at position 333 of its CH2 domain. In one embodiment, the Fc region of an antibody as described herein is of human IgG1 isotype and has the triple mutation S239D / I332E / A330L (which results in a higher affinity for FcγRIIIa and a lower affinity for FcγRIIb, resulting in enhanced ADCC) (such Fc modifications can be performed, for example, according to the method described by Lazar et al., 2006, PNAS 103:4005-4010). In one embodiment, the Fc region of the antibodies described herein is of the human IgG1 isotype and has the triple mutation S239D / I332E / G236A (which results in improved FcγRIIIa affinity and FcγRIIa / FcγRIIb ratio, which mediate enhanced phagocytosis of target cells by macrophages) (such Fc modifications can be performed, for example, according to the method described in Richards et al., 2008, Mol. Cancer Ther. 7:2517-27).

[0253] In specific embodiments, the anti-M(H)DM2 / 4 antibodies or fragments described herein are antibodies or fragments that mediate both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). In specific embodiments, the anti-M(H)DM2 / 4 antibodies or fragments described herein are antibodies or fragments that mediate complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). In other embodiments, antibodies or fragments that mediate only CDC or only ADCC activity are contemplated herein. The CDC and ADCC functions of the antibodies described herein can be tested by any in vitro and / or in vivo cytotoxicity assays known in the art. In certain embodiments, the antibodies or fragments used herein comprise one or more amino acid mutations or substitutions in the Fc region that improve their CDC or ADCC activity (e.g., any mutation or substitution described herein or known in the art (see, e.g., Idusogie et al., 2001. J Immunol. 166(4):2571-5; Strohl, 2009, Curr Opin Biotechnol. 20(6):685-91; Lazar et al., 2006, PNAS 103(11):4005–4010, the disclosures of which are incorporated herein by reference)).

[0254] In specific embodiments, the anti-M(H)DM2 / 4 antibody or fragment is unconjugated, eg, not conjugated to a cytotoxic drug).

[0255] In certain embodiments, the anti-M(H)DM2 / 4 antibodies or fragments described herein are not bound (e.g., not conjugated) to a drug (e.g., a cytotoxic drug). In some of these embodiments, the anti-M(H)DM2 / 4 antibodies or fragments mediate CDC and / or ADCC.

[0256] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof specifically binds to an extracellularly accessible segment (ie, an epitope) within amino acids 1 to 15, 15 to 25, or 475 to 491 of HDM2 (SEQ ID NO: 4).

[0257] In one embodiment, the anti-HDM2 antibody or fragment thereof specifically binds to HDM2 within the amino acids of SEQ ID NO: 1, which are amino acids 1 to 15 of HDM2 (SEQ ID NO: 4). The amino acids of SEQ ID NO: 1, which are amino acids 1 to 15 of SEQ ID NO: 4, are in an extracellularly accessible epitope of HDM2.

[0258] In one embodiment, the anti-HDM2 antibody or fragment thereof specifically binds to HDM2 within the amino acids of SEQ ID NO: 2, which are amino acids 15 to 25 of HDM2 (SEQ ID NO: 4). The amino acids of SEQ ID NO: 2, which are amino acids 15 to 25 of SEQ ID NO: 4, are in an extracellularly accessible epitope of HDM2.

[0259] In one embodiment, the anti-HDM2 antibody or fragment thereof specifically binds to HDM2 within amino acids 475 to 491 of SEQ ID NO: 3, which are amino acids 475 to 491 of HDM2 (SEQ ID NO: 4). The amino acids 475 to 491 of SEQ ID NO: 4 are in an extracellularly accessible epitope of HDM2.

[0260] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof specifically binds to an extracellularly accessible epitope of HDM2 within amino acids 50 to 60 of M(H)DM2 / 4 (SEQ ID NO: 4 or SEQ ID NO: 6).

[0261] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 within amino acids 100 to 110 of M(H)DM2 / 4 (SEQ ID NO: 4 or SEQ ID NO: 6).

[0262] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof specifically binds to an extracellular epitope of M(H)DM2 / 4 within amino acids 1 to 126 of M(H)DM2 / 4 (SEQ ID NO: 4 or SEQ ID NO: 6).

[0263] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 within amino acids 436 to 482 of M(H)DM2 / 4 (SEQ ID NO: 4 or SEQ ID NO: 6).

[0264] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 within the terminal 100 amino acids of the C-terminus of M(H)DM2 / 4 (e.g., a M(H)DM2 / 4 protein variant (splice variant) known or predicted to be expressed on the plasma membrane of cells of the cancer type being treated, or a M(H)DM2 / 4 protein variant (splice variant) determined to be expressed on the plasma membrane of cancer cells in a subject being treated).

[0265] The present invention also provides anti-M(H)DM2 / 4 antibodies or fragments thereof that compete for binding to HDM2 with an antibody that specifically binds to HDM2 within the amino acid sequence of SEQ ID NO: 1 (e.g., the NMC-103 antibody described herein, or any antibody or fragment having the VH of NMC-103 (i.e., the VH of SEQ ID NO: 36) and the VL of NMC-103 (i.e., the VL of SEQ ID NO: 37), or any antibody or fragment having the VH and VL CDRs of NMC-103). The present invention also provides anti-M(H)DM2 / 4 antibodies or fragments thereof that compete for binding to HDM2 with an antibody that specifically binds to HDM2 within the amino acid sequence of SEQ ID NO: 2 (e.g., the NMC-204 antibody described herein, or any antibody or fragment having the VH of NMC-204 (i.e., the VH of SEQ ID NO: 38) and the VL of NMC-204 (i.e., the VL of SEQ ID NO: 39), or any antibody or fragment having the VH and VL CDRs of NMC204). The present invention also provides anti-M(H)DM2 / 4 antibodies or fragments thereof that compete for binding to HDM2 with an antibody that specifically binds to HDM2 within the amino acid sequence of SEQ ID NO: 3 (e.g., the NMC-303 antibody described herein, or any antibody or fragment having the VH of NMC-303 (i.e., the VH of SEQ ID NO: 40) and the VL of NMC-303 (i.e., the VL of SEQ ID NO: 41), or any antibody or fragment having the VH and VL CDRs of NMC-303).

[0266] Any competition assay known in the art can be used to determine antibodies that compete with the antibodies described herein for binding to M(H)DM2 / 4 (see Harlow and Lane (1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY)). In an exemplary competition assay, immobilized M(H)DM2 / 4 (e.g., immobilized on a microtiter plate or well) is incubated in a solution containing a first labeled antibody that binds to M(H)DM2 / 4 and a second unlabeled antibody whose ability to compete with the first antibody for binding to M(H)DM2 / 4 is to be tested. As a control, immobilized M(H)DM2 / 4 can be incubated in a solution containing the first labeled antibody but not the second unlabeled antibody. Following incubation, excess unbound antibody is removed, and the amount of label associated with the immobilized M(H)DM2 / 4 is measured. A substantial decrease in the amount of label in the test sample relative to the control sample indicates that the second antibody is competing with the first antibody for binding to M(H)DM2 / 4.

[0267] In specific embodiments, an antibody that competes for binding to M(H)DM2 / 4 with an antibody described herein (e.g., an antibody having the VH and VL of NMC-103, NMC-204, or NMC-303) also binds to the same peptide derived from M(H)DM2 / 4 that is bound by such an antibody (e.g., a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3). In specific embodiments, an antibody that competes for binding to M(H)DM2 / 4 with an antibody described herein (e.g., an antibody having the VH and VL of NMC-103, NMC-204, or NMC-303) also binds to the same epitope in M(H)DM2 / 4 that is bound by such an antibody.

[0268] In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof binds to the same epitope of M(H)DM2 / 4 as an antibody or fragment having a VH of SEQ ID NO: 36 and a VL of SEQ ID NO: 37. In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein binds to the same epitope of M(H)DM2 / 4 as an antibody or fragment having a VH of SEQ ID NO: 38 and a VL of SEQ ID NO: 39. In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein binds to the same epitope of M(H)DM2 / 4 as an antibody or fragment having a VH of SEQ ID NO: 40 and a VL of SEQ ID NO: 41.

[0269] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof used in the methods described herein specifically binds to an extracellularly accessible epitope within amino acids 19 to 50 of HDM2 (SEQ ID NO: 4).

[0270] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof used in the methods described herein specifically binds to an extracellularly accessible epitope within amino acids 19 to 108 of HDM2 (SEQ ID NO: 4).

[0271] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof used in the methods described herein specifically binds to an extracellularly accessible epitope within amino acids 154 to 167 of HDM2 (SEQ ID NO: 4).

[0272] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof used in the methods described herein specifically binds to an extracellularly accessible epitope within amino acids 1 to 60 of HDM2 (SEQ ID NO: 4).

[0273] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof used in the methods described herein specifically binds to an extracellularly accessible epitope within amino acids 1 to 100 of HDM2 (SEQ ID NO: 4).

[0274] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof used in the methods described herein specifically binds to an extracellularly accessible epitope within amino acids 1 to 108 of HDM2 (SEQ ID NO: 4).

[0275] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof used in the methods described herein specifically binds to an extracellularly accessible epitope within amino acids 26 to 60 of HDM2 (SEQ ID NO: 4).

[0276] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof used in the methods described herein specifically binds to an extracellularly accessible epitope within the terminal 60 amino acids of the C-terminus of HDM2 (e.g., a HDM2 protein variant (splice variant) known or predicted to be expressed on the plasma membrane of cells of the cancer type being treated, or a HDM2 protein variant (splice variant) determined to be expressed on the plasma membrane of cancer cells in a subject being treated).

[0277] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof used in the methods described herein specifically binds to an extracellularly accessible epitope within the terminal 100 amino acids of the C-terminus of HDM2 (e.g., a HDM2 protein variant (splice variant) known or predicted to be expressed on the plasma membrane of cells of the cancer type being treated, or a HDM2 protein variant (splice variant) determined to be expressed on the plasma membrane of cancer cells in a subject being treated).

[0278] In one embodiment, the anti-M(H)DM2 / 4 antibody or fragment thereof used in the methods described herein specifically binds to an extracellularly accessible epitope within amino acids 101 to 200 of HDM2 (SEQ ID NO: 4).

[0279] In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof used in the methods described herein compete for binding to HDM2 with the antibody OP145 (monoclonal antibody purchased from Calbiochem, catalog number OP145-100UG; see Table 10 below for more details about OP145). In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof used in the methods described herein compete for binding to HDM2 with the antibody 965 (SMP14) (monoclonal antibody purchased from Santa Cruz, catalog number Sc-965; see Tables 3 and 10 below for more details about 965 (SMP14). In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof used in the methods described herein compete for binding to HDM2 with the antibody sc-813 (N-20) (polyclonal antibody purchased from Santa Cruz, catalog number Sc-813; see Table 10 below for more details about sc-813 (N-20). In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof used in the methods described herein compete for binding to HDM2 with the antibody sc-812 (C-18) (polyclonal antibody purchased from Santa Cruz, catalog number Sc-812; see Table 10 below for more details about sc-812 (C-18). In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof used in the methods described herein compete for binding to HDM2 with the antibody M01 clone 1A7 (monoclonal antibody purchased from Abnova, catalog number H00004193-M01; see Table 3 below for more details about M01 clone 1A7).

[0280] Any competition assay known in the art can be used to identify antibodies that compete with antibody OP145, SMP14, N-20, C-18, or M01 clone 1A7 for binding to M(H)DM2 / 4 (e.g., HDM2) (see Harlow and Lane (1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY)).

[0281] In specific embodiments, an antibody that competes for binding to M(H)DM2 / 4 with antibody OP145, SMP14, N-20, C-18, or M01 clone 1A7 also binds to the same epitope bound by such an antibody.

[0282] In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof used in the methods described herein bind to the same epitope of HDM2 as the antibody OP145 (see Table 10 below for more details about OP145). In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof used in the methods described herein bind to the same epitope of HDM2 as the antibody 965 (SMP14) (see Tables 3 and 10 below for more details about 965 (SMP14)). In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof used in the methods described herein bind to the same epitope of HDM2 as the polyclonal antibody sc-813 (N-20) (see Table 10 below for more details about 813 (N-20)). In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof used in the methods described herein bind to the same epitope of HDM2 as the polyclonal antibody sc-812 (C-18) (see Table 10 below for more details about sc-812 (C-18)). In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof used in the methods described herein bind to the same epitope of HDM2 as antibody M01 clone 1A7 (i.e., a monoclonal antibody purchased from Abnova, catalog number H00004193-M01; see Table 3 below for more details on M01 clone 1A7).

[0283] In specific embodiments, the anti-M(H)DM2 / 4 antibodies or fragments thereof described herein are purified. In certain embodiments, the antibodies or fragments are purified to a purity greater than 95% or 99% as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC) (see Flatman et al., J. Chromatogr. B 848:79-87 (2007) for a review of methods for assessing antibody purity).

[0284] The anti-M(H)DM2 / 4 antibodies or fragments described herein can be fused or coupled (e.g., covalently or non-covalently linked) to a detectable label or substance. Such labeled antibodies or fragments can be used to detect M(H)DM2 / 4 on the plasma membrane surface of cells.

[0285] Examples of detectable labels or substances include enzyme labels, radioactive isotopes (e.g., iodine, carbon, sulfur, tritium, indium, and technetium), luminescent labels, fluorescent labels, and biotin. This method can be used to determine whether certain cancer cells (e.g., cancer cells from a patient) express M(H)DM2 / 4 or certain splice variants of M(H)DM2 / 4 on the plasma membrane, wherein detection of M(H)DM2 / 4 using an antibody (or fragment) can indicate that the antibody (or fragment) (with or without a detectable label or substance) can be used to diagnose or treat cancer or prevent cancer metastasis.

[0286] 7.2 Antibody-drug conjugates

[0287] In a specific embodiment, the present invention provides an antibody-drug conjugate comprising an anti-M(H)DM2 / 4 antibody or fragment as described herein conjugated (e.g., covalently bound) to a cytotoxic drug. In such an embodiment, the antibody-drug conjugate is intended to mediate cytotoxicity by targeting cancer cells to which the cytotoxic drug is delivered.

[0288] Thus, the anti-M(H)DM2 / 4 antibodies or antigen-binding fragments described herein can be conjugated or coupled to one or more cytotoxic agents. A cytotoxic agent can be any agent that inhibits or prevents vital cellular functions (e.g., cell division) and / or causes cell death or destruction. Cytotoxic agents that can be conjugated or coupled to anti-M(H)DM2 / 4 antibodies or fragments include, but are not limited to, chemotherapeutic agents (e.g., any known in the art or described herein), toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), radioactive isotopes, growth inhibitors, and nucleolytic enzymes. Antibody-drug conjugates and methods for their preparation (including types of antibodies useful in such conjugates, drugs useful in such conjugates, and linkers useful for attaching antibodies to drugs) are known in the art (see, for example, Peters & Brown, 2015, Biosci. Rep. 35, e00225, doi: 10.1042 / BSR20150089).

[0289] Examples of cytotoxic agents that can be conjugated to the anti-M(H)DM2 / 4 antibodies or fragments described herein include, but are not limited to, anthracyclines, doxorubicin, methotrexate, antimetabolites, antifolates, auristatins (e.g., MMAE or MMAF), maytansinoids, calicheamicins, duocarymucins, and pyrrolobenzodiazepine (PBD) dimers.

[0290] In specific embodiments, the M(H)DM2 / 4 antibodies or fragments described herein are conjugated to one or more of the following drugs: a maytansinoid, an auristatin (such as the monomethyl auristatin drug moieties DE and DF (MMAE and MMAF)), a dolastatin, a calicheamicin or a derivative thereof, an anthracycline (such as daunomycin or doxorubicin), methotrexate, vindesine, a taxane (such as docetaxel), paclitaxel, larotaxel, tesetaxel, ortaxel, and a trichothecene.

[0291] In another embodiment, the M(H)DM2 / 4 antibody or fragment described herein is conjugated to a toxin or fragment thereof (e.g., diphtheria A chain, a non-binding active fragment of diphtheria toxin, exotoxin A chain, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii protein, dianthin, Phytolaca americana protein, momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, or a trichothecene).

[0292] In another embodiment, the M(H)DM2 / 4 antibodies or fragments described herein are conjugated to a radioisotope (e.g., At 211 , I 131 , I 125 、Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 、P 32 , Pb 212 or radioactive isotopes of Lu).

[0293] In another embodiment, the M(H)DM2 / 4 antibodies or fragments thereof described herein are coupled to nanoparticles or other targeting vehicles to facilitate focused delivery and retention of the antibodies to tumor sites.

[0294] 7.3 Antibody preparation

[0295] The anti-M(H)DM2 / 4 antibodies or fragments described herein can be produced by any method known in the art.

[0296] Methods for producing polyclonal antibodies are known in the art (see, for example, Chapter 11 of Short Protocols in Molecular Biology, (2002) 5th edition, Ausubel FM et al., eds., John Wiley and Sons, New York).

[0297] Methods for producing monoclonal antibodies are also known in the art, including the use of hybridomas, recombinant and phage display technologies, and the use of humanized mice. For example, monoclonal antibodies can be produced using hybridoma technology, such as in Harlow E and Lane D, Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd edition. 1988);Hammerling GJ et al., Monoclonal Antibodies and T-Cell Hybridomas 563681 (Elsevier, NY, 1981), or Kohler G and Milstein C (1975) Nature 256: taught in 495. In another example, humanized mice can be used to produce human monoclonal antibodies, such as, for example, Laffleur et al., 2012, Methods Mol.Biol.901: taught in 149-59.

[0298] Methods for producing specific antibodies using hybridoma technology are conventional and well known in the art. Specifically, a mouse or another suitable host animal can be immunized to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the target protein used for immunization (i.e., the extracellular region of M(H)DM2 / 4). The lymphocytes are then fused with myeloma cells to form hybridoma cells (see Goding JW (ed.), Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986); see also Kozbor D (1984) J Immunol 133: 3001-5; Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)). The hybridoma cells are then grown in a suitable culture medium and analyzed for the production of monoclonal antibodies against M(H)DM2 / 4. The binding specificity of the monoclonal anti-M(H)DM2 / 4 antibodies produced by this method can be determined by methods known in the art, such as immunoprecipitation or in vitro analysis, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). The hybridoma clones thus selected are then grown by standard methods (see Goding JW (ed.), Monoclonal Antibodies: Principles and Practice, supra). The monoclonal antibodies can then be isolated from the culture medium and purified.

[0299] In addition, the antibodies or fragments described herein can also be prepared using various phage display techniques known in the art (see Brinkman U et al., (1995) J Immunol Methods 182:41-50; Ames RS et al., (1995) J Immunol Methods 184:177-186; Kettleborough CA et al., (1994) Eur J Immunol 24:952-958; Persic L et al., (1997) Gene 187:9-18; and Burton DR & Barbas CF (1994) Advan Immunol 57:191-280).

[0300] Methods for producing chimeric antibodies (i.e., antibodies having variable regions from one species (e.g., murine) and constant regions from another species (e.g., human)) are known in the art (see Morrison SL (1985) Science 229: 1202-7; Oi VT & Morrison SL (1986) BioTechniques 4: 214-221; Gillies SD et al. (1989) J Immunol Methods 125: 191-202; and U.S. Pat. Nos. 5,807,715, 4,816,567, 4,816,397, and 6,331,415).

[0301] Methods for preparing antibody fragments are known in the art. For example, Fab and F(ab')2 fragments can be produced by proteolytic cleavage of immunoglobulin molecules using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments).

[0302] Methods for preparing humanized antibodies are also known in the art (see International Publication No. WO 91 / 09967; Padlan EA (1991) Mol Immunol 28(4 / 5):489-498; Studnicka GM et al., (1994) Prot Engineering 7(6):805-814; and Roguska MA et al., (1994) PNAS 91:969-973; International Publication No. WO 93 / 17105; Tan P et al., (2002) J Immunol 169:1119-25; Caldas C et al., (2000) Protein Eng. 13(5):353-60; Morea V et al., (2000), Methods 20(3):267-79; Baca M et al., (1997) J Biol Chem 272(16):10678-84; Roguska MA et al., (1996) Protein Eng 9(10):895 904; Couto JR et al., (1995) Cancer Res.55(23 Supp):5973s-5977s; Couto JR et al., (1995) Cancer Res 55(8):1717-22; Sandhu JS (1994) Gene 150(2):409-10 and Pedersen JT et al., (1994) J Mol Biol 235(3):959-73). In a specific embodiment, humanized antibodies are prepared by CDR grafting.

[0303] Methods for preparing human antibodies are known in the art, including phage display methods using antibody libraries derived from human immunoglobulin sequences (see U.S. Pat. Nos. 4,444,887, 4,716,111, and 5,885,793; and International Publications Nos. WO 98 / 46645, WO 98 / 50433, WO 98 / 24893, WO 98 / 16654, WO 96 / 34096, WO 96 / 33735, and WO 91 / 10741). In some embodiments, human antibodies can be produced using mouse-human hybridomas (see Shinmoto H et al., (2004) Cytotechnology 46: 19-23; Naganawa Y et al., (2005) Human Antibodies 14: 27-31).

[0304] Methods for preparing single domain antibodies, e.g., antibodies lacking light chains, are also known in the art (see Riechmann L & Muyldermans S (1999) J Immunol 231:25-38; Nuttall SD et al., (2000) Curr Pharm Biotechnol 1(3):253-263; Muyldermans S, (2001) J Biotechnol 74(4):277-302).

[0305] Methods for preparing single-chain Fv (scFv) antibodies are also known in the art (see Ahmad et al., 2012, Clinical and Developmental Immunology, doi: 10.1155 / 2012 / 980250; Wang et al., 2006, Anal. Chem. 78, 997–1004; Pansri et al., 2009, BMC Biotechnology 9: 6). For example, scFv antibodies can be constructed by fusing the variable domains of the heavy and light chains of immunoglobulins via a short polypeptide linker (using recombinant expression technology), and scFv antibodies with desired antigen-binding properties can be selected by phage display technology.

[0306] Methods for generating bispecific antibodies are well known in the art (Konterman, 2012, MAbs 4: 182-197; Gramer et al., 2013, MAbs 5: 962-973).

[0307] Methods for conferring CDC or ADCC activity to antibodies (e.g., antibodies that initially do not have CDC or ADCC activity) are known in the art (see Kellner et al., 2014, Methods 65: 105–113; International Publication No. WO 2012010562; Natsume et al., 2009, Drug Design, Development and Therapy 3(3): 7-16). Such methods include, but are not limited to, Fc region isotype shuffling, amino acid mutations in the Fc region that confer enhanced or optimized CDC and / or ADCC activity, and alterations in the Fc region glycosylation profile that confer enhanced or optimized CDC and / or ADCC activity.

[0308] 7.4 Antibody selection

[0309] If a candidate antibody or fragment for use in the therapeutic and diagnostic methods provided herein is not already known or demonstrated to bind to a region of M(H)DM2 / 4 exposed on the surface of a cancer cell, the antibody or fragment can optionally be tested by any of the following methods:

[0310] In certain aspects, provided herein are methods for identifying an anti-M(H)DM2 / 4 antibody or fragment thereof for use in the methods described herein (e.g., for diagnosing cancer, treating cancer, or preventing metastasis), comprising: (a) contacting an intact cancer cell (e.g., a cancer cell expected, known, or determined to express M(H)DM2 / 4) with an anti-M(H)DM2 / 4 antibody or fragment thereof; and (b) determining whether the antibody or fragment binds to the intact cancer cell, particularly to the extracellular surface of the cancer cell (e.g., relative to an intact cancer cell not contacted by the antibody or fragment), wherein binding of the anti-M(H)DM2 / 4 antibody or fragment to the intact cancer cell contacted with such an antibody or fragment indicates that the antibody or fragment is suitable for use in the methods described herein. In specific embodiments, the cancer cell is from a patient for whom treatment with the antibody or fragment is proposed.

[0311] In certain aspects, provided herein are methods for identifying an anti-M(H)DM2 / 4 antibody or fragment thereof for use in the methods described herein (e.g., for diagnosing cancer, treating cancer, or preventing metastasis), comprising: (a) contacting an intact cancer cell (e.g., a cancer cell expected, known, or determined to express M(H)DM2 / 4) with an anti-M(H)DM2 / 4 antibody or fragment thereof; and (b) determining whether the antibody or fragment binds to the intact cancer cell (particularly on the extracellular surface of the cancer cell) at an increased level relative to binding to intact normal cells (e.g., non-cancerous cells of the same tissue or organ type as the cancer cell), wherein increased binding of the anti-M(H)DM2 / 4 antibody or fragment to the intact cancer cell relative to normal cells indicates that the antibody or fragment is suitable for use in the methods described herein.

[0312] In certain aspects, provided herein are methods of identifying an anti-M(H)DM2 / 4 antibody or fragment thereof for use in the methods described herein (e.g., for treating cancer or for preventing metastasis), comprising: (a) contacting an intact cancer cell (e.g., a cancer cell known, expected, or determined to express M(H)DM2 / 4) with an anti-M(H)DM2 / 4 antibody or fragment thereof; and (b) determining whether the contacting step results in an increased amount of cell death or destruction of the intact cancer cell (e.g., as determined by staining with a cell death marker such as propidium iodide) relative to the amount of death or destruction of intact cancer cells not contacted with the antibody or fragment and / or relative to the amount of death or destruction of intact normal cells (e.g., non-cancerous cells from the same tissue or organ as the cancer cell) contacted with the antibody or fragment, wherein an increased amount of cell death or destruction of the intact cancer cell contacted with the antibody or fragment indicates that the antibody or fragment is suitable for use in the methods described herein.

[0313] In certain aspects, provided herein are methods of identifying an anti-M(H)DM2 / 4 antibody or fragment thereof for use in the methods described herein (e.g., for treating cancer or for preventing metastasis), comprising: (a) contacting an intact cancer cell (e.g., a cell known, expected, or determined to express M(H)DM2 / 4) with an anti-M(H)DM2 / 4 antibody or fragment; and (b) determining whether the contacting step results in an increased level of complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) against the intact cancer cell (as determined by one or more cytotoxicity assays) relative to the level of CDC or ADCC against intact cancer cells not contacted by the antibody or fragment and / or relative to the level of CDC or ADCC against intact normal cells (e.g., non-cancerous cells of the same tissue or organ as the cancer cell) contacted by the antibody or fragment, wherein an increased level of CDC or ADCC against intact cancer cells indicates that the antibody or fragment is suitable for use in the methods described herein.

[0314] In certain aspects, provided herein are methods for identifying an anti-M(H)DM2 / 4 antibody or fragment thereof for use in the methods described herein (e.g., for treating cancer or for preventing metastasis), comprising: (a) contacting an intact cancer cell (e.g., a cell known, expected, or determined to express M(H)DM2 / 4) with an anti-M(H)DM2 / 4 antibody or fragment thereof; and (b) determining whether the contacting step results in increased inhibition of growth and proliferation of the intact cancer cell relative to the inhibition of growth and proliferation of the intact cancer cell not contacted with the antibody or fragment and / or relative to the inhibition of growth and proliferation of intact normal cells (e.g., non-cancerous cells from the same tissue or organ as the cancer cell) contacted with the antibody or fragment, wherein increased inhibition of growth and proliferation of the intact cancer cell contacted with the antibody or fragment indicates that the antibody or fragment is suitable for use in the methods described herein.

[0315] 7.5 Pharmaceutical composition

[0316] Provided herein are pharmaceutical compositions comprising an anti-M(H)DM2 / 4 antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier. Also provided herein are pharmaceutical compositions comprising an antibody-drug conjugate as described herein and a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers (including, but not limited to, excipients and stabilizers) are known in the art (see, for example, Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA). The anti-M(H)DM2 / 4 antibody or fragment or antibody-drug conjugate in the pharmaceutical compositions described herein can be purified.

[0317] Pharmaceutically acceptable carriers can include isotonic agents, buffers, suspending agents, dispersants, emulsifiers, wetting agents, sequestering agents or chelating agents, pH buffers, dissolution enhancers, antioxidants, anesthetics and / or antimicrobials. Suitable excipients include but are not limited to water, saline, glycerol, ethanol, starch, lactose, sucrose, gelatin, malt, propylene, silica gel, sodium stearate, matrix cream and dextrose. If parenteral administration, suitable pharmaceutically acceptable carriers can include physiological saline or phosphate buffered saline (PBS), and containing solutions such as glucose, polyethylene glycol, polypropylene glycol or other medicaments.

[0318] In specific embodiments, the pharmaceutical compositions provided herein comprise an anti-M(H)DM2 / 4 antibody or antigen-binding fragment thereof or antibody-drug conjugate described herein, and optionally one or more additional therapeutic (e.g., anti-cancer) agents, in a pharmaceutically acceptable carrier.

[0319] The pharmaceutical composition can be formulated for any route of administration to a subject. Injectable preparations can be prepared as liquid solutions, suspensions, emulsions, or solid forms suitable for solution or suspension prior to injection.

[0320] The anti-M(H)DM2 / 4 antibody or fragment thereof or antibody-drug conjugate can be used or present in a pharmaceutical composition in a therapeutically effective amount. The therapeutically effective amount of the antibody or conjugate can be determined by standard clinical techniques.

[0321] In a specific embodiment, the pharmaceutical composition contemplated for use in the methods of treatment described herein comprises an anti-M(H)DM2 / 4 antibody, or an antigen-binding fragment thereof, or an antibody-drug conjugate described herein, and does not comprise any additional anti-cancer agent or anti-cancer treatment. In another specific embodiment, the pharmaceutical composition contemplated for use in the methods of treatment described herein comprises an anti-M(H)DM2 / 4 antibody, or an antigen-binding fragment thereof, or an antibody-drug conjugate described herein, and further comprises an additional anti-cancer agent or anti-cancer treatment (e.g., any one, two, or more additional anti-cancer agents or anti-cancer treatments described herein).

[0322] 7.6 Treatment

[0323] In one aspect, the present invention provides methods for treating cancer (e.g., inhibiting cancer proliferation, inhibiting cancer progression) in a subject in need thereof, comprising administering to the subject any of the anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibodies or fragments described herein. In a specific embodiment, the present invention provides a method for treating cancer in a subject in need thereof, comprising administering to the subject an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4. In another specific embodiment, the present invention provides a method for preventing metastasis in a subject in need thereof, comprising administering to the subject an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4. In specific embodiments of the methods described herein, the antibody or fragment is not conjugated to a cell-penetrating peptide.

[0324] In one aspect, the present invention provides a method for treating cancer (e.g., inhibiting cancer proliferation, inhibiting cancer progression) in a subject in need thereof, comprising administering to the subject an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2 exposed on the surface of a cancer cell (e.g., where cells of the cancer type being treated are known or expected to have such an extracellular region of HDM2 exposed on their plasma membrane surface), preferably wherein the antibody or fragment is not bound to a cell-penetrating peptide. In one embodiment, the method for treating cancer includes preventing metastasis of cancer. In one embodiment, the method for treating cancer is a method for reducing tumor size (as measured, for example, by tumor volume or diameter), inhibiting tumor growth, reducing tumor growth, or eradicating a tumor.

[0325] In another aspect, the present invention provides a method for preventing metastasis in a subject having cancer, comprising administering to the subject any of the anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibodies or fragments described herein. In another aspect, the present invention provides a method for preventing metastasis in a subject having cancer, comprising administering to the subject an antibody or fragment thereof that specifically binds to an extracellular region of HDM2 exposed on the surface of cancer cells (e.g., where cells of the type of cancer being treated are known or expected to have such an extracellular region of HDM2 exposed on their plasma membrane surface).

[0326] In another aspect, the present invention provides a method for reducing the number, size, or invasiveness of metastases or eradicating metastases in a subject having metastatic cancer, comprising administering to the subject any of the anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibodies or fragments described herein. In another aspect, the present invention provides a method for reducing the number, size, or invasiveness of metastases or eradicating metastases in a subject having metastatic cancer, comprising administering to the subject an antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of HDM2 exposed on the surface of cancer cells (e.g., where cells of the type of cancer being treated are known or expected to have such an extracellularly accessible epitope of HDM2 exposed on their plasma membrane surface).

[0327] In one aspect, the invention provides treatments for cancers that are resistant to one or more other cancer treatments, e.g., a vaccine, a targeted therapy (e.g., a small molecule targeted therapy), chemotherapy, radiation therapy, or immunotherapy (e.g., treatment with another monoclonal antibody). In one embodiment, the invention provides treatments for cancers that are resistant to chemotherapy (i.e., resistant to one or more chemotherapeutic drugs). In one embodiment, the invention provides treatments for cancers that are resistant to treatment with another one or more monoclonal antibodies. In one embodiment, the invention provides treatments for cancers that are resistant to radiation therapy. In one embodiment, the invention provides treatments for cancers that are resistant to one or more small molecule targeted therapies.

[0328] Disclosed herein are the therapeutic uses of anti-HDM2 / 4 (e.g., anti-HDM2) antibodies or antigen-binding fragments thereof in patients suffering from cancer (e.g., already diagnosed with cancer). In preferred embodiments, disclosed herein are the therapeutic uses of anti-HDM2 antibodies (or fragments thereof) in patients suffering from cancers known to metastasize (i.e., cancers generally known to become metastatic). In some embodiments, the patient being treated has metastatic cancer. In other embodiments, a patient suffering from a cancer that has not yet metastasized is treated according to the methods described herein to prevent the cancer from metastasizing. In some embodiments, the patient being treated has previously been treated with other cancer therapies (e.g., vaccines, targeted therapies, chemotherapy, immunotherapy). In specific embodiments, a patient suffering from a cancer that has already metastasized is treated according to the methods described herein to reduce, slow, or prevent metastasis, or to reduce the number or size of cancer metastases.

[0329] The methods described herein are suitable for treating cancers that are expected, known, or determined to express anti-M(H)DM2 / 4 (e.g., HDM2) on their cell surfaces. The HDM2 on the surface of cancer cells targeted by the methods described herein can be one of the splice variants of the HDM2 protein known in the art or described herein. Without being bound by the mechanism of action, it is believed that the HDM2 on the surface of cancer cells is generally a splice variant of the HDM2 protein that lacks at least one or all nuclear localization signals (e.g., a nuclear localization sequence at the N-terminal portion of HDM2, a nuclear localization signal at the C-terminal portion of HDM2, or both nuclear localization signals). In specific embodiments, the HDM2 on the surface of cancer cells is a splice variant of the HDM2 protein that lacks at least one or all nuclear localization signals and also lacks a nuclear export signal. In one embodiment, the HDM2 on the surface of cancer cells is HDM2 that lacks the nuclear localization signal at amino acids 179-185 of SEQ ID NO: 4 (i.e., lacks amino acids 179 to 185 of SEQ ID NO: 4). In one embodiment, the HDM2 on the surface of the cancer cell is a HDM2 that lacks the nuclear localization signal at amino acids 466-473 of SEQ ID NO: 4 (i.e., lacks amino acids 466 to 473 of SEQ ID NO: 4). In one embodiment, the HDM2 on the surface of the cancer cell is a HDM2 that lacks the nuclear localization signal at amino acids 179-185 and amino acids 466-473 of SEQ ID NO: 4 (i.e., lacks amino acids 179 to 185 and 466 to 473 of SEQ ID NO: 4). In some embodiments, the HDM2 on the surface of the cancer cell is a HDM2 that lacks a nuclear export signal, such as the nuclear export signal at amino acids 190-202 of SEQ ID NO: 4 (i.e., lacks amino acids 190 to 202 of SEQ ID NO: 4).

[0330] In certain embodiments, the HDM2 on the surface of a cancer cell targeted by the methods described herein is a splice variant of a HDM2 protein, such as one of the splice variants known in the art or described herein (see Tables 1 and 2 and Section 8 for a list of HDM2 variants). In some embodiments, the HDM2 on the surface of a cancer cell targeted by the methods described herein is a splice variant of a HDM2 protein designated MDM2-A (SEQ ID NO: 8), which lacks amino acids 28-222 of SEQ ID NO: 4. In some embodiments, the HDM2 on the surface of a cancer cell targeted by the methods described herein is a splice variant of a HDM2 protein designated MDM2-A1 (SEQ ID NO: 9), which lacks amino acids 28-222 and 275-300 of SEQ ID NO: 4. In some embodiments, the HDM2 on the surface of a cancer cell targeted by the methods described herein is a splice variant of a HDM2 protein designated MDM2-B (SEQ ID NO: 10), which lacks amino acids 28-300 of SEQ ID NO: 4. In some embodiments, the HDM2 on the surface of cancer cells targeted by the methods described herein is a splice variant of the HDM2 protein designated MDM2-C (SEQ ID NO: 11), which lacks amino acids 53-222 of SEQ ID NO: 4. In some embodiments, the HDM2 on the surface of cancer cells targeted by the methods described herein is a splice variant of the HDM2 protein designated MDM2-D (SEQ ID NO: 12), which lacks amino acids 30-388 of SEQ ID NO: 4. In some embodiments, the HDM2 on the surface of cancer cells targeted by the methods described herein is a splice variant of the HDM2 protein designated MDM2-E (SEQ ID NO: 13), which lacks amino acids 76-102 and 103-491 of SEQ ID NO: 4. In some embodiments, the HDM2 on the surface of cancer cells targeted by the methods described herein is a splice variant of the HDM2 protein designated MDM2-F (SEQ ID NO: 14), which lacks amino acids 53-97 of SEQ ID NO: 4. In some embodiments, the HDM2 on the surface of cancer cells targeted by the methods described herein is a splice variant of the HDM2 protein designated MDM2-G (SEQ ID NO: 15), which lacks amino acids 115-169 of SEQ ID NO: 4. In some embodiments, the HDM2 on the surface of cancer cells targeted by the methods described herein is a splice variant of the HDM2 protein designated MDM2-11 (SEQ ID NO: 16), in which amino acid M has been substituted with M→MVRSRQM in SEQ ID NO: 4.In some embodiments, the HDM2 on the surface of cancer cells targeted by the methods described herein is a splice variant of the HDM2 protein called MDM2-KB2 (SEQ ID NO: 17), which lacks amino acids 157-248 of SEQ ID NO: 4. In some embodiments, the methods described herein target splice variants of M(H)DM4 on the surface of cancer cells, for example, targeting one or more of the following splice variants: MDMX-S, MDM4-S, MDM4-A, MDM4-G, MDM4-XALT1 / XALT2, and MDM4-211 (or the human equivalents of the listed splice variants).

[0331] In specific embodiments, an anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibody or fragment thereof for use in the methods described herein has been tested and determined to be expected to bind to HDM2 exposed on the cell surface of the cancer to be treated. This binding to HDM2 can be demonstrated, for example, by the ability of the anti-HDM2 antibody or fragment to bind to intact cancer cells of the tissue type of the tissue from which the cancer to be treated is derived (which can, but need not, be from the subject to be treated). In one embodiment, prior to administering the antibody or fragment to the subject, it is tested and determined that the anti-HDM2 antibody or fragment thereof is expected to bind to intact cells of the subject's cancer. This testing can be performed, for example, by demonstrating binding of the anti-HDM2 antibody or fragment to the surface of intact cancer cells obtained by biopsy or to a cancer cell line of the appropriate tissue type.

[0332] Optionally, the cancer cells of a prospective patient to be treated can be tested for expression of M(H)DM2 / 4 (e.g., HDM2) on their surface using techniques known in the art to determine whether the subject is a suitable candidate for anti-HDM2 therapy as described herein; however, this is generally not considered necessary if the patient has a cancer of a tissue type known or expected to have an extracellularly accessible epitope of M(H)DM2 / 4. In specific embodiments, the cancer cells in the subject being treated have been tested and determined to have an extracellularly accessible epitope of HDM2 (targeted by an anti-HDM2 antibody or fragment thereof) exposed on their plasma membrane surface (e.g., determined to express a variant of HDM2 known to have such an extracellular region exposed on the plasma membrane surface). In certain embodiments, the cancer treated using the methods described herein is a cancer known or determined to express a splice variant of HDM2 (e.g., MDM2-A (SEQ ID NO: 8), MDM2-A1 (SEQ ID NO: 9), MDM2-B (SEQ ID NO: 10), MDM2-C (SEQ ID NO: 11), MDM2-D (SEQ ID NO: 12), MDM2-E (SEQ ID NO: 13), MDM2-F (SEQ ID NO: 14), MDM2-G (SEQ ID NO: 15), MDM2-11 (SEQ ID NO: 16), or MDM-KB2 (SEQ ID NO: 17) on the plasma membrane surface of its cells. This can be detected using techniques known in the art (e.g., RT-PCR on a nucleic acid sample from a cancer biopsy).

[0333] In specific embodiments, administration of an anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibody or antigen-binding fragment thereof according to the methods described herein can be performed to achieve or be found to achieve (e.g., in a subject with a cancerous tumor) at least one, two, three, four, or more of the following effects: (i) reduction in tumor size (e.g., volume or diameter), (ii) reduction in tumor growth, (iii) inhibition of progression of tumor growth, (iv) tumor regression, (v) inhibition of tumor recurrence, (vi) eradication of the tumor (e.g., primary tumor or metastatic tumor), (vii) prevention of tumor metastasis, (vii) reduction in the number, size, or invasiveness of tumor metastases, (viii) reduction or amelioration of the severity or duration of one or more symptoms of the tumor, (ix) inhibition of the development or onset of one or more symptoms associated with cancer, (x) enhancement or improvement of the therapeutic effect of another treatment, (xi) reduction in the subject's hospitalization (e.g., length of hospitalization), (xii) improvement in the subject's quality of life, (xiii) reduction in mortality, (xiv) increase in the subject's relapse-free survival or duration of remission. Any of these effects can be assessed by any method known in the art. For example, tumor size can be assessed using magnetic resonance imaging (MRI), dynamic contrast-enhanced MRI (DCE-MRI), X-rays, computed tomography (CT) scans, or positron emission tomography (PET) scans.

[0334] In certain embodiments, administration of an anti-HDM2 / 4 (e.g., anti-HDM2) antibody or antigen-binding fragment thereof according to the methods described herein, when used alone or in combination with another treatment, is effective to treat cancer in a subject (e.g., reduce tumor volume or diameter, reduce tumor growth, reduce tumor proliferation, eradicate a tumor, or ameliorate one or more symptoms of cancer). In certain embodiments, administration of an anti-HDM2 antibody or antigen-binding fragment thereof according to the methods described herein, when used alone or in combination with another treatment, is effective to prevent metastasis in a subject having cancer. In certain embodiments, administration of an anti-HDM2 antibody or antigen-binding fragment thereof according to the methods described herein, when used alone or in combination with another treatment, is effective to treat metastatic cancer (e.g., reduce the number, size, or invasiveness of metastases, or eradicate metastases).

[0335] In specific embodiments, administration of an anti-HDM2 / 4 (e.g., anti-HDM2) antibody or antigen-binding fragment thereof according to the methods described herein is effective for treating cancer or preventing metastasis in a subject when used alone (i.e., without additional treatment). In other specific embodiments, administration of an anti-HDM2 antibody or antigen-binding fragment thereof according to the methods described herein is effective for treating cancer or preventing metastasis in a subject when used in combination with one or more additional treatments described herein.

[0336] The effectiveness of the treatments described herein can be assessed by evaluating parameters (e.g., tumor size) before and after administering the treatments described herein to the treated subject. Alternatively, the effectiveness of the treatments can be assessed by evaluating parameters (e.g., tumor size) before and after administering the treatments described herein to an animal model (e.g., in an animal model for treating cancer, such as a mouse model, rat model, or hamster model). Any assay known in the art can be used to evaluate the therapeutic effect of the treatments described herein.

[0337] In the therapeutic methods described herein using anti-M(H)DM2 / 4 (eg, anti-HDM2) antibodies or antigen-binding fragments thereof, it will be appreciated that the antibody-drug conjugates described herein may alternatively be used.

[0338] 7.6.1 Cancer to be treated

[0339] Examples of cancers that can be treated according to the methods described herein include, but are not limited to, breast cancer, cervical cancer, ovarian cancer, endometrial cancer, uterine cancer, pancreatic cancer, skin cancer (e.g., melanoma), prostate cancer (e.g., hormone-resistant prostate cancer, such as castration-resistant prostate cancer), lung cancer (e.g., small cell lung cancer or non-small cell lung cancer), colorectal cancer (e.g., colon cancer or rectal cancer), gastrointestinal cancer, stomach cancer, small intestine cancer, appendix cancer, esophageal cancer, stomach cancer, kidney cancer, bladder cancer, In some embodiments, the cancer is selected from the group consisting of gallbladder cancer, kidney cancer (e.g., renal cell carcinoma or Wilms tumor), liver cancer (e.g., liver cancer or hepatoma), central nervous system cancer (e.g., brain cancer), peripheral nervous system cancer, bronchial cancer, oral or pharyngeal cancer (e.g., oropharyngeal cancer, laryngeal cancer), thyroid cancer, bile duct cancer, salivary gland cancer, thyroid cancer, adrenal cancer, vulvar cancer, testicular cancer, urethra cancer, vaginal cancer, penile cancer, bone cancer, eye cancer (e.g., retinoblastoma or uveal melanoma), and head and neck cancer (e.g., head and neck squamous cell carcinoma). In certain embodiments, the cancer is cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, melanoma, breast cancer, or colon cancer. In one embodiment, the cancer is pancreatic cancer. In one embodiment, the cancer is melanoma. In one embodiment, the cancer is breast cancer. In one embodiment, the cancer is ovarian cancer.

[0340] In certain embodiments, a cancer that can be treated according to the methods described herein is resistant to another cancer treatment or treatments, e.g., a vaccine, a targeted therapy (such as a small molecule targeted therapy), chemotherapy, radiation therapy, or immunotherapy (such as treatment with another monoclonal antibody). In one embodiment, a cancer that can be treated according to the methods described herein is resistant to chemotherapy. In one embodiment, a cancer that can be treated according to the methods described herein is resistant to treatment with another monoclonal antibody or antibodies. In one embodiment, a cancer that can be treated according to the methods described herein is resistant to radiation. In one embodiment, a cancer that can be treated according to the methods described herein is resistant to small molecule targeted therapy.

[0341] In a specific embodiment, the cancer treated according to the methods described herein is a solid cancer. In another specific embodiment, the cancer treated according to the methods described herein is a non-solid cancer (e.g., a hematological cancer).

[0342] In specific embodiments, the cancer treated according to the invention is a leukemia (e.g., an acute leukemia (e.g., acute lymphocytic leukemia or acute myeloid leukemia), a chronic leukemia (e.g., chronic myeloid leukemia or chronic lymphocytic leukemia), or hairy cell leukemia), a lymphoma (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, or T-cell lymphoma).

[0343] In specific embodiments, the cancer treated according to the present invention is a carcinoma (e.g., adenocarcinoma, basal cell carcinoma, renal cell carcinoma, squamous cell carcinoma, bone cancer, thymoma / thymic carcinoma, or choriocarcinoma), a germ cell tumor, a sarcoma (e.g., a soft tissue sarcoma, osteosarcoma, chondrosarcoma, rhabdomyosarcoma, or synovial sarcoma), a lymphoma, a leukemia, a germ cell tumor, a myeloma (e.g., multiple myeloma), a squamous cell carcinoma, a mesothelioma, a glioblastoma (e.g., glioblastoma multiforme), a glioma, a neuroblastoma, a melanoma, an astrocytoma, a medulloblastoma, a hepatoma, a seminoma, a craniopharyngioma, an ependymoma, a pinealoma, a hemangioblastoma, a neuroma, an oligodendroglioma, a meningioma, or a retinoblastoma.

[0344] In specific embodiments, the cancer treated in accordance with the methods described herein is a sarcoma or carcinoma, e.g., a fibrosarcoma, a myxosarcoma, a liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a mesothelioma, an Ewing's tumor, a leiomyosarcoma, a rhabdomyosarcoma, an endometrial stromal sarcoma, a mast cell sarcoma, an adult soft tissue sarcoma, a uterine sarcoma, a Kaposi's sarcoma, a Merkel cell carcinoma, an urothelial carcinoma, a colon carcinoma, a squamous cell carcinoma, a basal cell carcinoma, an adenocarcinoma, a sweat gland carcinoma, a sebaceous gland carcinoma, a papillary carcinoma, a papillary adenocarcinoma, a cystadenocarcinoma, a medullary carcinoma, a bronchogenic carcinoma, a renal cell carcinoma, a bile duct carcinoma, an embryonal carcinoma, a lung cancer (e.g., a small cell lung cancer), a bladder cancer, or an epithelial carcinoma.

[0345] In certain embodiments, the cancer treated according to the methods of the present invention is metastatic. In some embodiments, the cancer treated according to the methods described herein is metastatic melanoma, metastatic ovarian cancer, metastatic cervical cancer, metastatic endometrial cancer, metastatic pancreatic cancer, metastatic breast cancer, metastatic colon cancer, or metastatic brain cancer.

[0346] 7.6.2 Application method

[0347] The anti-HDM2 / 4 (e.g., anti-HDM2) antibodies or fragments described herein (and pharmaceutical compositions comprising such antibodies) can be administered to a subject by any suitable means, including, but not limited to, parenteral (e.g., intravenous, intraarterial, intramuscular, intraosseous, intracerebral, intraventricular, intrathecal, subcutaneous), intraperitoneal, intratumoral, intrapulmonary, intradermal, transdermal, conjunctival, intraocular, intranasal, intratracheal, oral, and topical intralesional routes of administration. In certain embodiments, the anti-HDM2 antibodies or fragments described herein are administered intravenously, intraarterially, intramuscularly, intraperitoneally, intratumorally, or subcutaneously. In one embodiment, the anti-HDM2 antibodies or fragments described herein are administered intravenously. In one embodiment, the anti-HDM2 antibodies or fragments described herein are administered intraperitoneally. In one embodiment, the anti-HDM2 antibodies or fragments described herein are administered intramuscularly. In one embodiment, the anti-HDM2 antibodies or fragments described herein are administered subcutaneously. In one embodiment, the anti-HDM2 antibodies or fragments described herein are administered intratumorally (e.g., by injection into a tumor of the cancer being treated). In specific embodiments, an anti-HDM2 antibody or fragment described herein is administered intravenously, intraperitoneally, or intratumorally.

[0348] In specific embodiments, nanoparticles coated with anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibodies or fragments thereof described herein are used for tumor targeting and treatment (for antibody-coated nanoparticles, see, e.g., Cardoso et al., 2012, Curr. Med. Chem. 19(19):3103-27 and Arruebo et al., 2009, J. of Nanomater. 2009: Article ID 439389). In one embodiment, provided herein are methods for treating cancer or preventing metastasis in a subject having cancer, comprising administering to the subject nanoparticles coated with anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibodies or fragments thereof.

[0349] Various dosing regimens of the anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibodies or fragments described herein (and pharmaceutical compositions comprising such antibodies) are contemplated, including single administration or multiple administrations over a period of time. Methods of administration include, but are not limited to, bolus administration, pulse infusion, and continuous infusion.

[0350] Treatment regimens for the methods described herein may include administering an anti-HDM2 / 4 (e.g., anti-HDM2) antibody or fragment thereof (and compositions comprising such an antibody) once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks, or once every twelve weeks (e.g., such that the subject receives at least two, at least three, at least four, at least five, at least six, at least eight, or at least ten doses of the antibody, or two to twenty doses of the antibody). In certain embodiments, the anti-HDM2 antibody or fragment thereof (and compositions comprising such an antibody) is administered daily, every other day, or twice, three times, or four times a week (e.g., for a period of time, such as one week, two weeks, three weeks, four weeks, six weeks, two months, or three months). Treatment regimens contemplated herein include regimens in which an initial higher dose of the antibody may be followed by one or more lower doses, or in which an initial lower dose of the antibody is followed by one or more higher doses. Exemplary treatment courses in which anti-HDM2 antibodies or fragments are administered may last for one week, two weeks, three weeks, four weeks, six weeks, two months, three months, four months, five months, six months, one year, or several years.

[0351] In some embodiments, an initial treatment period (in which the antibody is administered, for example, monthly, biweekly, weekly, twice weekly, or three times weekly) is followed by a drug-free period in which the antibody is not administered (for example, one week, two weeks, three weeks, four weeks, six weeks, two months, three months, four months, six months, or one year), followed by a second treatment period (in which, for example, the antibody is administered monthly, biweekly, weekly, twice weekly, or three times weekly). Such an initial treatment and such a second treatment period can last, for example, two weeks, three weeks, four weeks, six weeks, two months, three months, four months, or six months (in which the initial treatment period can be the same as or different from the second treatment period). This course of treatment (with an initial treatment period, a drug-free period, and a second treatment period) can be repeated two, three, four, five, six, ten, or more than ten times.

[0352] In some embodiments, two or more antibodies or fragments thereof with different binding specificities for M(H)DM2 / 4 (eg, HDM2) are administered simultaneously or sequentially to the subject being treated.

[0353] The appropriate dosage of an anti-HDM2 / 4 (e.g., anti-HDM2) antibody or fragment for use in the methods described herein will depend on the type of antibody administered, the type of cancer being treated, the severity of the cancer being treated, the route of administration, the target site, the condition of the patient (e.g., age, weight, health), the patient's responsiveness to the antibody, other medications the patient is taking, and other factors at the discretion of the treating medical practitioner.

[0354] In certain embodiments, the dose of an anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibody or fragment described herein administered to a subject may be from about 1 μg / kg to 200 mg / kg of patient body weight. In certain embodiments, the dose of an anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibody or fragment described herein administered to a subject may be from about 1 μg / kg to 100 mg / kg of patient body weight (e.g., from about 0.01 mg / kg to about 100 mg / kg, from about 0.05 mg / kg to about 100 mg / kg, or from about 0.5 mg / kg to about 100 mg / kg). In certain embodiments, the dose of an anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibody or fragment described herein administered to a subject may be from about 1 mg / kg to 200 mg / kg of patient body weight. In one embodiment, the dose of an anti-HDM2 antibody or fragment described herein administered to a subject is from 0.025 mg / kg to about 5 mg / kg. In one embodiment, the dose of an anti-HDM2 antibody or fragment described herein administered to a subject is from 0.05 mg / kg to about 2 mg / kg. In one embodiment, the dose of an anti-HDM2 antibody or fragment described herein administered to a subject is from 5 mg / kg to about 30 mg / kg. In specific embodiments, a dose (e.g., one or more doses) of about 0.025 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 7.5 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, 40 mg / kg, 50 mg / kg, 75 mg / kg, or 100 mg / kg of an anti-HDM2 antibody or fragment described herein can be administered to the treated subject. In one embodiment, (eg, when the antibody is administered intratumorally) a dose (eg, one or more doses) of about 0.1 mg / kg of an anti-HDM2 antibody or fragment described herein can be administered to the treated subject.

[0355] 7.7 Diagnostic, companion diagnostic, and prognostic methods

[0356] In one aspect, provided herein are methods for diagnosing cancer in a subject (e.g., a human), comprising: (a) detecting whether an antibody or fragment thereof (e.g., a labeled antibody or fragment) that specifically binds to M(H)DM2 / 4 (e.g., HDM2) is bound to the surface of intact cells of the subject, wherein the antibody or fragment is any anti-M(H)DM2 / 4 antibody or fragment described herein (particularly any antibody or fragment that specifically binds to SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3); and (b) if binding is detected in step (a), diagnosing the subject with cancer. In one embodiment, the diagnostic method further comprises obtaining intact cells from the subject prior to the detecting in step (a), and then performing the detecting by determining whether the labeled antibody or fragment binds to the intact cells from the subject, e.g., using a FACS or cell-based ELISA assay. In one embodiment, the diagnostic method comprises administering the antibody or fragment to the subject prior to the detecting in step (a), and wherein the detecting is performed by in vivo imaging of the subject.

[0357] In one aspect, based on the detection of binding of an anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibody or antibody fragment described herein to the surface of intact cancer cells obtained from the patient, a patient is selected for treatment with such an antibody or fragment. In certain embodiments, provided herein are methods for selecting a patient having cancer for treatment with an antibody or fragment that specifically binds to an extracellularly accessible epitope of HDM2, the method comprising obtaining intact cancer cells from the patient (e.g., by biopsy of the patient's cancerous tumor or by obtaining a blood sample with circulating cancer cells from the patient), and determining (using any method known in the art or described herein, such as using a cell-based ELISA or FACS analysis) whether the antibody or fragment binds to the surface of the patient's intact cancer cells, wherein detection of binding indicates that the patient can be treated with the antibody or fragment. In specific embodiments, provided herein are methods for selecting a patient having cancer for treatment with an antibody or fragment that specifically binds to an extracellularly accessible epitope of HDM2, comprising: obtaining intact cancer cells from the patient (e.g., by biopsy of the patient's cancerous tumor or by obtaining a blood sample with circulating cancer cells from the patient), determining (using any method known in the art or described herein, such as using a cell-based ELISA or FACS analysis) whether the antibody or fragment binds to the surface of the patient's intact cancer cells, and if binding is detected, administering the antibody or fragment to the patient. The antibody or fragment administered to the patient can be the same or different from the antibody or fragment used to select the patient to be treated. In one embodiment, provided herein are methods for selecting a patient having ovarian cancer for treatment with an antibody or fragment that specifically binds to an extracellularly accessible epitope of HDM2, comprising: obtaining intact ovarian cancer cells from the patient, determining whether the antibody or fragment binds to the surface of the patient's intact cancer cells, and if binding is detected, administering the antibody or fragment to the patient. In one embodiment, any antibody or fragment thereof that specifically binds to SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is used for such patient selection and / or treatment. In one embodiment, any antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 that does not bind to a cell-penetrating peptide is used for such patient selection and / or treatment. In one embodiment, any antibody or fragment thereof that specifically binds to an extracellularly accessible epitope of M(H)DM2 / 4 that does not bind to a cell-penetrating peptide is used for such patient selection, and any antibody or fragment thereof that specifically binds to SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is used for patient treatment.

[0358] Non-limiting exemplary samples that can be used in the diagnostic or patient selection methods using the anti-M(H)DM2 / 4 antibodies (e.g., anti-HDM2 antibodies) or fragments thereof described herein include: tissue biopsies, intact cells obtained from malignant tissue, and circulating cancer cells isolated from blood. For example, a tissue sample can be obtained from a patient, and immunohistochemistry can be performed to detect whether a labeled anti-M(H)DM2 / 4 antibody (e.g., anti-HDM2 antibody) or fragment thereof binds to the tissue sample. Alternatively, intact cells (known or suspected to be malignant) can be isolated from a patient, and FACS or cell-based ELISA analysis can be performed to detect whether a labeled anti-M(H)DM2 / 4 antibody (e.g., anti-HDM2 antibody) or fragment thereof binds to such cells. In yet another example, a blood sample containing circulating cancer cells can be obtained from a patient, and FACS or cell-based ELISA analysis can be performed to detect whether a labeled anti-M(H)DM2 / 4 antibody (e.g., anti-HDM2 antibody) or fragment thereof binds to such cells.

[0359] In one aspect, the duration and / or dosage of treatment with an anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibody or antibody fragment described herein is determined based on the detection of binding of such an antibody or fragment to the surface of intact cancer cells obtained from the patient. In certain embodiments, provided herein are methods for determining whether to continue treatment of a patient suffering from cancer with an antibody or fragment that specifically binds to an extracellularly accessible epitope of HDM2, the methods comprising: administering the antibody or fragment to the patient for a first period of time (e.g., wherein the patient has been selected for treatment as described above), obtaining intact cancer cells from the patient (e.g., by biopsy of the patient's cancerous tumor or by obtaining a blood sample with circulating cancer cells from the patient), and determining (using any method known in the art or described herein, e.g., using a cell-based ELISA or FACS analysis) whether the antibody or fragment binds to the surface of the patient's intact cancer cells, and if binding is detected, continuing administration of the antibody or fragment to the patient for a second period of time (but, for example, if no binding is detected, discontinuing treatment). In certain embodiments, provided herein are methods for determining whether to increase the dose of an antibody or fragment that specifically binds to an extracellularly accessible epitope of HDM2 for treating a patient having cancer, the methods comprising: administering a dose of the antibody or fragment to the patient over a period of time (e.g., wherein the patient has been selected for treatment as described above), obtaining intact cancer cells from the patient (e.g., by biopsy of the patient's cancerous tumor or by obtaining a blood sample with circulating cancer cells from the patient), and determining (using any method known in the art or described herein, e.g., using a cell-based ELISA or FACS analysis) whether the antibody or fragment binds to the surface of the patient's intact cancer cells, and if binding is detected, administering a dose of the antibody or fragment to the patient over a second period of time, wherein the dose administered over the second period of time is higher (e.g., two-fold or three-fold higher) than the dose administered over the first period of time (but, for example, if no binding is detected, discontinuing treatment or administering a lower dose of the antibody or fragment over the second period of time).

[0360] In another specific embodiment, treatment with an anti-M(H)DM2 / 4 (e.g., anti-HDM2) antibody or antibody fragment described herein is monitored in a patient by determining the amount of HDM2 expressed on the surface of cancer cells obtained from the patient before and after treatment, wherein a decrease in the amount is a positive prognosis.

[0361] 7.8 Patient population

[0362] Patients or subjects treated according to the methods described herein include, but are not limited to, humans and non-human vertebrates. In certain embodiments, the subject being treated is a mammal, such as a human, dog, cat, monkey, rabbit, cow, horse, goat, sheep, or pig. In a preferred embodiment, the subject being treated is a human.

[0363] In certain embodiments, the subject treated according to the methods described herein has been diagnosed with cancer (e.g., using a biopsy or any other method known in the art). In specific embodiments, the subject treated has been diagnosed with early-stage cancer. In other embodiments, the subject treated has been diagnosed with advanced cancer. In specific embodiments, the subject treated has been diagnosed with a high-grade tumor. In other embodiments, the subject treated has been diagnosed with a low-grade tumor. In certain embodiments, the subject treated has been diagnosed with a metastatic cancer. In specific embodiments, the subject treated has been diagnosed with a metastatic cancer.

[0364] In specific embodiments, the subject treated according to the methods described herein has been diagnosed with cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, melanoma, breast cancer, colorectal cancer (e.g., colon cancer), bladder cancer, astrocytoma, glioblastoma, childhood rhabdomyosarcoma, or lung cancer (e.g., non-small cell lung cancer). In specific embodiments, the subject treated according to the methods described herein has been diagnosed with melanoma, pancreatic cancer, breast cancer, or ovarian cancer. In one embodiment, the subject treated according to the methods described herein has been diagnosed with melanoma. In one embodiment, the subject treated according to the methods described herein has been diagnosed with pancreatic cancer. In one embodiment, the subject treated according to the methods described herein has been diagnosed with breast cancer. In one embodiment, the subject treated according to the methods described herein has been diagnosed with ovarian cancer. In one embodiment, the subject treated according to the methods described herein has been diagnosed with lung cancer.

[0365] In certain embodiments, the subject being treated has previously undergone one or more other cancer treatments (e.g., a vaccine, a targeted therapy (such as a small molecule targeted therapy), chemotherapy, radiation therapy, or immunotherapy (such as treatment with another monoclonal antibody)), and the subject's cancer has become resistant to one or more of the other cancer treatments. In one embodiment, the subject being treated is resistant to chemotherapy. In one embodiment, the subject being treated is resistant to radiation therapy. In one embodiment, the subject being treated is resistant to small molecule targeted therapy. In one embodiment, the subject being treated is resistant to treatment with another monoclonal antibody.

[0366] In certain embodiments, the subject being treated has a type of cancer known or expected to have M(H)DM2 / 4 (e.g., HDM2) on its cell surface. In specific embodiments, the subject being treated has a type of cancer whose cells express one or more of the splice variants of HDM2 on their cell surface, such as, but not limited to, one or more of the following splice variants: MDM2-A (SEQ ID NO: 8), MDM2-A1 (SEQ ID NO: 9), MDM2-B (SEQ ID NO: 10), MDM2-C (SEQ ID NO: 11), MDM2-D (SEQ ID NO: 12), MDM2-E (SEQ ID NO: 13), MDM2-F (SEQ ID NO: 14), MDM2-G (SEQ ID NO: 15), MDM2-11 (SEQ ID NO: 16), or MDM-KB2 (SEQ ID NO: 17).

[0367] In certain embodiments, the subject being treated has a cancer whose cells have been tested and determined (using any assay known in the art) to carry M(H)DM2 / 4 (e.g., HDM2) on their plasma membrane. In specific embodiments, the subject being treated has a cancer whose cells have been tested and determined (using any method known in the art) to expose an extracellular region of HDM2 on their plasma membrane surface that can be targeted by an anti-HDM2 antibody or fragment (and such an antibody can be administered to the subject). In specific embodiments, the subject being treated has a cancer whose cells have been tested and determined (using any method known in the art) to express one or more of the splice variants of HDM2 on their cell surface, such as, but not limited to, one or more of the following splice variants: MDM2-A (SEQ ID NO:8), MDM2-A1 (SEQ ID NO:9), MDM2-B (SEQ ID NO:10), MDM2-C (SEQ ID NO:11), MDM2-D (SEQ ID NO:12), MDM2-E (SEQ ID NO:13), MDM2-F (SEQ ID NO:14), MDM2-G (SEQ ID NO:15), MDM2-11 (SEQ ID NO:16), or MDM-KB2 (SEQ ID NO:17).

[0368] 7.9 Combination treatments and kits

[0369] In certain embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with one or more anti-cancer therapies other than the antibody or fragment, such as chemotherapy, surgery, radiation therapy, another antibody with anti-cancer activity, a cytokine, T cell therapy, a vaccine (e.g., a cellular vaccine), a small molecule with anti-cancer activity, an anti-hormonal agent, or any other anti-cancer treatment known in the art.

[0370] In certain embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with chemotherapy. Examples of types of chemotherapeutic agents that can be used in the methods described herein include, but are not limited to, alkylating agents, nitrosoureas, antimetabolites, topoisomerase inhibitors, aromatase inhibitors, antitumor antibiotics, plant-derived alkaloids, hormone antagonists, P-glycoprotein inhibitors, and platinum complex derivatives. Specific examples of chemotherapeutic agents that can be used in the methods described herein include, but are not limited to, taxol, paclitaxel, nab-paclitaxel, 5-fluorouracil (5-FU), gemcitabine, doxorubicin, daunorubicin, colchicine, mitoxantrone, tamoxifen, cyclophosphamide, mechlorethamine, melphalan, chlorambucil, busulfan, uracil, mechlorethamine hydrochloride, ifosfamide, bendamustine, carmustine, lomustine, semustine, fotemustine, streptozotocin, thiotepa, mitomycin, serquinone, tetrazine, hexamethylmelamine, dacarbazine, mitozolamide, temozolomide, procarbazine, hexamethyl Melamine (hexamethylmelamine), altretamine, kemaglin, trolofosamide, estramustine, susulfan, ganlusufan, triazoline, carboquinone, nimustine, ranimustine, azathioprine, sulfonamide, fluoropyrimidine, thiopurine, thioguanine, mercaptopurine, cladribine, capecitabine, pemetrexed, fludarabine, methotrexate, hydroxyurea, nelarabine or clofarabine, cytarabine, decitabine, pralatrexate, floxuridine, thioguanine (thioquanine), azacitidine, cladribine, pentostatin, Mercaptopurine, imatinib, dactinomycin D, daunorubicin, bleomycin, dactinomycin, luteolin, epirubicin, idarubicin, plicamycin, vincristine, vinblastine, vinorelbine, vindesine, vinflunine, paclitaxel, docetaxel, etoposide, teniposide, periwinkle, periwinkle, vinca roseus, taxanes, irinotecan, topotecan, camptothecin, teniposide, pirarubicin, novobiocin, mebarone, aclarubicin, amsacrine, antiandrogen, antiestrogen, bicalutamide, medroxyprogesterone acetate, fluoxymesterone, diethylstilbestrol, estradiol, octreotide, megestrol acetate, raloxazole Oxifen, toremifene, fulvestrant, prednisone, flutamide, leuprolide, goserelin, aminoglutethimide, testolactone, anastrozole, letrozole, exemestane, vorozole, formestane, fadrozole, androstenone, resveratrol, mysmine, catechin, apigenin, eriodictyol, isoliquiritigenin, mangostin, amiodarone, azithromycin, captopril, clarithromycin, cyclosporine, piperine, quercetin, quinidine, quinine, reserpine, ritonavir, talizine, verapamil, cisplatin, carboplatin, oxaliplatin, transplatin, nedaplatin, satraplatin, triplatin, and carboplatin.In specific embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with one or more of the following chemotherapeutic agents: gemcitabine, albumin-bound paclitaxel, capecitabine, irinotecan, and celecoxib. In specific embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with one or more of the following chemotherapeutic agents: gemcitabine, albumin-bound paclitaxel, cisplatin, 5-FU, and paclitaxel (e.g., paclitaxel formulated as albumin-bound particles, such as paclitaxel). In specific embodiments, the cancer treated using the combination therapies described herein is pancreatic cancer, breast cancer, lung cancer, or ovarian cancer.

[0371] In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with gemcitabine (e.g., for the treatment of non-small cell lung cancer, pancreatic cancer, or ovarian cancer). In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with capecitabine. In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with irinotecan. In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with celecoxib. In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with paclitaxel (e.g., paclitaxel formulated as albumin-bound particles, such as ) are administered to a subject in combination (e.g., for the treatment of metastatic breast cancer). In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with albumin-bound paclitaxel. In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with cisplatin. In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with 5-FU (e.g., for the treatment of colorectal cancer, such as colon cancer). In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with carboplatin. In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with gemcitabine and albumin-bound paclitaxel (e.g., for the treatment of pancreatic cancer). In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with gemcitabine and carboplatin (e.g., for the treatment of ovarian cancer). In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered with paclitaxel (e.g., paclitaxel formulated as albumin-bound particles, such as ) and gemcitabine are administered to a subject in combination (e.g., for the treatment of breast cancer or pancreatic cancer, such as pancreatic adenocarcinoma or metastatic pancreatic adenocarcinoma). In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with gemcitabine and cisplatin (e.g., for the treatment of non-small cell lung cancer). In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with gemcitabine and 5-FU. In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with paclitaxel (e.g., paclitaxel formulated as albumin-bound particles, such as ) and carboplatin (e.g., used to treat non-small cell lung cancer) are administered to a subject in combination.

[0372] In certain embodiments, wherein the subject is a human, gemcitabine is administered at 1,500 mg / m 2 In certain embodiments, wherein the subject is a human, nab-paclitaxel is administered at a dose of 300 mg / m 2 In certain embodiments, wherein the subject is a human, gemcitabine is administered at a dose of 1,000 mg / m 2 In certain embodiments, wherein the subject is a human, nab-paclitaxel is administered at a dose of 125 mg / m 2 Dosage administration.

[0373] In certain embodiments, the dose of gemcitabine and / or nab-paclitaxel administered is lower than the dose used when gemcitabine and / or nab-paclitaxel is not administered in combination with an anti-cancer antibody (such as an anti-M(H)DM2 / 4 antibody or fragment described herein). In certain embodiments, wherein the subject is a human, gemcitabine is administered at a dose of less than 1,500 mg / m 2 and / or nab-paclitaxel at a dose of less than 300 mg / m 2 In certain embodiments, wherein the subject is a human, gemcitabine is administered at a dose of less than 1,000 mg / m 2 and / or nab-paclitaxel at a dose of less than 125 mg / m 2 In one embodiment, wherein the subject is a human, gemcitabine is administered at a dose equal to or less than 500 mg / m 2 , 400mg / m 2 , 300mg / m 2 or 200 mg / m 2 and / or nab-paclitaxel at a dose equal to or less than 62.5 mg / m 2 , 50mg / m 2 , 40mg / m 2 , 30mg / m2 or 20 mg / m 2 In one embodiment, wherein the subject is a human, gemcitabine is administered at a dose equal to or less than 900 mg / m 2 , 800mg / m 2 , 700mg / m 2 or 600 mg / m 2 and / or nab-paclitaxel at a dose equal to or less than 110 mg / m 2 , 100mg / m 2 , 90mg / m 2 , 80mg / m 2 or 70 mg / m 2 In certain embodiments, gemcitabine and / or albumin-bound paclitaxel are administered at a frequency of every 2 weeks or less (e.g., every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks or less). In certain embodiments, gemcitabine is administered at a frequency of once a day, 4 times a week, 3 times a week, 2 times a week, or once a week. In certain embodiments, gemcitabine is administered at a frequency of once a day, 4 times a week, 3 times a week, 2 times a week, or once a week. In certain embodiments, albumin-bound paclitaxel is administered at a frequency of once a day, 4 times a week, 3 times a week, 2 times a week, or once a week. In certain embodiments, gemcitabine and albumin-bound paclitaxel are administered at a frequency of once a day, 4 times a week, 3 times a week, 2 times a week, or once a week. In certain embodiments, gemcitabine and albumin-bound paclitaxel are administered at a frequency of once a day, 4 times a week, 3 times a week, 2 times a week, or once a week. In certain embodiments, gemcitabine and / or albumin-bound paclitaxel are administered once a week. In certain embodiments, the total duration of treatment with gemcitabine and / or nab-paclitaxel is 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks or greater than 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks.

[0374] In certain embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject having cancer in combination with (a plurality of) chemotherapeutic agents suitable for the cancer, wherein the chemotherapeutic agent(s) may optionally be administered at a dose and / or administration regimen suitable for the cancer. Non-limiting examples of chemotherapeutic agents suitable for various cancers, as well as their doses and administration regimens, are provided below.

[0375] Ovarian cancer: The following information is taken from (Gemcitabine for Injection), Eli Lilly and Company, Highlights of Prescribing Information, Revised March 2017, http: / / pi.lilly.com / us / gemzar.pdf (last accessed July 27, 2017). Gemcitabine In combination with carboplatin, it is indicated for the treatment of patients with advanced ovarian cancer whose disease has relapsed at least 6 months after completion of platinum-based therapy. The recommended dose is 1000 mg / m 2 , administered as an intravenous infusion over 30 minutes on days 1 and 8 of each 21-day cycle, and on day 1 of each 21-day cycle Afterwards, it was administered in combination with intravenous carboplatin (AUC 4).

[0376] Breast cancer: The following information is taken from (Gemcitabine for Injection), Eli Lilly and Company, Highlights of Prescribing Information, Revised March 2017, http: / / pi.lilly.com / us / gemzar.pdf (last accessed July 27, 2017). Gemcitabine In combination with paclitaxel, it is indicated for the first-line treatment of patients with metastatic breast cancer who have failed prior adjuvant anthracycline-containing chemotherapy, unless anthracyclines are clinically contraindicated. The recommended dose is 1250 mg / m 2 , administered intravenously over 30 minutes on days 1 and 8 of each 21-day cycle that includes paclitaxel. Paclitaxel may be administered at 175 mg / m2 by intravenous infusion over 3 hours on day 1, followed by

[0377] Non-small cell lung cancer: The following information is taken from (Gemcitabine for Injection), Eli Lilly and Company, Highlights of Prescribing Information, Revised March 2017, http: / / pi.lilly.com / us / gemzar.pdf (last accessed July 27, 2017). Gemcitabine In combination with cisplatin, it is used as the first-line treatment for patients with inoperable, locally advanced (stage IIIA or IIIB) or metastatic (stage IV) non-small cell lung cancer. The recommended dose is 1000 mg / m 2 , administered intravenously over 30 minutes on days 1, 8, and 15; infusion On the first day after treatment, 100 mg / m 2 Cisplatin is administered intravenously. Every 3 weeks: combined with cisplatin therapy The recommended dose is 1250 mg / m 2 , administered intravenously over 30 minutes on days 1 and 8; infusion On the first day after treatment, 100 mg / m 2 Cisplatin was administered intravenously.

[0378] Pancreatic cancer: The following information is taken from (Gemcitabine for Injection), Eli Lilly and Company, Highlights of Prescribing Information, Revised March 2017, http: / / pi.lilly.com / us / gemzar.pdf (last accessed July 27, 2017). Gemcitabine It is indicated for the first-line treatment of patients with locally advanced (unresectable stage II or III) or metastatic (stage IV) pancreatic adenocarcinoma. Suitable for patients who have previously received 5-FU treatment. The recommended dose is 1000 mg / m 2 , administered intravenously over 30 minutes. The recommended treatment schedule is as follows: Weeks 1-8: weekly administration for the first 7 weeks, followed by a week off; after Week 8: weekly administration on Days 1, 8, and 15 of a 28-day cycle.

[0379] Metastatic Breast Cancer: The following information is taken from (Paclitaxel Protein-Bound Particles Injectable Suspension, Albumin-Bound), Celgene Corporation, Highlights of Prescribing Information, revised July 2015, http: / / www.abraxane.com / wp-content / pi / prescribing-info.html (last accessed July 27, 2017). Indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy or recurrence within 6 months of adjuvant chemotherapy. Unless clinically contraindicated, previous treatment should include an anthracycline. The recommended treatment regimen is 260 mg / m² administered intravenously over 30 minutes every 3 weeks. 2 .

[0380] Non-small cell lung cancer: The following information is taken from (Paclitaxel Protein-Bound Particles Injectable Suspension, Albumin-Bound), Celgene Corporation, Highlights of Prescribing Information, revised July 2015, http: / / www.abraxane.com / wp-content / pi / prescribing-info.html (last accessed July 27, 2017). In combination with carboplatin, it is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients who are not candidates for curative surgery or radiation therapy. The recommended dose is 100 mg / m 2 , administered by intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle.

[0381] Pancreatic adenocarcinoma: The following information is taken from (Paclitaxel Protein-Bound Particles Injectable Suspension, Albumin-Bound), Celgene Corporation, Highlights of Prescribing Information, revised July 2015, http: / / www.abraxane.com / wp-content / pi / prescribing-info.html (last accessed July 27, 2017). In combination with gemcitabine, it is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma. The recommended dose is 125 mg / m 2 Gemcitabine is administered by intravenous infusion over 30-40 minutes on days 1, 8, and 15 of each 28-day cycle. Apply immediately afterwards.

[0382] In a specific embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof as described herein is administered to a subject in combination with an immunomodulator (e.g., a cytokine, an antigen, or a checkpoint targeting agent). In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof as described herein is administered to a subject in combination with a checkpoint targeting agent, such as, but not limited to, an antagonist of PD-1, an antagonist of PD-L1, an antagonist of PD-L2, an antagonist of CTLA-4, an antagonist of TIM-3, an antagonist of GITR, an antagonist of OX40, an antagonist of LAG-3 (e.g., an antagonist of any of the above checkpoint molecules can be an antibody against these molecules, such as an inhibitory antibody, an antibody fragment, or a small molecule). In one embodiment, an anti-M(H)DM2 / 4 antibody or fragment thereof as described herein is administered to a subject in combination with an inhibitor of PD-1, an inhibitor of PD-L1, or an inhibitor of CTLA-4 (wherein the inhibitor can be an antagonist antibody, an antibody fragment, or a small molecule).

[0383] In specific embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with radiation therapy (eg, x-rays, gamma rays, or another radiation source).

[0384] In specific embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with surgery (eg, surgery to remove part or all of the cancerous tumor being treated).

[0385] In specific embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with a Treg-inhibitor.

[0386] In specific embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with T cell therapy.

[0387] In specific embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with a tumor vaccine.

[0388] In specific embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein is administered to a subject in combination with an EGFR inhibitor (eg, erlotinib).

[0389] In certain embodiments, the anti-M(H)DM2 / 4 antibodies or fragments thereof described herein are used to treat a subject not treated with a cell cycle inhibitor (i.e., the additional treatment is not an agent that inhibits the cell cycle). In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof described herein are used to treat a subject not concurrently (within the same treatment period) treated with a cell cycle inhibitor (i.e., the subject is not treated with an anti-M(H)DM2 / 4 antibody or fragment thereof and a cell cycle inhibitor within the same time period, e.g., a day or a week). In one embodiment, the anti-M(H)DM2 / 4 antibodies or fragments thereof described herein are used to treat a subject not previously treated and not concurrently treated with a cell cycle inhibitor.

[0390] In certain embodiments, an anti-M(H)DM2 / 4 antibody or fragment thereof described herein can be administered before, during, or after a second treatment (e.g., chemotherapy, radiation therapy, surgery, or any other therapy described herein or known in the art).

[0391] In certain embodiments, the subject treated according to the methods described herein has not received anti-cancer therapy prior to administration of the anti-M(H)DM2 / 4 antibody or fragment thereof. In other embodiments, the anti-M(H)DM2 / 4 antibody or fragment thereof is administered to a subject who has received anti-cancer therapy prior to administration of the antibody or fragment. In specific embodiments, the anti-M(H)DM2 / 4 antibody or fragment thereof is administered to a subject who is recovering from or receiving immunosuppressive therapy.

[0392] In certain embodiments, provided herein are kits comprising an anti-M(H)DM2 / 4 antibody or fragment thereof and one or more additional anti-cancer agents. In one embodiment, provided herein are kits comprising: (i) an anti-M(H)DM2 / 4 antibody or fragment thereof (e.g., in a therapeutically effective amount), and (ii) one or more chemotherapeutic agents, e.g., gemcitabine, paclitaxel, or gemcitabine and nab-paclitaxel (e.g., in a therapeutically effective amount, such as any amount described herein, which may be less than the therapeutically effective amount of the one or more drugs when used without the anti-M(H)DM2 / 4 antibody or fragment).

[0393] The following examples are offered by way of illustration and not limitation.Various other embodiments of the invention can be practiced given the general description provided herein.

[0394] 8. Examples

[0395] The data presented herein demonstrate that specific segments (i.e., epitopes) of HDM2 are extracellularly accessible on the plasma membrane surface of intact (i.e., living and non-permeabilized) cancer cells. Three (3) different extracellularly accessible epitopes have been identified. Specific extracellularly accessible segments of HDM2 include, but are not limited to, epitopes present in the NMC-P1, NMC-P2, and NMC-P3 peptide sequences (SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively). These extracellularly accessible sequences are suitable therapeutic and diagnostic targets for anti-HDM2 antibodies. Thus, cancer cells expressing HDM2 on their surface membranes can be targeted with antibodies directed against HDM2 for diagnostic and therapeutic (i.e., anti-tumor cytotoxic and inhibitory) purposes.

[0396] In particular, the data presented herein demonstrate that selected HDM2-specific antibodies bind to extracellularly accessible sequences of M(H)DM2 / 4 on the surface membranes of intact cells from several rodent and human cancer cell lines, as well as primary tumor cells from human patients. In contrast, the same HDM2-specific antibodies exhibit minimal binding to the surface membranes of normal human blood mononuclear cells. These HDM2-specific antibodies have been found to selectively bind to various cancer cells in vitro, such as intact human melanoma, uveal melanoma, pancreatic, breast, colon, lung, and ovarian cancer cells. Furthermore, the data presented herein demonstrate that HDM2-specific antibodies inhibit cancer cell growth in vitro and in vivo, strongly suggesting their potential use as in vivo therapeutic agents. Data from in vivo studies described herein demonstrate that selected HDM2-specific antibodies inhibit tumor growth and are cytotoxic to tumors in rodent tumor models. The following examples demonstrate that selected HDM2-specific antibodies are not only cytotoxic to tumor cells, but also inhibit tumor growth in mouse models of pancreatic, lung, and colon cancer. The data presented herein further demonstrate that only the selected antibodies recognize extracellularly accessible epitopes of HDM2.

[0397] Methods for preparing antibodies used in the examples:

[0398] Anti-HDM2 antibodies that specifically bind to the following were generated using a hybridoma method: (i) NMC-P1, a peptide of SEQ ID NO: 1 ("NMC-100s series monoclonal antibodies"), (ii) NMC-P2, a peptide of SEQ ID NO: 2 ("NMC-200s series monoclonal antibodies"), and (iii) NMC-P3, a peptide of SEQ ID NO: 3 ("NMC-300s series monoclonal antibodies"). NMC-P1, NMC-P2, and NMC-P3 peptides were coupled to keyhole limpet hemocyanin (KLH) using the Sulfo-SMCC method (Thermo Scientific, catalog number 22122). Briefly, protein-NH2 was prepared in coupling buffer (provided by the manufacturer). A twenty-fold molar excess of cross-linker was added to the protein solution, and the reaction mixture was incubated at room temperature for 30 minutes. Excess cross-linker was then removed using a desalting column equilibrated with coupling buffer. Then protein-SH and desalted protein-NH2 were merged, mixed and incubated at room temperature for 30 minutes. The coupling reaction was then terminated by adding a buffer containing reduced cysteine ​​at a concentration several times that of the sulfhydryl group of protein-SH. After peptide coupling, mice (BALB / cc female) were immunized with peptide NMC-P1, NMC-P2 or NMC-P3 by intraperitoneal injection at 100 μg / mouse. 5-7 boosters were injected to stimulate the immune response. The production of specific antibodies was then evaluated by peptide-ELISA of mouse serum to perform antibody titration. Mouse spleens with high antibody titers were then harvested from each mouse, and single-cell suspensions of splenocytes were prepared. Splenocytes were then fused with SP2 / 0 myeloma cells (ratio of 1:5). In brief, 250 μl of EDTA were added to a mixture of splenocytes and myeloma cells. The cells were then centrifuged and the supernatant was removed. Then the cell pellet is loosened and 1mL PEG is slowly distributed along the edge of the tube in 1 minute, and the mixture is hatched in 37 ℃ of water baths for 5 minutes. Then 1mL of 100x FBS and 10mL of IMDM culture medium (10% FBS) are added and placed in an incubator for 1 hour. The cells are then centrifuged and the supernatant is removed. The cell pellet is then resuspended in the HAT fusion culture medium (hypoxanthine-aminopterin-thymidine culture medium) containing IMDM (20% FBS). The cells are then plated in a 96-well culture dish and incubated for approximately 10 to 14 days. After 10-14 days, when the clone becomes visible, the combination of the culture supernatant of each well and its corresponding specific immunogenic peptide (NMC-P1, NMC-P2 or NMC-P3) is tested by ELISA. The ELISA positive wells are then selected for further clone selection, single cell subcloning and monoclonal antibody purification. Monoclonal antibody selection was performed by peptide ELISA using NMC-P1, NMC-P2, or NMC-P3 peptide antigens.To further select antibodies reactive with peptide antigens as well as plasma membrane HDM2, binding analysis on intact cancer cells was also performed by cell-ELISA for mAb selection.

[0399] Predicted reactivity of generated antibodies:

[0400] Tables 1 and 2 give the predicted reactivity of the NMC-100s series, NMC-200s series, and NMC-300s series monoclonal antibodies with different HDM2 isoforms / variants. The predictions were made based on whether the corresponding isoform contained a sequence corresponding to that of P1, P2, or P3 (and knowledge of which peptide (P1, P2, or P3) the corresponding NMC series mAb bound, based on which peptide was used as the immunogen for which series).

[0401] Table 1. Predicted reactivity of monoclonal antibodies of the NMC-100s series, NMC-200s series, and NMC-300s series with different HDM2 isoforms / variants

[0402]

[0403]

[0404] Table 2. Predicted reactivity of monoclonal antibodies of the NMC-100s series, NMC-200s series, and NMC-300s series with different HDM2 isoforms / variants

[0405]

[0406]

[0407]

[0408] Antibodies used in the examples:

[0409] Monoclonal antibody NMC-103 is an antibody that binds to NMC-P1 (SEQ ID NO: 1) (one of the antibodies in the NMC-100s series). Monoclonal antibody NMC-204 is an antibody that binds to NMC-P2 (SEQ ID NO: 2) (one of the antibodies in the NMC-200s series). Monoclonal antibody NMC-303 is an antibody that binds to NMC-P3 (SEQ ID NO: 3) (one of the antibodies in the NMC-300s series). The heavy chain / light chain framework region sequences, complementary determining region (CDR) sequences, and variable region sequences of these antibodies are listed in Section 8 below.

[0410] The following anti-HDM2 antibodies were used in the experiments described in Examples 1-9: (i) purified NMC-103 mouse monoclonal antibody (mAb) of the IgG1 isotype (NMC-103 mAb produced by a single-cell clone hybridoma was purified on a protein G / A column), (ii) purified NMC-204 mouse mAb of the IgG3 isotype (NMC-204 mAb produced by a single-cell clone hybridoma was purified on a protein G / A column); (iii) purified NMC-303 mouse mAb of the IgM isotype b (NMC-303 mAb produced by a single-cell clone hybridoma cell line was purified on a protein G / A column); (iv) an anti-HDM2 antibody designated “MDM2 monoclonal antibody (M01) clone 1A7” (Abnova, catalog number H00004193-M01); (v) an anti-HDM2 antibody designated “MDM2 antibody (D-7)” (Santa Cruz, catalog number sc-13161); (vi) an anti-HDM2 antibody designated “p-MDM2 antibody (2G2)” (Santa Cruz, catalog number sc-13161); Cruz, catalog number sc-53368); (vii) an anti-HDM2 antibody designated “MDM2 Antibody (SPM344)” (Santa Cruz, catalog number sc-56430); (viii) an anti-HDM2 antibody designated “MDM2 Antibody (SMP14)” (Santa Cruz, catalog number sc-965); (ix) an anti-HDM2 antibody designated “Anti-MDM2 Clone 4B2C1.11” (EMD Millipore, catalog number MABE331); (x) an anti-HDM2 antibody designated “Anti-MDM2 Clone 3G9” (EMD Millipore, catalog number 04-1530); (xi) an anti-HDM2 antibody designated “Anti-MDM2 Clone 2A10” (EMD Millipore, catalog number MABE281); (xii) an anti-HDM2 antibody designated “Anti-MDM2 (Ab-1) Mouse mAb (IF2)” (EMD Millipore, catalog number OP46); (xiii) an anti-HDM2 antibody designated as "anti-MDM2 (Ab-3) mouse mAb (4B11)" (EMD Millipore, catalog number OP143); (xiv) an anti-HDM2 antibody designated as "anti-MDM2 (Ab-4) mouse mAb (2A9C1.18)" (EMD Millipore, catalog number OP144); (xv) an anti-MDM2 antibody designated as "anti-MDM2 (Ab-5) mouse mAb (4B2C1.(xvi) an anti-HDM2 antibody designated “MDM2 Antibody (C-18): sc-812” (Santa Cruz, polyclonal, catalog number sc-812); and (xvii) an anti-HDM2 antibody designated “MDM2 Antibody (N-20): sc-813” (Santa Cruz, polyclonal, catalog number sc-813).

[0411] 8.1 Example 1: Selection of HDM2-specific mAbs targeting extracellularly accessible epitopes of HDM2

[0412] Using enzyme-linked immunosorbent assay (ELISA), the data provided herein show that mAb NMC-103 specifically binds to the peptide NMC-P1 (SEQ ID NO: 1) corresponding to amino acids 1-15 of HDM2, while mAb NMC-204 specifically binds to the NMC-P2 peptide (SEQ ID NO: 2) corresponding to amino acids 15-25 of HDM2, and mAb NMC-303 specifically binds to the NMC-P3 peptide (SEQ ID NO: 3) corresponding to amino acids 475-491 of HDM2. In addition, immunoblot analysis provided herein shows that mAbs NMC-103, NMC-204, and NMC-303 recognize full-length recombinant HDM2 protein.

[0413] Peptide-ELISA Method: 5 μg / ml of NMC-P1, NMC-P2, or NMC-P3 peptide antigen was dried overnight on a 96-well ELISA plate. The plate was then blocked with 5% BSA in 1x phosphate-buffered saline (PBS) (100 μl / well) for 2 hours at room temperature. The microplate wells were then washed five times with 300 μl of ice-cold 1x PBS. Appropriately diluted monoclonal antibodies NMC-103, NMC-204, or NMC-303 were then incubated with their corresponding peptides (NMC-P1, NMC-P2, or NMC-P3, respectively) in 1% bovine serum albumin (BSA) in PBS at room temperature. After 2 hours, the wells were washed 5 times with 300 μl ice-cold PBS / well and 100 μl of secondary antibody (HRP-labeled goat anti-mouse F(ab')2H&L cross-adsorbed secondary antibody (HRP-GaM F(ab')2), ThermoFisher, catalog number A24524) diluted 1:2500 to 1:5000 in PBS-1% BSA solution was added and incubated at room temperature. After 1 hour, the wells were washed 5 times again with 200 μl ice-cold PBS and 50 μl of TMB substrate solution (1-Step™ Ultra TMB-ELISA, ThermoFisher, catalog number 34028) was added to each well and developed for 30 minutes at room temperature. The reaction was stopped by adding 50 μl of stop solution (ThermoFisher, catalog number SS04) to each well and the absorbance of each well was immediately read to obtain the optical density (OD) at 450 nm.

[0414] Competition Assays: For peptide antigen binding competition experiments, 1 μl / ml of mAb NMC-103 was preincubated with 10 μl / ml of NMC-P1, NMC-P2, or NMC-P3 for 1 hour at room temperature. mAb NMC-103 was then incubated with ELISA plates coated with NMC-P1 as described above.

[0415] Western Blot: For immunoblotting, 1 μg / well of recombinant HDM2 protein (GST-tagged, Abcam, catalog number ab188727) was separated on an 8-16% sodium dodecyl sulfate (SDS) polyacrylamide gel and then transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with 5% milk and then incubated with 1 μg / ml of monoclonal antibody NMC-103, NMC-204, or NMC-303 in 1% milk in PBS for 2 hours. The membrane was then washed three times (10 minutes each) and incubated with the corresponding HRP-conjugated secondary antibody (goat anti-mouse IgG (H&L), F(ab')2Frag cross-adsorbed HRP (HRP-GaM F(ab')2), ThermoFisher, catalog number A24524) diluted 1:5000 in 1% BSA-PBS for 1 hour. The membrane was then washed three times and incubated with Pierce ECL Plus Western Blotting Substrate (ThermoFisher, catalog #32132) for 10 minutes before development on a LICOR scanner.

[0416] The peptide-ELISA experiments shown in Figure 1 demonstrate the selective and specific binding of monoclonal antibodies (mAbs) NMC-103, NMC-204, and NMC-303 to their corresponding peptide antigens. Figure 1A shows that NMC-103 binds to the NMC-P1 peptide, while NMC-204 does not bind to NMC-P1. Figure 1B shows that mAb NMC-204 binds to the NMC-P2 peptide, while mAb NMC-103 does not bind to NMC-P2. Figure 1C shows that mAb NMC-303 binds to the NMC-P3 peptide, while NMC-204 does not bind to NMC-P3. Therefore, the peptide-ELISA results show that each of mAbs NMC-103, NMC-204, and NMC-303 selectively binds to its corresponding antigenic peptide on the ELISA plate, while not binding to other peptides. Figure 1D shows that although mAb NMC-103 binds to NMC-P1, preincubation of the NMC-P1 peptide with mAb NMC-103 abolishes the binding of NMC-103 to the NMC-P1 peptide on the plate. In contrast, preincubation of mAb NMC-103 with either NMC-P2 or NMC-P3 did not affect the binding of mAb NMC-103 to NMC-P1. These experiments demonstrate the specificity of mAbs NMC-103, NMC-204, and NMC-303 for their corresponding peptide antigens.

[0417] Figure 2The results of the immunoblot experiments in Figure 3 show that mAbs NMC-103, NMC-204, and NMC-303 react with recombinant full-length HDM2 protein. The recombinant protein has a GST tag at its N-terminus, which brings the molecular weight to approximately 83 kD. Lane 2 of the immunoblot shows the reactivity of a commercially available antibody raised against amino acids 100-320 of human MDM2 (MDM2(D-7); Santa Cruz, catalog number sc-13161) to the full-length recombinant HDM-2 protein. Lane 3 of the immunoblot shows the reactivity of mAb NMC-103 with a single band at approximately 83 kD, which corresponds to the recombinant HDM2-GST protein. Lane 4 of the immunoblot shows that mAb NMC-204 binds to a single band at approximately 83 kD, which corresponds to the recombinant HDM2-GST protein. Lane 5 of the immunoblot shows the reactivity of mAb NMC-303 with the recombinant HDM2-GST protein at 83 kD. In contrast, control mouse IgG (Abcam, catalog number ab18447) did not react with recombinant HDM2-GST protein in lane 1. The data presented here further demonstrate that mAbs NMC-103, NMC-204, and NMC-303 recognize full-length HDM2.

[0418] 8.2 Example 2: HDM2-specific antibodies bind to cancer cells from different rodent and human cancer cell lines and newly isolated Extracellularly accessible epitopes of M(H)DM2 / 4 on intact cancer cells but not on normal cells in primary human cancer cells

[0419] General Description: Using ELISA, the data presented herein demonstrate that mAbs NMC-103, NMC-204, and NMC-303 bind to extracellularly accessible epitopes of M(H)DM2 / 4 within the NMC-P1, NMC-P2, and NMC-P3 sequences, respectively, on the plasma membrane of human breast cancer cells, human triple-negative breast cancer cells, human melanoma cells, chemotherapy-resistant human ovarian cancer cells, and primary patient-derived human ovarian cancer cells, human and mouse pancreatic cancer cells, mouse colon cancer cells, and mouse lung cancer cells. The data presented herein also demonstrate selective binding of these mAbs to cancer cells, but not to normal, untransformed cells. Furthermore, peptide-antigen competition results demonstrate that each of these mAbs specifically binds to its corresponding NMC-P1, NMC-P2, or NMC-P3 region of plasma membrane M(H)DM2 / 4.

[0420] Cell-ELISA method: 8,000-10,000 cells / well of a 96-well microplate were cultured overnight. The next day, unbound cells were rinsed off with sterile 1x PBS. The cells in each well were fixed with freshly prepared 4% buffered paraformaldehyde (pH 7.2) for 1 hour and then washed three times with 1x PBS. The wells were then blocked with 5% BSA in PBS (100 μl / well) for 2 hours at room temperature. The microplate wells were then washed five times with 300 μl of ice-cold 1x PBS. 1 μg / mL of mAb NMC-103, NMC-204, or NMC-303 was then incubated with various cancer or normal untransformed cells in 1% BSA / PBS for 2 hours at room temperature. The wells were then washed five times with 300 μl of ice-cold 1x PBS, and the corresponding secondary antibody HRP-GaM F(ab')2 diluted 1:2500 or 1:5000 in PBS containing 1% BSA was added at 100 μl / well, left at room temperature for 1 hour, and then washed five times with 300 μl of ice-cold 1x PBS. 50 μL of TMB substrate solution (1-StepTM Ultra TMB-ELISA, ThermoFisher, catalog number 34028) was then added to each microplate well and incubated at room temperature for 30 minutes. The reaction was terminated by adding 50 μL of stop solution (ThermoFisher, catalog number SS04) to each well, and the absorbance of each well was measured at OD450 nm. The absorbance value of each experimental well was corrected to the absorbance value obtained from the wells treated with the same mAb of the isotype included in each experiment. The results are therefore expressed as "relative binding".

[0421] Figures 3-5 show the relative binding of mAbs NMC-103, NMC-204, and NMC-303 to intact cells of different types of human (A) and rodent (B) cancers. Figure 3 shows the reactivity of mAb NMC-103 to human breast cancer MCF-7 cells, human triple-negative breast cancer HCC1806 cells, human pancreatic cancer MIA PaCa-2 cells, doxorubicin-, melphalan-, and cisplatin-resistant human ovarian cancer OVCAR-3 cells, primary patient-derived human ovarian cancer OVCA4 cells, human melanoma A2058 cells, human uveal melanoma 92.1 cells, mouse colon cancer MC-38 cells, mouse Lewis lung LL / 2 cells, and mouse pancreatic Panc02 cells. Figure 4 shows the reactivity of the NMC-204 monoclonal antibody against human breast cancer MCF-7 cells, human triple-negative breast cancer HCC1806 cells, human pancreatic cancer MIA PaCa-2 cells, human ovarian cancer OVCAR-3 cells, primary patient-derived human ovarian cancer OVCA4 cells, human melanoma A2058 cells, human uveal melanoma 92.1 cells, mouse colon cancer MC-38 cells, mouse Lewis lung LL / 2 cells, and mouse pancreatic Panc02 cells. Figure 5 shows the reactivity of the NMC-303 monoclonal antibody against human breast cancer MCF-7 cells, human triple-negative breast cancer HCC1806 cells, human pancreatic cancer MIA PaCa-2 cells, human ovarian cancer OVCAR-3 cells, primary patient-derived human ovarian cancer OVCA.4 cells, human melanoma A2058 cells, human uveal melanoma 92.1 cells, mouse colon cancer MC-38 cells, mouse Lewis lung LL / 2 cells, and mouse pancreatic Panc02 cells.

[0422] Figure 6 NMC-204 was shown to not react with normal human PBMCs. In contrast to cancer cells, mAbs NMC-103, NMC-204, and NMC-303 did not bind to normal intact cells (data not shown for NMC-103 and NMC-303). The data presented herein show that although mAb NMC-204 reacts with human pancreatic cancer MIA PaCa-2 cells, no binding was seen above background when mAb NMC-204 was incubated with freshly isolated normal human peripheral blood mononuclear cells (PBMCs). In addition, Figure 6 showed that although mAb NMC-204 did not react with normal human PBMC ( Figure 6 Left; white histogram), but these cells were strongly reactive to mAb against CD3e, a cell surface marker for T cells ( Figure 6 Left; shaded bars).

[0423] Figure 7 depicts saturation curves for mAb NMC-103 and NMC-204. Figure 7A shows that cell-ELISA binding of mAb NMC-103 to intact MIA PaCa-2 cells increased with increasing antibody concentration. However, this binding reached equilibrium at mAb NMC-103 concentrations above 50 μg / mL, indicating that the specific antibody NMC-103 can saturate the antigen binding site. In addition, Figure 7B depicts the saturation curve for binding of mAb NMC-204 to intact MIA PaCa-2 cells. At mAb NMC-204 concentrations above 50 μg / mL, binding of mAb NMC-204 to its antigen on intact MIA PaCa-2 cells reached saturation, indicating that mAb NMC-204 was saturated at the antigenic site.

[0424] 8.3 Example 3: mAbs NMC-103, NMC-204, and NMC-303, respectively, for HDM2 expression on intact cancer cells The externally accessible NMC-P1, NMC-P2, and NMC-P3 sequences are specific

[0425] The data shown in Figure 8 show the specificity of mAb NMC-103, NMC-204 and NMC-303 for the NMC-P1, NMC-P2 and NMC-P3 sequences of extracellular accessible HDM2 on cancer cell membranes. Figure 8A shows the binding of mAb NMC-103 to intact human pancreatic cancer MIA PaCa-2 cells (left, solid bars). When mAb NMC-103 competed with soluble NMC-P1, the binding of monoclonal antibody NMC-103 to its accessible HDM2 epitope on the plasma membrane of MIA PaCa-2 cells was completely abolished (middle column, solid bars). In contrast, competition with NMC-P2 had no effect on the reactivity of NMC-103 to the epitope of HDM2 that is bound to it and accessible on the cell surface of MIA PaCa-2 cells (solid, filled bars).

[0426] On the other hand, as shown in Figure 8B , the reactivity of mAb NMC-204 with whole MIA PaCa-2 cells competed with the NMC-P2 peptide but not with NMC-P1, indicating epitope specificity for another extracellularly accessible epitope / peptide of HDM2 expressed on the plasma membrane of MIA PaCa-2 cells.

[0427] The observation that the newly generated mAbs are specific for certain epitopes on HDM2 was further extended by the observation that the binding of mAb NMC-303 to intact MIA PaCa-2 competed with the NMC-P3 peptide but not with NMC-P2 (Figure 8C). Taken together, these data demonstrate the specificity of mAbs NMC-103, NMC-204, and NMC-303 for three different extracellularly accessible sequences of HDM2 (i.e., NMC-P1, NMC-P2, and NMC-P3, respectively).

[0428] like Figure 9 As shown, when mAb NMC-103 was preincubated with full-length recombinant HDM2, the binding of the antibody to intact MIA PaCa-2 cells was reduced. This result further confirmed the specific binding of the NMC antibody to HDM2.

[0429] 8.4 Example 4: Plasma membrane marker antibodies, namely antibodies NMC-103 and NMC-204, make the plasma membrane of intact cells Surface staining occurs, whereas antibodies to intracellular markers do not stain it.

[0430] The data provided in this article ( Figure 10 ) showed that selected HDM2-specific antibodies bound to extracellularly accessible HDM2 on the plasma membrane of intact cancer cells (human pancreatic MiaPaCa-2 cells) treated with EDTA (10 mmols; pH 7.2; 5 min, 37°C). Thus, EDTA treatment appears to have little or no effect on the expression of HDM2 on the surface membrane of cancer cells, strongly suggesting that the HDM2 protein antigen is an essential membrane protein. Other data presented here show that antibodies against plasma membrane markers such as E-cadherin (Transduction Lab, catalog number C37020) bind to intact cells, while antibodies specific for intracellular markers such as cytochrome C (Santa Cruz, catalog number sc-13156) are unable to bind to their targets due to the inaccessibility of intracellular compartments in intact cells.

[0431] 8.5 Example 5: Extracellular protease digestion of intact cancer cells removes M(H)DM2 from the plasma membrane of intact cancer cells Extracellularly accessible sequences

[0432] mAbs NMC-103, NMC-204, and NMC-303 were generated against amino acids 1-15 (NMC-P1), 15-25 (NMC-P2), and 475-491 (NMC-P3) of HDM2, respectively, and were highly specific for HDM2. Figure 2 As shown by immunoblotting, all three mAbs NMC-103, NMC-204, and NMC-303 recognized and bound to the purified HDM2 protein, providing evidence that the unique antigenic epitopes recognized by the three mAbs in NMC-P1, NMC-P2, and NMC-P3, respectively, are actual structures of intact HDM2. The results of the cell-ELISA in Figures 3-5 and 8 further the observations by providing evidence that the M(H)DM2 epitope is expressed extracellularly on the surface membrane of intact rodent and human cancer cells: (1) mAbs NMC-103, NMC-204, and NMC-303 bind to intact cancer cells (Figures 3-5); (2) the binding of each mAb is effectively competed by its specific peptide, but not by the other peptides (Figure 8); and (3) the binding of the NMC-mAbs is also effectively competed by the intact HDM2 protein (Figure 8). Figure 9 ); (4) Almost no mAb NMC-103, NMC-204 or NMC-303 bound to intact normal human PBMC ( Figure 6 ).

[0433] To further consolidate the finding that M(H)DM2 is expressed on the surface membrane of cancer cells, the binding of mAbs NMC-103, NMC-204, and NMC-303 to cancer cells was examined by indirect immunofluorescence before and after protease treatment of the cells. Extracellular protease digestion has been shown to be a powerful tool for evaluating the cell surface localization of plasma membrane proteins (Besingi and Clark, 2015, Nat. Protoc. 10(12): 2074–2080; Schülein et al., 1996, J. Biol. Chem. 271(46): 28844–28852): after protease treatment, the loss of binding of cell surface antigen-specific antibodies to cells indicates not only that the antigen is susceptible to proteolysis, but also, most importantly, that the antigen is exposed on the extracellular surface of the cells. Therefore, the accessibility of extracellularly displayed M(H)DM2 protein antigens, particularly those with the amino acid sequences of NMC-P1, NMC-P2, and NMC-P3, was evaluated by the antigen's sensitivity to trypsin digestion. The effect of trypsin on the binding of mAbs NMC-103, NMC-204, and NMC-303 was then examined using cell-based ELISA and HRP reactivity at OD 450 nm as described above.

[0434] Flow cytometry method: EDTA (10 mmols; pH 7.2; 5 min, 37 ° C) or trypsin (Gibco TrypLE Express) were used to release the cells and allow them to grow at 25 cm 2 Cells grown to approximately 80% confluence in tissue culture flasks were fixed with freshly prepared 4% buffered (pH 7.4) paraformaldehyde for 1 hour at room temperature, washed several times with plenty of ice-cold PBS, and blocked with 5% human serum albumin in PBS for 30 minutes at room temperature (intact, non-permeabilized cells). After establishing viability, the cell number was adjusted to 10 6 Cells were collected and stored in ice-cold PBS until staining. Another group of identical cells was released with EDTA or trypsin and fixed with 4% buffered paraformaldehyde as described above. The cells were then washed and blocked with 5% human serum albumin in PBS and treated with Triton X-100 (0.1% in PBS) (International Biotechnologies Inc. 07100) for 5 minutes at room temperature to permeabilize the membrane. After rinsing off the Triton X-100 solution with PBS, the cells were adjusted to 106 Cells from each preparation (10 6 Cells were incubated with 5 μg / ml of Na+ / K+ ATPase α-1 mAb (Abcam, catalog number ab2826), 5 μg / ml mAb NMC-103, or 5 μg / ml mAb NMC-204 at room temperature for 90 min. After primary antibody incubation, cells were washed three times with ice-cold PBS and then incubated with rabbit anti-mouse PE-Cy5-labeled secondary antibody (PE-Cy5-RaM IgG (H&L); Invitrogen, catalog number M35018) at room temperature. After 60 minutes, cells were washed three times with PBS and analyzed by flow cytometry (BD Canto flow cytometry). Controls for background fluorescence included analysis of samples of unstained cells and samples of cells treated with secondary antibodies under the same conditions as used in the experimental samples.

[0435] To evaluate the extracellular and intracellular accessibility of antibodies on intact cells, intact human pancreatic cancer MiaPaCa-2 cells were used to test the binding of antibodies to the plasma membrane marker E-cadherin (Transduction Lab C37020) and the intracellular protein cytochrome C (Santa Cruz sc-13156). Figure 10 The cell-ELISA results in Figure 2 demonstrate binding of E-cadherin antibodies to intact, EDTA-released MiaPaCa-2 cells (first bar from the left). In contrast, mAbs to cytochrome C showed only minimal binding to EDTA-released cells (second bar from the left), suggesting the inaccessibility of intracellular targets in intact cells to macromolecules such as antibodies. On the other hand, both mAbs NMC-103 and NMC-204 bound to intact, EDTA-released MIAPaCa-2 cells, providing strong evidence for their interaction with epitopes present in extracellularly accessible sequences of HDM2.

[0436] To further verify that the epitope of plasma membrane M(H)DM2 is actually an extracellularly accessible sequence on cancer cells, the binding of mAbs NMC-103, NMC-204, and NMC-303 was tested on mouse Lewis lung LL / 2 cancer cells under EDTA and trypsin treatment conditions. These two conditions were also tested on intact and permeabilized cells. Figure 11Figures A, B, and C show flow cytometry data for the percentage of cells stained with mAb NMC-103, NMC-204, and anti-Na+ / K+ ATPase α-1, respectively. Each antibody reacted with cells from the following four treatment conditions: intact cells treated with EDTA, permeabilized cells treated with EDTA, intact cells treated with trypsin, and permeabilized cells treated with trypsin. Intact cells treated with EDTA showed staining with mAb NMC-103 (70.4%), NMC-204 (51.2%), and anti-Na+ / K+ ATPase α-1 antibody (29.9%). When EDTA-treated cells were permeabilized, staining with NMC-103, NMC-204, and anti-Na+ / K+ ATPase α-1 increased to 75.8%, 52.85%, and 63.8%, respectively. However, when compared to EDTA-treated cells, binding of mAbs NMC-103, NMC-204, and anti-Na+ / K+ ATPase α-1 to intact cells treated with trypsin was reduced to 36.8%, 27%, and 20.5%, respectively, due to extracellular protease digestion of the antibody recognition epitope. However, when trypsin-treated cells were permeabilized, this reduction in binding was compensated by the reactivity of the antibodies to intracellular MDM2 or Na+ / K+ ATPase α-1. Taken together, the results presented herein further demonstrate the accessibility of the extracellular sequence of the transmembrane M(H)DM2 on intact cancer cells, which can be cleaved by extracellular protease treatment.

[0437] 8.6 Example 6: Specific HDM2 Antibodies Inhibit the Growth of Intact Cancer Cells in Vitro

[0438] The data presented herein demonstrate that antibodies that recognize extracellularly accessible sequences of HDM2 are able to inhibit the growth of cancer cells in vitro.

[0439] Methods used: Human pancreatic cancer MIAPaCa-2 cells (8,000 cells / well) were pre-incubated with 1, 5, and 10 μg / mL of mAb NMC-103, NMC-204, and anti-cytochrome C antibody (Santa Cruz, catalog number sc-13156). The cells were then plated in triplicate in 96-well cell culture plates overnight in the presence of one of the antibodies at various concentrations. The next day, morphological analysis was performed on each plate well, and photos were taken from each well using an EVOS FL microscope. Cell counts were also performed, and the number of viable cells was plotted as a percentage of the control.

[0440] Figure 12 (AD) shows that human pancreatic cancer MIAPaCa-2 cells treated with mAb NMC-103 or NMC-204 show concentration-dependent growth inhibition, while antibodies for intracellular markers (i.e., cytochrome C) have no effect on the growth of these cancer cells. As shown in Figure 12A, MIAPaCa-2 cells treated with 1 μg / mL (upper figure, left figure), 5 μg / mL (upper figure, middle figure) and 10 μg / mL (upper figure, left figure) mAbNMC-103 show an increased effect of inhibiting their growth. Figure 12B shows images of cells treated with 1, 10 and 20 μg / mL mAb NMC-204, showing concentration-dependent inhibition of cell growth. In contrast, Figure 12C shows that MIAPaCa-2 cells treated with antibodies for cytochrome C have no effect on the growth of these cells under any one of 1, 10 and 20 μg / mL concentrations, and the cytochrome C is used as an intracellular marker control. Figure 12D The growth inhibition of mAb NMC-103 at 1 μg / mL (65%), 5 μg / mL (84%), and 10 μg / mL (91%) (solid black line) and NMC-204 at 1 μg / mL (65%), 5 μg / mL (73%), and 10 μg / mL (77%) (dashed black line) were quantified. In contrast, treatment with an antibody directed against cytochrome C (an intracellular target; Santa Cruz, catalog number sc-13156) showed no signs of growth inhibition at 1 μg / mL (100%), 5 μg / mL (100%), and 10 μg / mL (104%) (solid gray line).

[0441] 8.7 Example 7: HDM2-specific Antibodies Trigger Complement-Dependent Cytotoxicity (CDC) Against Cancer Cells

[0442] The data presented herein show that HDM2-specific antibodies are not only able to bind to extracellularly accessible sequences of HDM2 on the surface membrane of cancer cells, but can also induce potent cytotoxic effects in the presence of fresh normal human serum (NHS). Cytotoxic effects were measured in pancreatic cancer cells as well as normal human fibroblasts. The data presented herein demonstrate one such cytotoxic effect when mAb NMC-103 was used to treat human pancreatic cancer MIAPaCa-2 cells in the presence of NHS.

[0443] Methods used: Cells seeded in 24-well culture dishes were grown overnight at 37°C in a humidified atmosphere provided with a 5% CO2–95% air mixture. The next day, cells were washed thoroughly with ice-cold PBS and incubated with HDM2-specific mAb NMC-103 diluted to a final antibody concentration of 30 μg / ml in culture medium containing 1% BSA. Thirty minutes later, NHS was added to the cells at a final concentration of 1:10 in culture medium containing 1% BSA and 1% propidium iodide (PI). Cells were then incubated with NHS for 2 hours, and images were captured using an EVOS FL fluorescence microscope (Life Technologies).

[0444] Figure 13 shows the cytotoxic effect of HDM2-specific mAb NMC-103 on human pancreatic cells. In the presence of NHS, mAb NMC-103 triggers complement-mediated cytotoxicity in cancer cells, leading to cancer cell death, as evidenced by nuclear uptake of the cell death marker propidium iodide (PI). Figure 13C A quantitative schematic diagram of complement-dependent cytotoxicity (CDC) of HDM2-specific antibodies against human pancreatic cancer cells is provided. Cells treated with mAb NMC-103 in the presence of NHS ( FIG. 13B ) showed cytotoxicity within 2 hours after treatment ( FIG. 13A ) compared to cells treated with NHS in the absence of any antibody. Control experiments were performed using anti-cytochrome C antibodies or untreated cells in the presence of NHS.

[0445] 8.8 Example 8: Other Anti-HDM2 mAb Antibodies and Their Effects on NMC-P1, NMC-P2, and NMC-P3, as well as on Intact Cancer Cells Combined evaluation

[0446] There are many commercially available HDM2-specific monoclonal antibodies. To evaluate the binding of commercially available mAbs to HDM2, we tested the binding of many of these mAbs to intact cancer cells using peptide and cell-ELISA. These mAbs included antibodies raised against various regions from the N-terminus or C-terminus or segments in the middle of the HDM2 protein and were tested for binding to the newly identified extracellularly accessible NMC-P1 and NMC-P2 sequences as well as to intact cancer cells.

[0447] Table 3 summarizes the commercially available mAbs tested, the companies that produced them, and the amino acid residues of HDM2 against which the mAbs were generated.

[0448] Table 3. Commercially available monoclonal antibodies tested

[0449]

[0450] 14A and 14B show the lack of binding of any of these mAbs to either NMC-P1 or NMC-P2 using peptide-ELISA. In contrast, NMC-103 and NMC-204 showed strong binding to NMC-P1 and NMC-P2, respectively.

[0451] In these experiments, we further evaluated whether HDM-2 binding components (e.g., peptides such as PNC-27) interfered with the binding of mAbs to NMC-P1 and NMC-P2. Although the exact binding site of the HDM2 binding components of the PNC-27 and PNC-28 peptides on HDM2 is unknown, it has been reported to bind within amino acids 25-109 of HDM2 (Do et al., 2003, Oncogene 22(10):1431-1444 ("Do 2003"); Chène, 2003, Nat. Rev. Cancer 3(2):102-109). To exclude the possibility that the PNC-27 and PNC-28 peptides bind to NMC-P1 or NMC-P2, we evaluated the binding of the peptides to these HDM2 sequences by peptide-ELISA. As shown in Figures 14A and 14B, PNC-27 (10 μg / mL) did not compete with the binding of NMC-103 and NMC-204 (1 μg / mL) to NMC-P1 and NMC-P2, respectively. PNC-27 was found not to bind to the NMC-P1 or NMC-P2 regions of HDM2. Overall, these observations suggest that the HDM2-binding component of PNC-27 does not react with NMC-P1 or NMC-P2. Furthermore, it has been demonstrated that the HDM-2-binding components of PNC-27 and PNC-28 do not possess anticancer activity on their own but are only active when attached to membrane-resident peptides (MRP or penetratin sequences) (see Kanovsky 2001, Do 2003, and Bowne 2008).

[0452] During the analysis of mAbs by cell-ELISA, despite the fact that none of the commercially available antibodies tested bound to either NMC-P1 or NMC-P2, an anti-HDM2 antibody “anti-MDM2 (Ab-5) mouse mAb (4B2C1.11)” raised against amino acid residues 19-50 of HDM2 (EMD Millipore, catalog number OP145) and an anti-HDM2 antibody designated “MDM2 monoclonal antibody (M01) clone 1A7” (Abnova, catalog number H00004193-M01) were determined to be reactive with intact cancer cells (see Figure 15A, data are shown for MDM2 monoclonal antibody (M01) clone 1A7. MDM2 monoclonal antibody (M01) clone 1A7 was generated against amino acids 101 to 200 of full-length HDM2. Thus, the data suggest that epitopes of HDM2 other than NMC-P1, NMC-P2, and NMC-P3 may be extracellularly accessible on cancer cells for binding. In similar experiments, two HDM2-specific monoclonal antibodies ( Figure 15B One mAb is an anti-HDM2 antibody, designated "anti-MDM2 (Ab-4) mouse mAb (2A9C1.18)" (EMD Millipore, catalog number OP144), which is raised against amino acids 153 to 222 of full-length HDM2 (SEQ ID NO: 4), including a nuclear localization signal (NLS) and a nuclear export signal (NES). Another HDM2-specific mAb that does not react with intact cancer cell membranes is an anti-HDM2 antibody, designated "anti-MDM2 (Ab-1) mouse mAb (IF2)" (EMD Millipore, catalog number OP46), which is raised against amino acids 26-169 of HDM2 ( Figure 15B ).

[0453] 8.9 Example 9: In vivo anti-tumor effects of antibodies targeting extracellularly accessible sequences of HDM2 in cancer cells

[0454] As described above, there are selected epitopes of HDM2 that are extracellularly accessible on cancer cells. Three (3) such extracellularly accessible segments of HDM2 are described herein, namely NMC-P1 (SEQ ID NO: 1), NMC-P2 (SEQ ID NO: 2), and NMC-P3 (SEQ ID NO: 3). The data herein demonstrate that selected antibodies raised against these 3 segments selectively and specifically bind to various types of cancer, but not to normal, healthy cells (Figures 3-9). Furthermore, the results provided herein demonstrate the extracellular accessibility of these 3 segments of HDM2 on cancer cells ( Figure 10 and 11 Furthermore, the data presented here show that HDM2-specific antibodies have growth inhibitory and cytotoxic effects on cancer cells in vitro. Finally, the anti-tumor activity of HDM2-specific antibodies was evaluated in vivo. For example, mAbs NMC-103 and NMC-204 were tested for their efficacy against lung, colon, and pancreatic cancers.

[0455] Methods used (syngeneic mouse models of lung, colon, and pancreatic cancer): To investigate the in vivo antitumor effects of HDM2-specific antibodies against lung, colon, and pancreatic tumors, three well-known syngeneic mouse models of lung, colon, and pancreatic cancer were used (Sharma et al., 1999, J. Immunol. 163(9):5020-5028; McIntyre, 2015, Bioassays 37(8):909-920; Li et al., 2015, Sci. Rep. 5:7856). 8-week-old female C57BL / 6 mice (n=6-7) were implanted with Lewis lung carcinoma LL / 2 cells (2.5×10 5 cells / mouse), mouse colon cancer MC-38 cells (5x10 5 cells / mouse) or mouse pancreatic cancer Panc-2 cells (2x10 6 Subcutaneous tumors were pre...

Claims

1. An antibody or fragment thereof that specifically binds to HDM2, the antibody or fragment comprising (a) a heavy chain variable region (VH) and (b) a light chain variable region (VH), the heavy chain variable region (VH) comprising a VH complementarity determining region ("CDR") 1, a VH CDR 2 and a VHCDR 3, the light chain variable region (VL) comprising a VL complementarity determining region ("CDR") 1, a VL CDR 2 and a VL CDR 3, wherein: (i) the amino acid sequence of the VH CDR 1 is GFTFTHY (SEQ ID NO: 18), the amino acid sequence of the VH CDR 2 is RNKAKGYT (SEQ ID NO: 19), the amino acid sequence of the VH CDR 3 is DIGDN (SEQ ID NO: 20), and the amino acid sequence of the VL CDR 1 is RSSKNLLHSNGITYLY (SEQ ID NO: 21), the amino acid sequence of the VL CDR 2 is RVSNLAS (SEQ ID NO: 22), and the amino acid sequence of the VL CDR 3 is AQLLELPYT (SEQ ID NO: 23); (ii) the amino acid sequence of the VH CDR 1 is GFTFTHYYMS (SEQ ID NO:42), the amino acid sequence of the VH CDR 2 is FIRNKAKGYTAE (SEQ ID NO:45), the amino acid sequence of the VH CDR 3 is DIGDN (SEQ ID NO:20) and the amino acid sequence of the VL CDR 1 is RSSKNLLHSNGITYLY (SEQ ID NO:21), the amino acid sequence of the VL CDR 2 is RVSNLAS (SEQ ID NO:22), and the amino acid sequence of the VL CDR 3 is AQLLELPYT (SEQ ID NO:23); (iii) the amino acid sequence of the VH CDR 1 is HYYMS (SEQ ID NO:43), the amino acid sequence of the VH CDR 2 is FIRNKAKGYTAEYSASVKG (SEQ ID NO:46), the amino acid sequence of the VH CDR 3 is DIGDN (SEQ ID NO:20), and the amino acid sequence of the VL CDR 1 is RSSKNLLHSNGITYLY (SEQ ID NO:21), the amino acid sequence of the VL CDR2 is RVSNLAS (SEQ ID NO:22), and the amino acid sequence of the VL CDR 3 is AQLLELPYT (SEQ ID NO:23); (iv) the amino acid sequence of the VH CDR 1 is THYYMS (SEQ ID NO:44), the amino acid sequence of the VH CDR 2 is WLGFIRNKAKGYTAE (SEQ ID NO:47), the amino acid sequence of the VH CDR 3 is ARDIGD (SEQ ID NO:48) and the amino acid sequence of the VL CDR 1 is LHSNGITYLYWY (SEQ ID NO:49), the amino acid sequence of the VL CDR 2 is LLISRVSNLA (SEQ ID NO:50), and the amino acid sequence of the VL CDR 3 is AQLLELPY (SEQ ID NO:51); or (v) the amino acid sequence of the VH CDR 1 is FTFTHYY (SEQ ID NO: 144), the amino acid sequence of the VH CDR 2 is IRNKAKGYTA (SEQ ID NO: 145), the amino acid sequence of the VH CDR 3 is ARDIGDN (SEQ ID NO: 146) and the amino acid sequence of the VL CDR 1 is KNLLHSNGITY (SEQ ID NO: 147), the amino acid sequence of the VL CDR 2 is RVS, and the amino acid sequence of the VL CDR 3 is AQLLELPYT (SEQ ID NO: 23).

2. The antibody or fragment of claim 1, comprising a VH having the amino acid sequence of SEQ ID NO: 36, or a VH having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:

36.

3. The antibody or fragment of claim 2, comprising a light chain variable region (VL) having the amino acid sequence of SEQ ID NO: 37, or a VL having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:

37.

4. The antibody or fragment of any one of claims 1-3, wherein the antibody is a humanized antibody.

5. The antibody or fragment of any one of claims 1-3, wherein the antibody is a human antibody.

6. The antibody or fragment of any one of claims 1-3, wherein the antibody is a chimeric antibody.

7. The antibody or fragment of any one of claims 1-3, wherein the antibody is a monoclonal antibody.

8. The antibody or fragment according to any one of claims 1 to 3, which is an immunoglobulin.

9. The antibody or fragment of claim 8, wherein the immunoglobulin is IgG.

10. The antibody or fragment of claim 8, wherein the immunoglobulin is of the IgG1 isotype.

11. The antibody or fragment of claim 8, wherein the immunoglobulin is of the IgG3 isotype.

12. The antibody or fragment of any one of claims 1-3, comprising an Fc region, and wherein the Fc region is a human IgG1, human IgG2, human IgG3, human IgG4, or human IgM Fc region.

13. The antibody or fragment of claim 12, wherein the antibody or fragment mediates complement dependent cytotoxicity (CDC) or antibody dependent cell-mediated cytotoxicity (ADCC).

14. The antibody or fragment of claim 13, wherein the antibody or fragment mediates complement dependent cytotoxicity (CDC).

15. The antibody or fragment of any one of claims 1 to 3, which is a Fv fragment, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, or a single-chain antibody molecule.

16. The antibody or fragment of claim 15, wherein the single-chain antibody molecule is a single-chain Fv (scFv).

17. The antibody or fragment of any one of claims 1-3, wherein the HDM2 is a HDM2 variant lacking a nuclear localization signal domain, a HDM2 variant lacking the sequence of amino acids 179 to 185 of SEQ ID NO:4, and / or a HDM2 variant lacking the sequence of amino acids 464 to 471 of SEQ ID NO:

4.

18. The antibody or fragment of any one of claims 1-3 which is purified.

19. The antibody or fragment of any one of claims 1-3, which inhibits the proliferation of tumor cells in vivo.

20. An antibody-drug conjugate comprising the antibody or fragment of any one of claims 1 to 19 conjugated to a cytotoxic drug.

21. A pharmaceutical composition comprising a therapeutically effective amount of the antibody or fragment of any one of claims 1 to 19 or the antibody-drug conjugate of claim 20.

22. Use of the antibody or fragment of any one of claims 1-19, the antibody-drug conjugate of claim 20, or the pharmaceutical composition of claim 21 in the preparation of a medicament for treating cancer, wherein the cancer expresses an extracellularly accessible epitope of HDM2, wherein the cancer is pancreatic cancer, lung cancer, or colon cancer.

23. Use of the antibody or fragment of any one of claims 1-19, the antibody-drug conjugate of claim 20, or the pharmaceutical composition of claim 21 in the preparation of a medicament for inhibiting or preventing metastasis in a subject having a cancer expressing an extracellularly accessible epitope of HDM2, wherein the cancer is pancreatic cancer, lung cancer, or colon cancer.

24. Use of the antibody or fragment of any one of claims 1 to 19, the antibody-drug conjugate of claim 20, or the pharmaceutical composition of claim 21 in the preparation of a medicament for preventing cancer recurrence or preventing cancer recurrence, wherein the cancer expresses an extracellularly accessible epitope of HDM2, wherein the cancer is pancreatic cancer, lung cancer or colon cancer.

25. The use of any one of claims 22-24, wherein the extracellularly accessible epitope of HDM2 is within amino acids 19 to 50 of SEQ ID NO:

4.

26. The use of any one of claims 22-24, wherein the extracellularly accessible epitope of HDM2 is within amino acids 154 to 167 of SEQ ID NO:

4.

27. The use of any one of claims 22-24, wherein the extracellularly accessible epitope of HDM2 is within amino acids 1 to 60 of SEQ ID NO:

4.

28. The use of any one of claims 22-24, wherein the extracellularly accessible epitope of HDM2 is within amino acids 26 to 60 of SEQ ID NO:

4.

29. The use of any one of claims 22-24, wherein the extracellularly accessible epitope of HDM2 is within amino acids 101 to 200 of SEQ ID NO:

4.

30. The use of any one of claims 22-24, wherein the extracellularly accessible epitope of HDM2 is within amino acids 50 to 60 of SEQ ID NO:

4.

31. The use of any one of claims 22-24, wherein the extracellularly accessible epitope of HDM2 is within the terminal 60 amino acids of the C-terminus of HDM2 on the plasma membrane of cancer cells.

32. The use of any one of claims 22-24, wherein the HDM2 is a HDM2 variant lacking a nuclear localization signal domain, a HDM2 variant lacking the sequence of amino acids 179 to 185 of SEQ ID NO:4, and / or a HDM2 variant lacking the sequence of amino acids 464 to 471 of SEQ ID NO:

4.

33. The use of any one of claims 22-24, wherein the cancer is an advanced cancer.

34. The use of any one of claims 22-24, wherein the cancer is a metastatic cancer.